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Abstract 
 
Investigation of Long Noncoding RNAs in the  
P53 Response to Oncogenic Stress 
 
 




The tumor suppressor protein p53 plays a central role in sensing and 
responding to cellular stress, and loss of normal p53 activity is a feature of 
most human cancers. P53, functioning as a transcription factor, regulates a 
wide network of genes that coalesce to drive many diverse tumor suppressive 
cellular processes. Despite three decades of extensive study, it is unclear 
which p53 targets are most critical for these tumor suppressive functions 
and under which biological contexts. More recent studies have revealed that 
the p53 network is not solely comprised of protein coding genes but also 
includes many long noncoding RNAs (lncRNAs), which are an abundant but 
poorly characterized class of heterogenous RNA molecules. This work aimed 
to expand our understanding of the role of lncRNAs in the p53 
transcriptional network and the importance of these diverse RNAs in 
various p53-regulated processes and/or tumor suppression. 
We focused on characterizing the p53 response to stress generated by 
hyperactive oncogenes (i.e. oncogenic stress), which is an important but 
understudied facet of p53-mediated tumor suppression. By performing 
genome-wide analysis of p53 regulation across a panel of cancer cell lines 
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established from a genetically-engineered mouse model of p53-driven lung 
adenocarcinoma, sarcoma, and lymphoma, we uncovered oncogenic stress-
specific, tumor type-specific, and p53 outcome-specific patterns of p53 gene 
activation and repression, including the activation of several novel and 
previously described lncRNAs. We interrogated the contributions of many 
of these lncRNAs to p53 pathway function, using a number of locus-specific 
genetic and molecular approaches to down- or upregulate lncRNA 
expression in vitro. These characterization efforts revealed that local gene 
regulation, also known as cis-regulation, is the dominant mode of action for 
lncRNAs within the p53 network, in contrast to most previous reports on 
individual p53-regulated lncRNAs. We show that this regulation is largely in 
the positive direction, suggesting that lncRNAs do not significantly 
contribute to p53-mediated gene repression, and demonstrate that lncRNA 
cis-regulation can be important for p53-dependent growth arrest in certain 
tumor contexts.  
Altogether, this work provides novel insights into the p53 response 
across different cellular contexts and clarifies the contributions of lncRNAs 
to the p53 tumor suppressor network. Namely, we propose that lncRNAs 
primarily serve as an important fine-tuning regulatory mechanism. As such, 
this work has broader implications on the mechanisms by which lncRNAs as 
a class may influence other complex transcriptional networks important in 
human health and disease. 
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Chapter 1: Background  
Long noncoding RNAs and the p53 tumor suppressor network 
 
 
Sifting through the “junk” 
One of the most surprising revelations of the early 21st century, aided by the 
advent of modern genomics, was the prodigious amount of transcription present 
in the mammalian genome. The discovery that as much as 75% of the human 
genome is transcribed, despite less than 2% of it encoding for proteins, challenged 
the traditionally held view that in the flow of genetic information, RNAs primarily 
serve as intermediary messengers for dictating protein production (with a few 
important regulatory exceptions) (Djebali et al. 2012; Rinn and Chang 2012). One 
interpretation of this unexpected abundance of expressed RNAs is that many of 
these transcripts represent non-functional transcriptional noise, conceptually 
progressing from “junk DNA” to “junk RNA.” However, a growing body of work 
suggests that noncoding RNAs (ncRNAs) of many different classes can contribute 
to biology in important, versatile ways that are continuously being expanded upon. 
Long noncoding RNAs (lncRNAs) are one class of ncRNAs, defined by 
two simple criteria: a length exceeding 200 nucleotides and a lack of protein coding 
potential, as determined by various bioinformatic and/or experimental strategies 
(Mercer et al. 2009; Rinn and Chang 2012). LncRNAs have garnered much interest 
in recent years, in part due to the sheer number of lncRNA transcripts that have 
been uncovered in the human and mouse transcriptomes. According to NONCODE 
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v5 (2018), which is an integrated database of published ncRNA datasets, the 
human genome could contain as many as 95,000 lncRNA genes, corresponding to 
roughly 170,000 transcripts, while the mouse genome encodes around 90,000 
lncRNA genes, producing roughly 130,000 transcripts (Fang et al. 2018). Thus, in 
both humans and mice, the number of lncRNA genes and transcripts greatly 
surpasses the number of protein coding genes and mRNAs.  
Furthermore, transcriptome profiling studies have shown that many 
lncRNAs have expression patterns that correlate with specific cell- or tissue-types, 
biological processes, or disease states (Cabili et al. 2011; Rinn and Chang 2012; Iyer 
et al. 2015; Hung et al. 2011; Guttman et al. 2009). While these associations are 
tantalizing, determining whether they reflect functionality remains a massive on-
going endeavor. Encouragingly, large scale efforts to tackle this question on a 
genome-wide scale have suggested that dozens, if not hundreds of lncRNA loci 
could contribute to essential cellular processes (Liu et al. 2017). Additionally, 
several recent studies have revealed important roles for a myriad of individual 
lncRNAs, including in cell cycle regulation (Dimitrova et al. 2014; Marín-Béjar et 
al. 2013; Marchese et al. 2016), genome maintenance (Lee et al. 2016; Hu et al. 
2018), pluripotency (Loewer et al. 2010; Jain et al. 2016), genomic imprinting 
(Mancini-Dinardo et al. 2006; Latos et al. 2012), nuclear organization (Sunwoo et 
al. 2009; Hacisuleyman et al. 2014; Chen et al. 2016), cell death and survival (Hung 
et al. 2011; Li et al. 2017; Chaudhary et al. 2017), differentiation (Kretz et al. 2013; 
Yin et al. 2015; Ritter et al. 2019), and immune signaling (Petermann et al. 2019; 
Mineo et al. 2020), to name a few examples [also reviewed more extensively in 
(Fatica and Bozzoni 2014; Yao et al. 2019)]. However, the rate of lncRNA detection 
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has far out-stripped the rate of lncRNA characterization, leaving the question of 
whether this ever-expanding catalogue of lncRNA transcripts consists mostly of 
functional “wheat” or biologically insignificant “chaff” an important unanswered 
question. 
 
Modes of lncRNA function  
LncRNAs greatly increase the complexity of the mammalian genome and 
can be expressed from a multitude of genic configurations, including overlapping, 
sharing promoters with, or being entirely enclosed within other genes. LncRNAs 
can also be expressed from regulatory DNA or noncoding portions of coding 
regions, such as promoters, enhancers, and introns (Rinn and Chang 2012) (Fig. 
1A). Thus, lncRNAs are highly heterogenous at the level of genomic anatomy as 
well as function. Despite this frequent complexity in gene structure, the biogenesis 
of most lncRNAs closely resembles that of mRNAs, though this may also be a 
reflection of a sequencing-based sampling bias towards the detection of 
polyadenylated transcripts (Uszczynska-Ratajczak et al. 2018). Nonetheless, most 
identified lncRNA transcripts are produced by RNA polymerase II and are capped, 
spliced, and polyadenylated. LncRNAs are, however, in general less efficiently 
spliced, less abundant, and less conserved at the primary sequence level than 
mRNAs (Derrien et al. 2012; Quinn and Chang 2015), and lncRNA examples with 
exceptional processing do exist [e.g. unique 3’ end processing (Wilusz et al. 2012; 
Yang et al. 2011a), circularization (Li et al. 2018)].  
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So, what do lncRNAs do, and how do they do it? Perhaps unsurprisingly, it 
is impossible to productively answer this question with a single answer, in part due 
to the inclusive definition of a lncRNA. While this definition is useful for 
distinguishing lncRNAs from protein coding genes and other small regulatory 
ncRNAs with well-defined functions (e.g. microRNAs, tRNAs, snRNAs), it is less 
helpful in guiding the study of lncRNAs themselves (Rinn and Chang 2012). 
However, regardless of the inherent heterogeneity of lncRNAs as a class, all 
lncRNAs are fundamentally large RNA molecules. Accordingly, it is predicted that 
any lncRNA functions are principally mediated through the formation of complex, 
modular RNA structures that interact with other molecules (e.g. protein, RNA, 
DNA) in versatile, combinatorial ways (Goff and Rinn 2015) (Fig. 1B). 
 One way to further classify lncRNAs is based on where in the cell a lncRNA 
transcript is normally found. A broad but conceptually useful distinction is 
between nuclear and cytoplasmic lncRNAs. This is because lncRNA localization 
patterns can vary greatly and have important implications on feasible functions. 
Most lncRNAs are nuclear-enriched (Derrien et al. 2012; Cabili et al. 2015), but 
many lncRNAs are also found in the cytoplasm. Cytoplasmic lncRNAs have been 
reported to play a variety of roles, many related to post-transcriptional gene 
regulation. Examples of this include binding to and competing away microRNAs 
from target mRNAs (Chen et al. 2015; Faghihi et al. 2010; Hu et al. 2018), serving 
as microRNA precursors (Keniry et al. 2012), and directly influencing mRNA 
stability (Kretz et al. 2013; Gong and Maquat 2011) or translation (Carrieri et al. 
2012; Zhang et al. 2013a) through specific RNA-protein interactions. Nuclear 
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lncRNAs have been linked to regulating gene expression through a variety of 
mechanisms, discussed further below. 
LncRNAs can also be categorized according to broad modes of action. While 
such classifications cannot be made a priori functional interrogation of a lncRNA 
locus, limiting their usefulness in predicting lncRNA function, they can prove 
helpful in elucidating patterns of function that subsequently expand our 
understanding of the various ways lncRNAs can contribute to biology. One such 
distinction is between lncRNAs that act near their site of transcription, or in cis, 
versus those that exert a function elsewhere, deemed trans-acting lncRNAs (Sun 
et al. 2018; Gil and Ulitsky 2020). While cytoplasmic lncRNAs are trans-acting by 
definition, nuclear lncRNAs can function in either cis or trans to regulate gene 
expression (Sun et al. 2018) (Fig. 1B). Many well-characterized lncRNAs fall into 
the category of nuclear, cis-acting lncRNAs and have served as useful paradigms 





























Figure 1: LncRNAs are highly heterogenous but can be grouped by gene structure 
and/or broad regulatory modes of action. (A) Examples of the various genomic 
architectures lncRNA loci can exhibit. LncRNA genes are often categorized by their relationship to 
nearby (intergenic, bidirectional) or overlapping (antisense, sense, intronic) protein coding genes 
or regulatory DNA elements (promoters, enhancers). (B) LncRNAs can also be categorized by 
modes of action, whether acting locally (cis) or distally (trans) from their sites of transcription to 
influence gene expression. Both cis-acting and trans-acting lncRNAs are thought to fundamentally 
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function through the formation of RNA-protein, RNA-RNA, and/or RNA-DNA interactions. TF= 
transcription factor. RBP= RNA binding protein. 
 
 
One important example is XIST (X-Inactive Specific Transcript), which is 
amongst one of the first lncRNAs described (Brown et al. 1991). XIST plays a 
central role in orchestrating dosage compensation in mammals by driving the 
heterochromatinization of one of the two X chromosomes present in females in a 
process called X chromosome inactivation (XCI) (Sahakyan et al. 2018). XIST 
establishes XCI through multiple mechanisms involving specific interactions 
between XIST RNA and various protein complexes. Several chromatin modifying 
complexes interact with XIST, including PRC2 (Polycomb Repressive Complex 2) 
and SHARP (SMRT- and HDAC-Associated Repressor Protein), and contribute to 
epigenetically silencing the chromosome XIST is expressed from (Loda and Heard 
2019). In addition to facilitating epigenetic regulation, XIST also promotes cis 
repression by interacting with nuclear matrix components to recruit the silenced 
X chromosome to the transcriptionally repressive nuclear laminar compartment 
(Loda and Heard 2019; Chen et al. 2016). Thus, XIST is able to regulate gene 
expression in cis through recruiting and/or otherwise interacting with proteins 
that modulate gene expression. Though XIST is unique in its ability to drive 
chromosome-wide gene repression, this basic mechanism is broadly applicable to 
many nuclear acting lncRNAs, including lncRNAs that act in cis to activate gene 
expression (Werner et al. 2017; Gil and Ulitsky 2020), as well as those that regulate 
gene expression in trans. 
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Nuclear lncRNAs are uniquely poised to regulate gene regulation, as 
illustrated by XIST’s localization being intrinsically linked to its function in 
organizing XCI. The lncRNA Airn (Antisense Igf2r ncRNA) is another well-studied 
example of lncRNA-mediated cis regulation that drives this point home further. 
Airn is expressed from the Igf2r imprinted cluster and is important for the 
paternal imprinting of several protein coding genes in this locus, which Airn 
accomplishes through multiple mechanisms (Quinn and Chang 2015). Airn is 
oriented antisense to and overlapping Igf2r. The act of Airn being transcribed 
through Igf2r’s promoter is sufficient to repress Igf2r expression via 
transcriptional interference, strongly suggesting that Airn RNA is unlikely to be 
important for the silencing of Igf2r (Latos et al. 2012). Thus, Airn exemplifies one 
RNA-independent mechanism by which lncRNA loci can still exert cis-regulation: 
lncRNA biogenesis. However, Airn RNA may be important for silencing other 
genes in the Igf2r imprinted cluster, illustrating the potential multifunctionality of 
lncRNA loci. One proposed model for the silencing of Slc22a3, located upstream 
of Airn in the same cluster, is that Airn promotes epigenetic silencing through the 
recruitment of the H3K9 histone methyltransferase G9a (Nagano et al. 2008). 
Therefore, by virtue of both its genomic architecture and localization, the Airn 
lncRNA locus is able to modulate local gene expression in both RNA molecule-
dependent and RNA molecule-independent ways.  
It is important to note that these broad modes of lncRNA locus-mediated 
cis-regulation are not restricted to gene silencing, and have in fact been more 
widely described for lncRNA loci that positively influence the expression of their 
neighboring genes (Anderson et al. 2016; Engreitz et al. 2016; Werner et al. 2017; 
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Joung et al. 2017; Gil and Ulitsky 2020). Thus, there is a growing appreciation for 
the unique ability of nuclear lncRNAs to enact local gene regulation. Less clear is 
the broader impacts of lncRNA-mediated cis-regulation on gene regulatory 
networks as a whole, and, ultimately, how important lncRNA cis-regulation is for 
the myriad of biological processes lncRNAs have been implicated in.  
 
LncRNAs in cancer 
Historically, efforts to elucidate the molecular mechanisms underlying 
cancer pathogenesis have focused on genetic and epigenetic alterations in protein-
coding genes. However, several pieces of evidence suggest that lncRNAs may also 
be important contributors, discussed below and also recently reviewed in (Olivero 
and Dimitrova 2020). 
First, many lncRNA genes have been found to associate with disease-
associated genomic alterations, including single nucleotide polymorphisms (SNPs) 
and copy number variations (CNVs). One comparison of over 900 GWAS 
(Genome-Wide Association Studies) revealed that more than 90% of disease-
associated SNPs fall within noncoding regions (Maurano et al. 2012), though this 
is to some degree expected given the predominance of noncoding regions in the 
human genome. Nevertheless, multiple recent efforts to characterize noncoding 
transcription across the human genome have found that genomic regions encoding 
lncRNAs are enriched for trait-associated SNPs over background intergenic 
regions (Hangauer et al. 2013; Iyer et al. 2015). These observations suggest a 
possible link between lncRNA loci and disease-associated SNPs, though the 
significance of most of these associations remains to be determined.  
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A few examples of cancer-associated SNPs connected to lncRNA expression 
have been described. One such lncRNA locus is NBAT1 (Neuroblastoma 
Associated Transcript 1), in which a germline SNP located in NBAT1’s second 
intron is associated with high risk neuroblastoma and correlated with NBAT1 
expression (Pandey et al. 2014). Another example is the lncRNA ANRIL (Antisense 
Noncoding RNA in the INK4 Locus; also known as CDKN2B-AS), which is 
transcribed antisense to the CDKN2A/B locus (encoding the tumor suppressive 
proteins ARF, CDKN2A, and CDKN2B) (Kong et al. 2018). This complex locus 
harbors several cancer risk-associated SNPs, some of which interestingly associate 
with ANRIL expression levels, but not with those of its overlapping protein coding 
genes (Cunnington et al. 2010). As ANRIL expression is increased in many 
different cancers and associated with aggressive disease (Kong et al. 2018), 
exploring the ways these variants influence the regulation of this locus could be 
informative as a model for how such cancer-associated SNPs may mechanistically 
contribute to pathophysiology. 
 Cancer genomes are marked by genomic instability and frequently undergo 
amplifications or deletions leading to somatic CNVs (SCNVs) that can contribute 
further to malignancy. Common alterations in cancer cells include amplifications 
of oncogenes, such as MYC, and loss of tumor suppressor genes, such as those 
encoded by the CDKN2A/B locus (Beroukhim et al. 2010). Several lncRNAs have 
also been observed to exhibit SCNVs linked to tumorigenesis (Huarte 2015; Hu et 
al. 2014). LncRNA FAL1 (Focally Amplified lncRNA on Chromosome 1) was 
identified as one of nearly 3,000 lncRNA loci frequently exhibiting copy number 
alterations across thousands of patient tumor samples and is overamplified in 
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multiple cancers. Moreover, shRNA knockdown of lncRNA FAL1 was shown to 
restrict proliferation in vitro and restrict tumor growth in xenograft experiments 
in vivo, demonstrating the oncogenic consequences of overamplifying this lncRNA 
(Hu et al. 2014).   
PVT1 (Plasmacytoma Variant Translocation 1) is another lncRNA locus 
that is frequently over-amplified in cancer, most often with its nearest neighbor, 
the proto-oncogene MYC, which is located 70 kb upstream (Guan et al. 2007; 
Tseng et al. 2014). In one study, addition of a single extra copy of the genomic 
region spanning and including PVT1 and MYC but not MYC alone was shown to 
promote tumorigenesis in a breast cancer mouse model, whereas deleting the 
entire 300 kb PVT1-MYC locus in HCT116 cells reduced cellular proliferation and 
xenograft tumor growth (Tseng et al. 2014), suggesting that PVT1 cooperates with 
MYC to drive cancer. However, the complexity of this locus, which includes several 
regulatory DNA elements (Cho et al. 2018; Fulco et al. 2016) and multiple RNA 
isoforms of PVT1 (Olivero et al. 2020), make it somewhat difficult to interpret 
these data and say whether amplification of PVT1 RNA outright drives or 
suppresses tumorigenesis. It is likely that both tumor suppressive and oncogenic 
mechanisms are at play at this lncRNA locus. 
Lastly, it has long been appreciated that lncRNA expression patterns are 
often associated with many biological phenomena and/or cellular states. In one 
recent comprehensive analysis of over 7,000 RNA-seq datasets, spanning 27 
distinct human tissues and cancer states, nearly 60,000 human lncRNAs were 
identified. Of these lncRNAs, over 10,000 were found to be significantly 
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dysregulated (i.e. downregulated or upregulated) in various cancers compared to 
matched normal tissues. Furthermore, the authors were able to segregate cancers 
of similar tissues of origin by their lncRNA expression patterns, further 
demonstrating the exquisite disease-specificity lncRNAs can have (Iyer et al. 
2015). In some cases, lncRNA expression patterns can further be associated with 
specific features of cancer prognosis, such as recurrence (Zhou et al. 2018), 
metastasis (Ji et al. 2003), invasiveness (Lim et al. 2020), and overall survival 
(Gupta et al. 2010; Lim et al. 2020). 
 
Functional studies of cancer-associated lncRNAs 
Despite these key observations, the broader role of lncRNAs in cancer 
remains poorly understood, primarily due to fact that the majority of these cancer-
associated lncRNAs have not yet been functionally dissected using robust loss-of-
function (LOF) and gain-of-function (GOF) models. Whether lncRNA expression 
patterns are the drivers or transcriptional by-products of oncogenic 
transformation remains an open-ended question in the field (Olivero and 
Dimitrova 2020). Still, a handful of lncRNAs have been suggested to functionally 
contribute to cancer development, demonstrating the value of careful case-by-case 
interrogation of lncRNA loci. The following is a discussion of three illustrative 
examples. 
One well-studied example is MALAT1 (Metastasis Associated Lung 
Adenocarcinoma Transcript 1). MALAT1 is a highly abundant, conserved lncRNA 
that was initially identified in a screen for potential biomarkers for metastatic lung 
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cancer, in which high MALAT1 expression was found to be highly predictive of 
metastasis and overall poor prognosis in non-small cell lung cancer (NSCLC) 
patients (Ji et al. 2003). MALAT1 has since been observed to be upregulated in 
many human cancers and has been at the center of efforts to understand the ways 
in which lncRNAs can contribute to tumorigenesis [reviewed in (Zhang et al. 
2017)]. Early investigations into Malat1 function using mouse models of lung and 
breast cancer revealed that exogenous overexpression of Malat1 led to increased 
tumor growth and metastasis, whereas Malat1 loss [using antisense 
oligonucleotides (ASOs) or promoter deletion strategies (Zhang et al. 2012)] 
impaired these processes (Gutschner et al. 2013; Arun et al. 2016). These data 
provided some of the earliest functional evidence for a lncRNA directly influencing 
tumorigenesis in vivo. However, in more recent work, Malat1 knockout was shown 
to promote metastasis in the same murine breast cancer model. Even more 
remarkably, this pro-metastasis phenotype was rescued in a targeted Malat1 
overexpression transgenic mouse, suggesting a provocative tumor suppressive role 
for this lncRNA (Kim et al. 2018). Notably, this latter study used a different genetic 
model for Malat1 knockout, in which a LacZ and synthetic polyadenylation signal 
(LacZ+PAS) cassette was inserted roughly 100 bp downstream of Malat1’s 
endogenous transcription start site (TSS), leading to premature transcriptional 
termination of Malat1-Lacz without disrupting Malat1’s promoter. However, it is 
not immediately apparent why these two genetic Malat1 LOF models would yield 
completely opposing phenotypes. 
 Mechanistically, Malat1 localizes to nuclear speckles (Tripathi et al. 2010), 
where various roles in regulating transcription have been proposed. These include 
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modulating alternative splicing through interactions with splicing factors (Tripathi 
et al. 2010) and interacting with chromatin modifying complexes to promote the 
relocalization of genes from transcriptionally repressive to transcriptionally active 
nuclear bodies (Yang et al. 2011b). Moreover, mapping the genomic binding sites 
of MALAT1 RNA in human breast cancer cells using capture hybridization analysis 
of RNA targets (CHART) revealed that MALAT1 associates with sites of active 
transcription (West et al. 2014). Thus, while Malat1’s exact cellular functions 
remain unclear, it is likely that Malat1 acts as a nuclear RNA scaffold to coordinate 
gene expression, possibly in a tissue or otherwise context-specific manner. Equally 
unresolved is the precise role of Malat1 in tumorigenesis, perhaps in part due to 
this functional context-specificity. 
The lncRNA HOTAIR (HOX Transcript Antisense RNA) is another well-
studied transcript with altered expression across several cancers compared to 
normal tissues (Iyer et al. 2015; Kogo et al. 2011; Gupta et al. 2010). HOTAIR was 
initially found in a search for ncRNAs contributing to the temporal and spatial 
collinearity of vertebrate HOX gene expression and is expressed antisense to the 
HOXC gene cluster (Rinn et al. 2007). Similar to MALAT1, the molecular details of 
HOTAIR function remain incompletely understood, despite clear associations 
between HOTAIR expression and cancer. Early siRNA knockdown experiments 
and in vitro RNA pull down assays suggested that HOTAIR functions in trans to 
direct the localization of repressive chromatin modifying complexes (i.e. PRC2 and 
CoREST), leading to the epigenetic silencing of genes in the distally located HOXD 
cluster and elsewhere in the genome (Rinn et al. 2007; Tsai et al. 2010). HOTAIR 
has thus been proposed to contribute to tumorigenesis through driving aberrant 
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epigenetic alterations, and indeed high HOTAIR expression correlates with 
aggressive disease and/or poor prognosis in colorectal and breast cancers (Kogo et 
al. 2011; Gupta et al. 2010). Furthermore, exogenous overexpression of HOTAIR 
in murine breast cancer cells was shown to drive the metastatic potential of these 
cells in xenograft experiments and lead to global gene dysregulation, possibly 
through PRC2 (Gupta et al. 2010). However, more recent work has called into 
question the specificity of this proposed lncRNA-PRC2 interaction (Davidovich et 
al. 2013), or its necessity for HOTAIR’s ability to drive transcriptional repression 
(Portoso et al. 2017).  
Genetic dissections of HOTAIR function have also proven perplexing. In 
one mouse model in which murine Hotair had been deleted, HoxD gene 
derepression and apparent homeotic transformations consistent with 
dysregulated HoxD expression were observed (Li et al. 2013). This remarkable 
phenotype starkly contrasted with the essentially unchanged HoxD expression 
patterns observed in a second knockout mouse in which the entire HoxC cluster, 
including Hotair, had been ablated (Schorderet and Duboule 2011). Further 
characterization of these and additional Hotair knockout alleles (Lai et al. 2015) 
conclusively demonstrated that Hotair loss does not significantly affect mouse 
development or HoxD expression (Amândio et al. 2016). Nonetheless, these data 
suggesting the dispensability of Hotair in normal development do not preclude the 
possibility of HOTAIR dysregulation contributing to tumorigenesis, either through 




 One additional, well-studied lncRNA with ties to cancer is XIST. 
Correlative links between defects in XCI and cancer development have long been 
noted, such as the loss of Barr bodies seen in some advanced breast and ovarian 
cancers (Pageau et al. 2007). However, it wasn’t until the development of a 
conditional knockout mouse in which XIST was deleted in hematopoietic 
progenitor cells during embryogenesis, but after the establishment of XCI, that a 
direct link between XIST-mediated dosage compensation and tumor suppression 
was demonstrated in vivo. In these mice, hematopoietic XIST depletion leads to 
global gene dysregulation, including notable X-linked gene reactivation, and the 
rapid onset of female-specific hematologic cancer with 100% penetrance (Yildirim 
et al. 2013). The potential significance of aberrant XCI in other cancers remains to 
be seen.  
 In summary, several lines of evidence suggest that lncRNAs may contribute 
to cancer-related processes, in both oncogenic and tumor suppressive capacities. 
However, the number of lncRNAs demonstrated to be important in modulating 
tumorigenesis remains only a small fraction of the thousands of lncRNA 
transcripts that are expressed in the human and mouse transcriptomes (Iyer et al. 
2015; Djebali et al. 2012). More careful in vitro and in vivo dissections of candidate 
cancer-associated lncRNAs will be needed to determine whether correlative links 
to disease reflect true functional involvement, and ideally, opportunities for 





The p53 tumor suppressor pathway 
One approach to find functional lncRNAs involved in cancer that our group 
and others have adopted has been to look for lncRNAs regulated by key oncogenes 
[e.g. Myc (Kim et al. 2015; Marchese et al. 2016)] or tumor suppressors, such as 
p53 (reviewed below).  
p53, encoded by the TP53 gene in humans and Trp53 in mice, is an 
important tumor suppressor in the mammalian genome. One commonly used 
moniker for p53 is the “guardian of the genome,” due to its central role in sensing 
and responding to various cellular stressors (Kastenhuber and Lowe 2017; 
Vousden and Prives 2009). Mice deficient for p53 (Trp53-/- or Trp53+/-) are 
significantly more prone to spontaneous tumorigenesis (Donehower et al. 1992; 
Jacks et al. 1994), and human patients with germline mutations in TP53 suffer Li 
Fraumeni Syndrome, which is a disease marked by dramatically increased 
susceptibility to a broad spectrum of cancers (Olivier et al. 2010). Furthermore, 
p53 is the most frequently somatically mutated gene in human cancer and p53 loss 
is often associated with poor clinical indicators, such as advanced tumor grade and 
decreased survival (Kandoth et al. 2013). 
Key to p53’s tumor suppression is its function as a stress-stabilized 
transcription factor (Brady et al. 2011; Kaiser and Attardi 2018), though 
transcription-independent roles for cytosolic p53 in regulating mitochondrial 
permeabilization and apoptosis have also been observed (Speidel 2010). Indeed, 
most p53 mutations that arise in cancer are missense mutations that fall within 
p53 protein’s DNA binding domain (Kastenhuber and Lowe 2017), further 
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suggesting that the ability of p53 to bind to and regulate target genes is needed for 
tumor suppression. In unstressed cells, p53 protein is constitutively expressed but 
rapidly degraded. However, upon exposure to various types of stress (e.g. DNA 
damage, oncogene activation, hypoxia, nutrient-starvation), p53 protein 
accumulates. This is primarily due to the acquisition of post-translational 
modifications that disrupt interactions with its main negative regulator, Mdm2 
(Mouse double minute 2), which is an E3 ubiquitin ligase that promotes the 
proteasomal degradation of p53. The activation of ARF (Alternate Reading Frame 
of CDKN2A; also known as p14 in humans and p19 in mice) in response to 
oncogenic signaling is another central mechanism by which p53 protein is 
stabilized, as ARF binds to Mdm2 and further inhibits Mdm2-p53 interactions 
(Horn and Vousden 2007). Once stabilized, p53 transcriptionally regulates a wide 
network of genes by binding to specific DNA motifs known as p53 response 
elements (p53REs) found in the promoters or gene bodies of targets (Riley et al. 
2008).  
Activation of the p53 transcriptional network by stress can lead to a myriad 
of cellular outcomes and can paradoxically promote both survival and death, 
depending on various context-specific factors that are still incompletely 
understood. A non-exhaustive list of biological processes in which p53 has been 
implicated includes the so-called “canonical” p53 responses of apoptosis and cell 
cycle arrest, as well as more recently discovered roles in regulating autophagy, 
cellular metabolism, pluripotency, DNA repair, ferroptosis, and genome 
maintenance, to name a few examples [reviewed in (Kaiser and Attardi 2018; 
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Kruiswijk et al. 2015)]. Elucidating how the many different functions ascribed to 
p53 synergize to culminate in tumor suppression is a major area of research. 
Another unresolved question related to the remarkable functional diversity of p53 
is how this one transcription factor specifies so many different cellular outcomes, 
or in other words, what are the molecular determinants of p53 cell fate decision-
making? Perhaps unsurprisingly, decades of research have yet to uncover a single 
universally-applicable answer to this question (Kastenhuber and Lowe 2017). 
One setting this question has been explored in is comparing the p53 
outcomes of senescence and apoptosis, which are two alternative, permanent ways 
by which p53 limits aberrant growth to suppress tumorigenesis (Childs et al. 2014; 
Kaiser and Attardi 2018). Apoptosis, or programmed cell death, can be triggered 
by severe DNA damage (e.g. genotoxic compounds, irradiation) in many cell types, 
but can also be preferentially initiated in certain cell types in a more stress-agnostic 
manner (Lowe et al. 1993b; Ventura et al. 2007; Childs et al. 2014). In vivo, 
apoptosis can suppress tumor growth through the physical elimination of tumor 
cells (Ventura et al. 2007; Symonds et al. 1994). Senescence is a stable state of cell 
cycle arrest that is morphologically, epigenetically, and metabolically distinct from 
temporary or reversible cell cycle arrest (Campisi and d’Adda di Fagagna 2007). 
Multiple stress stimuli can promote senescence, most of which are tied to DNA 
damage signaling. For example, elevated levels of reactive oxygen species (ROS), 
genotoxic compounds, and, in human cells, natural telomere shortening (leading 
to what is referred to as “replicative senescence”) can all trigger senescence 
(Muñoz-Espín and Serrano 2014). Persistent oncogenic signaling can also trigger 
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senescence (sometimes referred to as “oncogene induced senescence” or OIS), 
likely through the activation of similar DNA damage signaling pathways by 
oncogene-driven defects in DNA replication or ROS production (Bartkova et al. 
2006; Di Micco et al. 2006; Muñoz-Espín and Serrano 2014). Senescence can have 
pleiotropic effects on tumorigenesis, at times promoting preneoplastic growth 
(Krtolica et al. 2001) or triggering tumor-permissive immune suppression through 
the secretion of a characteristic host of inflammatory molecules, extracellular 
matrix components, and growth factors known as SASP (senescence-associated 
secretory phenotype) (Ruhland et al. 2016; Muñoz-Espín and Serrano 2014). In 
other situations, senescence can serve to restrict hyperproliferation (Ventura et al. 
2007) or signal the immune clearance of tumor cells (Xue et al. 2007), contributing 
to tumor suppression. Thus, apoptosis and senescence are two p53-regulated 
cellular processes that are important for tumor suppression, though what factors 
govern the initiation of one versus the other in any given situation are unclear. 
Much effort has been exerted towards characterizing the p53 regulated 
transcriptome, hoping to identify either a core set of universal p53 targets central 
to tumor suppression or specific subsets of targets important for specific p53 
functions (discussed more in Chapter 2). One early proposed model for how the 
latter could come about was based on biochemical observations that p53 bound 
with higher affinity to the promoters of target genes involved in cell cycle arrest 
than those involved in apoptosis, suggesting that different thresholds of p53 levels 
could lead to the preferential activation of either high or low affinity targets, 
leading to cell cycle arrest or apoptosis, respectively (Weinberg et al. 2005; Hafner 
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et al. 2019). However, this line of thinking has been thrown into question as an 
increasing number of genome-wide analyses of p53-dependent gene regulation 
show that p53 outcome-specificity does not correlate with the activation of protein 
coding genes important for specific p53 functions (Fischer 2017; Andrysik et al. 
2017; Verfaillie et al. 2016). For example, p21 (encoded by the gene Cdkn1a) and 
Puma (encoded by Bbc3) are key mediators of p53-dependent cell cycle arrest 
(Brugarolas et al. 1995) and apoptosis (Nakano and Vousden 2001), respectively. 
However, both are consistently activated by p53 across many studies, irrespective 
of cell type, stressor, or ultimate p53 outcome initiated (Fischer 2017). Thus, one 
main take-away from these global analyses has been that p53 outcome-specificity 
is most likely driven by many different mechanisms and contingent upon the type, 
intensity, and/or duration of stress encountered, as well as by cell- or tissue-
specific factors (Hafner et al. 2019).  
Related to these context-specific determinants could be the activation of 
individual p53 targets with context-specific functions. Such targets may be 
overlooked in large-scale metanalyses of “universal” p53 targets due to either 
tissue- or stressor-specific activation. While the first p53 targets identified were 
protein coding genes, as our understanding of the breadth of the noncoding 
genome grows, so too has our appreciation for the numerous noncoding genes 
regulated by p53, first with the identification of microRNA targets of p53 (Raver-
Shapira et al. 2007; Vousden and Prives 2009) and more recently, lncRNAs. 
Elucidating how these newly emerging lncRNA targets fit into the broader p53 
network is an important, on-going area of research.  
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LncRNAs in the p53 pathway 
Several recent studies have employed a variety of transcriptome profiling 
techniques to identify p53-regulated lncRNAs, many of which will be discussed 
shortly. Most focus has been spent on lncRNAs that are transcriptionally activated 
by p53, though there is also some evidence for the repression of lncRNA loci by p53 
having physiological importance. For example, lncPRESS1 (p53 Regulated and 
Embryonic Stem cell Specific) is highly expressed in human embryonic stem cells 
and repressed by p53 during differentiation (Jain et al. 2016). shRNA-mediated 
knockdown of lncPRESS1 leads to loss of pluripotency and gene expression 
changes consistent with differentiation (Jain et al. 2016), suggesting that 
repression of lncPRESS1 may be an important aspect of p53’s general role in 
restricting pluripotency (Li et al. 2012; Kastenhuber and Lowe 2017). Nonetheless, 
most p53-regulated lncRNAs that have been shown to contribute to p53 pathway 
function are transcriptionally activated by p53. 
Below is a detailed catalogue of p53-activated lncRNAs, with a focus on 
lncRNA examples for which evidence of direct regulation by p53 has been 
experimentally provided (e.g. p53 binding at lncRNA associated p53REs, p53RE 
reporter assays). A comprehensive summary of direct p53-activated lncRNAs can 
also be found in Table 1.1. 
 
Nuclear-acting p53-activated lncRNAs 
Most p53-activated lncRNAs have been reported to play various roles in the 
nucleus. LincRNA-p21 was amongst the earliest identified p53-activated 
23 
 
lncRNAs, found to be upregulated in a p53-dependent manner in both genotoxic 
and oncogenic stress conditions, and is named after its genomic proximity to p21, 
located ~15 kb upstream in the mouse genome (Huarte et al. 2010). LincRNA-p21 
is conserved, and early siRNA knockdown studies suggested trans-acting roles for 
both mouse and human lincRNA-p21: driving global gene repression and 
apoptosis in mouse embryonic fibroblasts (MEFs) and repressing translation in 
Hela cells (Huarte et al. 2010; Yoon et al. 2012). However, subsequent experiments 
using either a genetically engineered mouse in which the lincRNA-p21 promoter 
had been deleted or ASO-mediated RNA knockdown suggested that lincRNA-p21 
acts solely to promote p21 expression in cis and that the global changes in gene 
expression observed upon lincRNA-p21 loss can be attributed to decreased p21 
expression (Dimitrova et al. 2014). It is worth noting that this more limited, local 
role for lincRNA-p21 is easier to reconcile with its low copy number per cell and 
spatial restriction to its site of transcription in MEFs. However, it is conceivable 
that human lincRNA-p21, which is exported into the cytoplasm, may have 
additional roles.  
Mechanism-wise, both lncRNA-mediated recruitment of hnRNP-K 
(Dimitrova et al. 2014) and DNA regulatory elements in the lincRNA-p21 locus 
(Groff et al. 2016) have been reported to contribute to the cis-activation of p21. 
Importantly, MEFs in which lincRNA-p21 has been either genetically or co-
transcriptionally depleted have a growth advantage (Dimitrova et al. 2014), 
consistent with defects in the G1/S checkpoint, demonstrating the potential for 
lncRNA locus-mediated cis-regulation to functionally contribute to p53-regulated 
cellular processes.  
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Pvt1b is a p53-induced isoform of Pvt1 and another lncRNA our group has 
recently demonstrated to regulate gene expression in cis downstream of p53 
activation. However, unlike lincRNA-p21’s reinforcing effect on p21 expression, 
Pvt1b activation leads to the repression of Myc, located roughly 50 kb upstream in 
mice. In MEFs and murine cancer cells, Pvt1b knockdown by ASOs or genetic 
disruption of Pvt1b’s p53RE leads to Myc derepression and increased proliferation 
in vitro. Most strikingly, in vivo targeting of Pvt1b’s p53RE leads to increased 
tumor growth in an autochthonous mouse model of lung cancer, suggesting that 
Pvt1b is an important lncRNA component of p53’s tumor suppressive 
transcriptional program (Olivero et al. 2020). Precisely how lincRNA-p21 and 
Pvt1b mediate positive and negative cis-regulation, respectively, remains 
incompletely understood and is likely locus-specific, involving both RNA-
dependent and -independent mechanisms (Olivero et al. 2020; Cho et al. 2018; 
Dimitrova et al. 2014; Groff et al. 2016). 
PANDA (p21 Associated NcRNA DNA Damage Activated) was originally 
identified in a tiling array screen for novel ncRNAs associated with cell cycle 
regulation and is transcribed roughly 5 kb upstream of and antisense to CDKN1A 
(p21) (Hung et al. 2011). In human fibroblasts, PANDA expression is induced by 
both DNA damage and oncogenic stress (Hung et al. 2011; Puvvula et al. 2014). 
Interestingly, PANDA does not seem to be conserved between humans and mice, 
despite the syntenic conservation of other p53-regulated lncRNAs encoded in the 
CDKN1A/Cdkln1a locus [e.g. LincRNA-p21, DINO (discussed below)]. PANDA has 
been reported to play multiple nuclear roles following p53 activation, mediated 
through interactions with transcription factors and chromatin modifying 
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complexes. In human fibroblasts exposed to DNA damage, PANDA was observed 
to limit DNA damage-induced apoptosis by sequestering the transcription factor 
NF-YA (Hung et al. 2011).  
In more recent work, PANDA was shown to regulate proliferation as well 
through distinct, context-specific mechanisms. In unstressed, proliferating human 
fibroblasts, PANDA interacts with hnRNP-U (Heterogeneous Nuclear 
Ribonucleoprotein U) and BMI1 (BMI1 proto-oncogene, Polycomb Ring Finger), 
which is a component of the repressive PRC1 complex. siRNA knockdown of 
PANDA in unstressed cells led to the derepression of several genes involved in cell 
cycle regulation and the onset of cellular arrest, suggesting that PANDA-hnRNP-
U-BMI1 interactions may be important for epigenetically silencing pro-arrest 
genes (Puvvula et al. 2014). In senescent human fibroblasts, PANDA was observed 
to interact with NF-YA and prevent NF-YA-mediated activation of pro-
proliferation genes (Puvvula et al. 2014). Interestingly, either siRNA knockdown 
of PANDA or dysregulation of NF-YA protein levels was sufficient to allow escape 
from senescence, although p21 levels were also reduced by PANDA knockdown. As 
p21 has a well-established role in promoting senescence (Serrano et al. 1997; 
Campisi and d’Adda di Fagagna 2007), it is difficult to disentangle the 
contributions of PANDA from this effect on p21 RNA. siRNAs have been previously 
shown to be able to reduce lncRNA transcription at the chromatin (Stojic et al. 
2016), posing the possibility that PANDA regulates p21 expression in cis (being 
located only 5 kb downstream). However, it is important to note that Hung et al. 
also used siRNAs to knockdown PANDA and did not see a concomitant effect on 
p21 RNA levels. Thus, this discrepancy highlights the difficulties of interpreting 
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siRNA experiments targeting nuclear lncRNAs. Unfortunately, genetic dissection 
of the PANDA locus is currently lacking, making it impossible to determine 
whether PANDA truly regulates p21 in cis during cellular stress, similar to 
lincRNA-p21.  
DINO (Damage Induced Noncoding) is a conserved lncRNA also expressed 
from the CDKN1A/Cdkn1a locus. In humans, DINO is transcribed divergently 
from the CDKN1A promoter, while mouse Dino is transcribed immediately 
upstream of Cdkn1a on the same strand. Though induced by both genotoxic and 
oncogenic stress, DINO levels are most drastically elevated in response to DNA 
damage, reaching several hundred copies per cell in human fibroblasts treated with 
Doxorubicin (Doxo) (Schmitt et al. 2016). Consequently, DINO has thus far been 
best characterized in the context of the p53 response to acute DNA damage. In 
Doxo-treated cells, DINO depletion by RNAi led to reduced p53 transcriptional 
activity and impaired damage-induced cell cycle arrest, suggesting that DINO was 
required for full activation of the p53 network. This contribution to p53’s 
transcriptional activity was further supported by experiments demonstrating that 
DINO directly interacts with and stabilizes p53 protein and that DINO RNA 
localizes to the p53REs of several direct p53 targets, perhaps reflecting a role in 
directing p53’s localization as well. Importantly, these data were further supported 
by experiments performed in MEFs isolated from a Dino promoter deletion mouse. 
Dino knockout MEFs treated with Doxo had less p53 protein, decreased p53 
transactivity, and increased cellular proliferation, consistent with Dino expression 
being important for robust p53 pathway function (Schmitt et al. 2016). 
Intriguingly, DINO levels were recently shown to also influence p53 protein 
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stability in primary human foreskin keratinocytes expressing viral oncogene 
HPV16 E7 (Sharma and Munger 2020). Whether DINO regulates p53 levels during 
oncogenic stress through mechanisms similar to or distinct from those employed 
during the DNA damage response remains to be investigated.    
Similar to DINO, PURPL (p53 Upregulated Regulator of p53 Levels) is a 
p53-activated lncRNA that in turn regulates p53 levels. PURPL was identified by 
RNA-seq as a nuclear-enriched, DNA damage-induced lncRNA in three human 
colorectal cancer cell lines (Li et al. 2017). Either genetic disruption of a PURPL-
associated p53RE in clonal HCT116 cells or ASO knockdown of PURPL in multiple 
human colorectal cancer cell lines led to increased p53 protein levels (Li et al. 
2017). These effects were observed both in the presence and absence of DNA 
damage, suggesting PURPL may be important for maintaining appropriately low 
levels of p53 in conditions of low stress. RNA pulldown and RNA 
immunoprecipitation experiments demonstrated that PURPL interacts with 
MYBBP1A and HuR, leading to the disruption of nucleoplasmic MYBBP1A-p53 
protein interactions and subsequent p53 protein destabilization. Functionally, 
PURPL loss was observed to decrease proliferation and increase apoptosis in vitro 
and limit tumor growth in xenograft experiments in vivo, consistent with increased 
p53 protein in the absence of PURPL (Li et al. 2017). Thus, PURPL is a p53-
activated lncRNA that negatively regulates p53 levels, perhaps to restrict improper 
p53 pathway activation.  
Linc-Pint (p53-Induced Transcript; also known as lincRNA-Mkln1) is a 
nuclear-enriched intergenic lncRNA that was first identified as a direct p53 target 
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induced by genotoxic and oncogenic stress in the same microarray profiling 
experiment that uncovered lincRNA-p21 (Huarte et al. 2010; Marín-Béjar et al. 
2013). Under conditions of genotoxic stress, ASO knockdown of linc-Pint in MEFs 
and lung cancer cells led to decreased proliferation and increased apoptosis. 
Moreover, exogenous overexpression of linc-pint from a retroviral transgene 
rescued this phenotype, suggesting linc-pint acts in trans downstream of p53 
activation to modulate growth and survival (Marín-Béjar et al. 2013). Mice in 
which linc-Pint expression was ablated through a LacZ reporter knockin were 
significantly smaller than controls, further suggesting a role for this lncRNA in 
growth regulation (Sauvageau et al. 2013). Murine linc-Pint and human orthologue 
LINC-PINT have both been reported to interact with PRC2 and regulate the 
repression of gene networks related to proliferation, survival, and invasion (Khalil 
et al. 2009; Marín-Béjar et al. 2013, 2017). In line with this, ASO knockdown of 
LINC-PINT also increased proliferation in multiple human cancer cell lines, while 
exogenous overexpression decreased proliferation and invasion in vitro and 
decreased tumor growth and metastasis in vivo in xenograft and liver metastasis 
mouse models, respectively (Marín-Béjar et al. 2017). Intriguingly, a short, highly 
conserved region located within exon 2 of LINC-PINT was shown to be necessary 
and sufficient for this anti-invasion phenotype in human colorectal cancer cells 
(Marín-Béjar et al. 2017). However, these data must be considered in the context 
of recent reports of an exon 2-encoded micropeptide with anti-proliferative effects 
expressed from a circular isoform of LINC-PINT (Zhang et al. 2018). Nevertheless, 
these studies suggest that the linc-Pint/LINC-PINT locus may play a tumor 
suppressive role downstream of p53. 
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NEAT1 (Nuclear Enriched Abundant Transcript 1) is a highly abundant, 
conserved lncRNA and is best known as an integral architectural component of 
nuclear paraspeckles. The functional role of Neat1 in these nuclear bodies is still 
incompletely understood but likely related to the regulation of gene expression 
(Sunwoo et al. 2009; Clemson et al. 2009; West et al. 2014). Neat1 knockout mice 
are viable and develop largely normally, barring subtle defects in mammary gland 
and corpus luteum development (Nakagawa et al. 2011; Standaert et al. 2014; 
Nakagawa et al. 2014). These data suggest that Neat1 and/or paraspeckles may not 
be functionally important under normal physiological conditions but do not 
preclude their importance during stress.  
In support of this hypothesis, Neat1/NEAT1 is a direct target of p53 and is 
induced by DNA damage in multiple mouse and human primary and transformed 
cell lines (Mello et al. 2017; Adriaens et al. 2016). In one study, Neat1 knockout 
mice were observed to be resistant to carcinogen-induced skin cancer and skin 
keratinocytes in carcinogen-exposed knockout mice were seen to proliferate more 
slowly than WT controls. These data suggest that Neat1 acts as an oncogene in this 
context, likely by preventing the accumulation of DNA damage that would lead to 
p53 stabilization and tumor cell death in WT mice (Adriaens et al. 2016). Tumor 
suppressive functions have also been ascribed to Neat1 post-p53 activation. In 
MEFs expressing the oncogenes E1A and HRasV12, Neat1 knockout promoted 
cellular transformation, while exogenous overexpression of Neat1 decreased 
transformation, similar to the effects of p53 loss and overexpression in these cells, 
respectively (Mello et al. 2017). Neat1 loss also promoted in vivo pancreatic cancer 
initiation in a genetically engineered mouse model of pancreatic ductal 
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adenocarcinoma, further suggesting that Neat1 may be an important downstream 
mediator of p53 tumor suppression in some settings (Mello et al. 2017). Thus, like 
many lncRNAs, the contributions of Neat1 to stress responses downstream of p53 
activation are likely to be context-specific.   
 TUG1 (Taurine Upregulated Gene 1) was originally characterized as a 
regulator of retinal development (Young et al. 2005) but has since been linked to 
many biological processes, including tumorigenesis. TUG1 has been reported to 
regulate gene expression through multiple mechanisms, including sponging 
miRNAs (Zhou et al. 2019) and recruiting repressive chromatin modifying 
complexes to genomic loci (Khalil et al. 2009; Zhang et al. 2014; Zhou et al. 2019). 
Within the p53 network, TUG1 is activated by p53 under conditions of genotoxic 
stress in multiple primary and transformed cell lines (Guttman et al. 2009; Zhang 
et al. 2014). RNAi knockdown of TUG1 in human NSCLC cells led to increased 
proliferation in vitro and increased tumor growth in xenograft mouse experiments, 
possibly through the epigenetic derepression of HOXB7 (Zhang et al. 2014). While 
these data suggest that TUG1 plays a tumor suppressive role downstream of p53 in 
these cells, it is important to note that both oncogenic and tumor suppressive roles 
have been observed for this lncRNA in other human cancer cell lines (Zhou et al. 
2019), suggesting that TUG1 function may be highly context-specific. TUG1 is 
conserved in mice as well, and interestingly, a LacZ replacement Tug1 knockout 
mouse was shown to have impaired spermatogenesis with no other obvious gross 
morphological defects (Lewandowski et al. 2020; Sauvageau et al. 2013), though it 
is difficult to say whether this spermatogenesis phenotype stemmed from the loss 
of Tug1 expression or the genetic disruption of its neighboring gene, Morc2a, with 
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which Tug1 shares a promoter. Nevertheless, this study illuminated the complexity 
of the Tug1 genomic locus, which was revealed to contain previously unappreciated 
cis-regulatory DNA elements and a conserved, expressed micropeptide 
(Lewandowski et al. 2020). Employing similar genetic strategies in the context of 
cellular stress will shed further light on the ways these trans- and cis-acting 
components of the Tug1/TUG1 locus contribute to cellular processes within the 
p53 pathway and beyond.  
A recent genome-wide assessment of HCT116 cells treated with DNA 
damage identified several p53-regulated (PR) lncRNAs, including two that were 
further characterized and named PR-lncRNA 1 and PR-lncRNA 10 (Sánchez et 
al. 2014). Both PR-lncRNAs were shown to be required for robust p53 transactivity 
in response to genotoxic stress, as ASO knockdown of either led to decreased 
induction of several p53 targets. Consistent with decreased p53 activity, PR-
lncRNA depleted HCT116 cells grew more quickly and were more resistant to DNA 
damage-induced apoptosis (Sánchez et al. 2014). The mechanisms by which these 
two lncRNAs regulate p53 activity are still unclear, though it is worth noting that 
our own closer examination of PR-lncRNA 1’s sequence revealed the presence of 
two highly conserved sORFs, one conserved amongst primates and a second 
conserved through mice at both the amino acid and nucleotide levels. This raises 
the possibility of PR-lncRNA 1 representing a micropeptide-encoding lncRNA, as 
has been described at the Tug1 locus and other lncRNA loci (Lewandowski et al. 
2020; Anderson et al. 2015; Zhang et al. 2018). The development of additional, 
genetic LOF models could greatly facilitate addressing this and other questions 
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regarding how these lncRNA loci contribute to p53 pathway function, as well as 
directly test their importance in tumor suppression.  
In addition to binding to promoters and gene bodies, p53 also frequently 
associates with enhancers (Melo et al. 2013; Allen et al. 2014; Younger et al. 2015). 
This enhancer binding activity can be important for modulating the expression of 
distally located protein coding and lncRNA genes (Melo et al. 2013, 2016). Linc-
475 is one lncRNA regulated by a p53 bound enhancer and is induced by genotoxic 
stress in human breast cancer and melanoma cell lines. Both siRNAs and CRISPR-
Cas9 deletion of the p53 bound enhancer element in clonal MCF7 cells led to 
depleted linc-475 levels and cell cycle defects that could be attributed to decreased 
p21 levels (Melo et al. 2016). Further experiments demonstrated that less RNA Pol 
II and p53 were present at p21’s promoter in the absence of linc-475, suggesting 
that this lncRNA is important for optimal p21 induction, and subsequently a robust 
cell cycle arrest response to DNA damage. How linc-475 exerts this apparent trans 
nuclear function is unclear.  
LED (LncRNA Activator of Enhancer Domains) is another lncRNA 
associated with p53 activity at enhancers. LED is activated by DNA damage in a 
p53-dependent manner in multiple human cancer cell lines (Léveillé et al. 2015; 
Allen et al. 2014). siRNA knockdown of LED in MCF7 cells led to the dysregulation 
of hundreds of genes and increased proliferation. This could be explained in part 
by significantly less p21 levels in LED depleted cells. In a transcriptional reporter 
assay, LED knockdown was shown to decrease the transcriptional activity of a p53 
bound enhancer associated with p21, suggesting that LED promoted p21 
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expression by affecting the activity of this p53 bound enhancer, possibly through 
regulating H3K9 acetylation (Léveillé et al. 2015). As LED RNA also associated 
with hundreds of sites in the human genome and LED knockdown correlated with 
decreased enhancer RNA (eRNA) production from several other p53-responsive 
enhancers, LED seems to be an important lncRNA mediator of p53-dependent 
enhancer activation through yet-to-be fully fleshed out mechanisms (Léveillé et al. 
2015). Interestingly, LED’s promoter is often hypermethylated in cancer, 
particularly in acute lymphocytic leukemia, suggesting that epigenetic 
dysregulation of this lncRNA is associated with disease (Léveillé et al. 2015).  
PINCR (p53-Induced Noncoding RNA) is another lncRNA directly 
activated by p53 and linked to enhancer activity (Chaudhary et al. 2017). PINCR 
was identified as a lncRNA induced by DNA damage in a panel of human colorectal 
cancer cell lines, and ASO knockdown or genetic PINCR knockout in clonal cell 
lines was observed to sensitize cells to stress-induced apoptosis. Interestingly, 
exogenous overexpression of PINCR was able to partially rescue this phenotype, 
suggesting a trans-acting mechanism for PINCR. Transcriptomic analysis revealed 
that PINCR depletion impaired the DNA damage-dependent induction of several 
p53 target genes involved in cell cycle arrest and survival. Mechanistic studies 
revealed that PINCR interacts with nuclear matrix component Matrin 3, likely 
facilitated by six Matrin 3 binding motifs present in PINCR RNA, and that PINCR-
Matrin 3 interactions were important for p53 binding to enhancers associated with 
three tested p53 target genes (Chaudhary et al. 2017). Thus, PINCR appears to act 
as an RNA scaffold to facilitate interactions between some p53 regulated genes and 
distal enhancers during the p53 response to DNA damage. How pervasive this 
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transcriptional co-activator role is throughout the genome or its importance in 
other biological contexts remains an interesting open-ended question.  
 
Cytoplasmic-acting p53-activated lncRNAs 
Given that most p53-regulated lncRNAs identified thus far are 
predominantly nuclear localized and appear to exert nuclear functions, less is 
known about the role(s) p53-activated lncRNAs play in the cytoplasm. Below are 
two examples for which we have some mechanistic understanding.  
GUARDIN is a lncRNA activated by p53 during the DNA damage response 
and has been implicated in modulating p53’s genome maintenance functions (Hu 
et al. 2018). In multiple human cancer cell lines, shRNA knockdown of GUARDIN 
led to decreased proliferation and increased cell death in vitro, and GUARDIN 
depleted HCT116 cells contributed to significantly smaller tumors in xenograft 
mouse experiments. Interestingly, GUARDIN knockdown only affected cell 
viability in p53-proficient cells, suggesting that GUARDIN tempers the cytotoxic 
effects of p53 stabilization in some cancer cells. In line with this, exogenous 
overexpression of GUARDIN was sufficient to reverse this p53-dependent 
cytotoxicity in one human NSCLC cell line (Hu et al. 2018). Mechanism-wise, 
GUARDIN was shown to promote genome stability and cell survival under 
conditions of genotoxic stress in multiple ways. These include stabilizing TERF2 
(Telomeric Repeat Binding Factor 2) by sequestering mir23a (TERF2 being an 
important component of the telomere protecting Shelterin complex) and 
stabilizing BRCA1 (Breast Cancer Type 1), which plays a central role in DNA repair, 
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by facilitating interactions between BRCA1 and its stabilizing binding partner 
BARD1 (BRCA1 Associated RING Domain 1) (Hu et al. 2018). Thus, GUARDIN 
acts in the cytoplasm to post-transcriptionally regulate multiple targets involved 
in genome maintenance and repair. 
LincRNA-RoR (Regulator of Reprogramming) was first identified in a 
microarray screen for lincRNAs involved in pluripotency, where it was 
demonstrated to positively regulate reprogramming through RNAi LOF and 
exogenous overexpression GOF experiments (Loewer et al. 2010). Later work 
revealed that lincRNA-RoR is directly activated by p53 in human cancer cell lines 
treated with DNA damage and that, intriguingly, lincRNA-RoR and p53 protein 
levels are negatively correlated (Zhang et al. 2013a). siRNA knockdown and 
transgene overexpression experiments demonstrated that lincRNA-RoR 
negatively regulates DNA damage-induced p53 translation, likely through 
interacting with phosphorylated hnRNP-I (also known as PTBP1) in the cytoplasm 
(Zhang et al. 2013a). hnRNP-I has been previously shown to bind to p53 mRNA 
and regulate cap-independent p53 translation (Grover et al. 2008), which is an 
important aspect of p53’s activation during stress (Halaby et al. 2015), suggesting 
that lincRNA-RoR may interfere with this stress-driven p53 activation. Indeed, 
lincRNA-RoR overexpression reduced apoptosis and prevented cell cycle arrest in 
cells exposed to genotoxic stress, suggesting that lincRNA-RoR GOF prevented 
robust p53 pathway activation. Thus, lincRNA-RoR represents yet another p53-
activated lncRNA that adjusts the p53 response to DNA damage by tuning p53 




Despite decades of research, many questions regarding how p53 senses and 
responds to such a wide range of stress inputs to suppress tumorigenesis remain 
incompletely answered. Studying lncRNAs in the p53 network can provide 
valuable new insights into these old questions, as well as provide perspective on 
the roles lncRNAs may play in cancer more broadly. The above examples illustrate 
the many ways by which p53-activated lncRNAs can contribute to p53 pathway 
function. In reviewing in vitro, and when available, in vivo functional 
characterization data regarding these lncRNAs, it becomes readily apparent that 
p53-activated lncRNAs can perform many diverse functions through a myriad of 
mechanisms of action. One over-arching theme that emerges, however, is that 
lncRNA loci often modulate the transcriptional output of the p53 network, whether 
globally (e.g. by modulating p53 protein levels or p53 transactivity), at a limited 
subset of p53 targets, or on an individual locus basis. Another commonality that 
emerges is that p53-activated lncRNAs often have tissue- or stress-specific 
functions. To this point, it is important to note that most searches for p53-activated 
lncRNAs have focused on lncRNAs induced in response to DNA damage. The 
functional characterizations of lncRNAs in other stressor contexts has the potential 
to expand our understanding of the ways in which the p53 network integrates and 
responds to different stresses. Nevertheless, this growing body of work suggests 
that p53-activated lncRNAs add an important regulatory layer to the p53 network 
and may represent an underexplored pool of “effectors” of p53 pathway function(s) 
and/or tumor suppression.  
37 
 
Table 1.1: LncRNAs reported to be directly activated by p53 
 
Cons= conservation (m= mouse; h= human); Geno= genotoxic stress; Onco= oncogenic stress 
LncRNA Cons Context 
studied 
Proposed function(s) in  
p53 pathway 
Ref(s) 
DINO m & h Geno Nuclear: Promote p53 transactivation; 
(Unknown): Promote p53 protein stability  
ensure robustness of p53 response to DNA 
damage 
(Schmitt et al. 
2016) 
GUARDIN h Geno Cytoplasmic: Stabilize TERF2 by sponging 
mir23a; stabilize BRCA1-BARD1 interactions  
promote genome stability and survival 
(Hu et al. 
2018) 
LED h Onco Nuclear: Promote enhancer activity at a subset 
of p53-responsive enhancers; promote p21 
expression   regulate proliferation 
(Léveillé et al. 
2015) 
Linc-475 h Onco Nuclear: Promote p21 expression  regulate 
proliferation and oncogene-induced senescence 
(Melo et al. 
2016) 
Linc-Pint m & h Geno; 
Onco 
Nuclear: Recruit PRC2 to epigenetically 
silence a network of genes  restrict 
proliferation and invasion 
(Huarte et al. 
2010; Marín-




m & h Geno Nuclear: Positive cis-regulation of p21  G1/S 
check-point reinforcement.  
Cytoplasmic: (human) Repress translation 
(Dimitrova et 
al. 2014; Yoon 
et al. 2012; 




m & h Geno Cytoplasmic: Repress p53 translation during 
stress  restrict p53 pathway activation 
(Zhang et al. 
2013a) 
Loc285194 h Geno Cytoplasmic: Negatively regulate miR-211  
restrict cellular proliferation 
(Liu et al. 
2013b) 
Neat1 m & h Geno; 
Onco 
Nuclear: (1) Dampen DNA damage response 
 restrict p53 stabilization; promote 
tumorigenesis in vivo (2) Regulate global gene 
expression restrict transformation in vitro 
and tumorigenesis in vivo 
(Adriaens et 
al. 2016; Mello 
et al. 2017) 
PANDA h Geno; 
Onco 
Nuclear: (1) Sequester NF-YA  promote 
survival or restrict proliferation; (2) Recruit 
hnRNP-U and BMI1 to repress a subset of genes 
 promote proliferation 
(Hung et al. 
2011; Puvvula 
et al. 2014) 
PR-lncRNA 
1 
m & h Geno Nuclear: Promote p53 transactivation  
ensure robustness of p53 response to DNA 
damage 




h Geno Nuclear: Promote p53 transactivation  
ensure robustness of p53 response to DNA 
damage 
(Sánchez et al. 
2014) 
PINCR h Geno Nuclear: Promote promoter-enhancer 
interactions at a subset of p53 targets through 
Matrin 3 interactions promote survival 
(Chaudhary et 
al. 2017) 
PURPL h Geno; 
Onco 
Nuclear: Destabilize p53 protein in low stress 
conditions  regulate proliferation and 
promote survival 
(Li et al. 2017) 
Pvt1b m & h Geno; 
Onco 
Nuclear: Negative cis-regulation of Myc  
restrict proliferation in vitro and tumorigenesis 
in vivo 
(Olivero et al. 
2020) 
TUG1 m & h Onco Nuclear: Recruit epigenetic machinery to 
repress HOX7B  restrict proliferation 
(Zhang et al. 
2014) 
TRMP h Onco Cytoplasmic: Suppress IRES-dependent p27 
translation  regulate proliferation  








LncRNAs are increasingly being implicated in a wide array of complex 
cellular and organismal processes [see Chapter 1; also recently reviewed in (Yao 
et al. 2019)]. Most lncRNAs have been proposed to function by regulating gene 
expression through a variety of mechanisms, including influencing transcription 
(Dimitrova et al. 2014; Marín-Béjar et al. 2013; Melo et al. 2016), post-
transcriptionally regulating mRNA localization, stability, or translation (Hu et al. 
2018; Kretz et al. 2013; Carrieri et al. 2012), or post-translationally modulating 
protein localization or stability (Li et al. 2017; Schmitt et al. 2016; Hung et al. 2011; 
Lee et al. 2016; Hu et al. 2018). Additionally, many lncRNAs are dysregulated in 
numerous diseases, including several human cancers (Iyer et al. 2015; Olivero and 
Dimitrova 2020), suggesting that lncRNA expression could be tied to cancer 
pathogenesis. However, the importance of lncRNA-mediated gene regulation in 
human health and disease is incompletely understood.  
P53 is a universal tumor suppressor that transactivates a wide network of 
protein coding and noncoding target genes in response to stress to restrict 
tumorigenesis (Vousden and Prives 2009). As reviewed in Chapter 1, several 
studies within the past decade have identified lncRNAs that are transcriptionally 
activated by p53 and important for various p53-regulated processes. However, 
comparisons across studies in which individual p53-activated lncRNAs are 
characterized make it difficult to gain an accurate sense of the true extent to which 
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lncRNAs contribute to the p53 pathway. Additionally, a comprehensive 
understanding of the mechanisms by which p53-activated lncRNAs modulate this 
important transcriptional network is also lacking. This is in part due to the fact that 
most genome-wide searches for p53-regulated lncRNAs have been performed in 
the context of genotoxic stress (i.e. stress induced by DNA damaging agents) (see 
Table 1.1). p53 can also be activated by the aberrant expression of oncogenes (e.g. 
over-amplification or the acquisition of constitutively activating mutations) 
(Serrano et al. 1997; Horn and Vousden 2007), which leads to cellular 
hyperproliferation and a multifaceted stress called oncogenic stress. Key 
characteristics of oncogenic stress that lead to p53 stabilization include the 
persistent activation of mitogenic and DNA damage response pathways (Bartkova 
et al. 2006; Di Micco et al. 2006; Meek 2009; Collado and Serrano 2010).    
Seminal work from the Attardi lab (Stanford) suggests that the p53 
transcriptional response to oncogenic stress is likely distinct from that initiated by 
acute DNA damage. p53 regulates transcription through two transactivation 
domains (TADs) (Sullivan et al. 2018). Simultaneous mutation of both TADs 
significantly impairs the ability of mouse embryonic fibroblast (MEFs) to respond 
to either genotoxic or oncogenic stress, as p53’s ability to activate a robust p53 
network is severely compromised. Double TAD mutated p53 is also unable to 
suppress tumorigenesis in vivo in cancers of multiple tissues of origin, reinforcing 
the importance of p53-dependent transcriptional regulation in tumor suppression 
(Brady et al. 2011; Jiang et al. 2011).   
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However, the cellular consequences of mutating either TAD independently 
are surprisingly dependent on the type of stressor faced, despite both TAD 
mutations compromising p53 activation to varying extents (Brady et al. 2011). In 
MEFs exposed to genotoxic stress, loss of TAD1 is sufficient to significantly impair 
DNA damage-induced cell cycle arrest and apoptosis. In contrast, TAD1 mutation 
does not impede the initiation of oncogene-induced senescence in MEFs, 
suggesting that the antiproliferative p53 response to oncogenic signaling does not 
rely on the same p53 targets as the response to genotoxic stress (Brady et al. 2011). 
Interestingly, the lncRNA Neat1 is one p53 target that has been reported to 
function in a similar, stress-specific manner, namely in that Neat1 activation 
downstream of genotoxic stress is dispensable for the p53 response to DNA 
damage but essential for p53 pathway function in response to oncogene-induced 
cellular transformation (Mello et al. 2017). These observations beg the question 
whether a distinct cohort of lncRNAs are activated by p53 during the response to 
oncogenic stress. 
Another set of related, important questions in the p53 field is what 
determines the spectrum of targets that are activated by p53 in any given setting 
and how target selection relates to the distinct downstream cellular outcomes of 
p53 activation. In an effort to address these questions, recent years have seen many 
research groups employ genome-wide p53 binding and RNA profiling to 
characterize the p53 transcriptional response across a number of biological 
contexts. These include the response to genotoxic stress (Kenzelmann Broz et al. 
2013; Younger et al. 2015; Li et al. 2012; Catizone et al. 2019; Zhang et al. 2013b), 
as well as the p53 response to oncogenic signaling, either by pharmacologically 
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stabilizing p53 in cancer cell lines or driving the overexpression of specific 
oncogenes (Allen et al. 2014; Tonelli et al. 2017; Andrysik et al. 2017; Menendez et 
al. 2013). Table 2.1 provides a detailed catalogue and cross-study comparison of 
these genome-wide profiling experiments. 
However, despite the variety of biological settings sampled, disentangling 
the contributions of cell type-intrinsic versus stimuli-intrinsic effects of p53 
activation has proven extremely challenging. Some studies have concluded that 
p53 function is primarily determined by the type of stress stimuli encountered 
(Menendez et al. 2013). Others have suggested that cell identity plays a pivotal role 
in determining where p53 binds in the genome (Nikulenkov et al. 2012; Botcheva 
and McCorkle 2014) and/or which genes are transactivated (Tonelli et al. 2017; 
Catizone et al. 2019; Zhang et al. 2013b), regardless of stress stimuli or ultimate 
cellular outcome. In contrast to both models, one recent metanalysis of fifteen 
human p53 ChIP-Seq datasets observed that p53 binding is largely invariant, 
irrespective of either cell or stimuli identity (Verfaillie et al. 2016). However, eleven 
of the datasets analyzed in this study were collected under genotoxic conditions, 
highlighting the need for further investigation of the p53 response to oncogenic 
stress. Especially lacking in the field are comparisons across diverse tumor types. 
In order to answer these important questions related to p53-regulated 
lncRNAs and broader p53 pathway function, my research broadly aimed to (1) 
characterize the p53 transcriptional response to oncogenic stress, and (2) identify 
and functionally interrogate the contributions of p53-activated lncRNAs in a 
number of cellular responses triggered by oncogenic stress. In Chapter 3, I work 
42 
 
towards addressing these aims through surveying the p53-regulated 
transcriptomes of three different tumor types, revealing important principles of 
gene regulation in the p53 pathway and implications for lncRNAs in these 
processes. In Chapter 4 and Chapter 5, I focus on the careful molecular 
dissection of several p53-activated lncRNA loci identified in Chapter 3 to further 
address aim (2), namely asking whether lncRNAs function downstream of p53 to 
modulate the decision between initiating apoptosis or senescence in response to 




Central to this work were two in vitro model systems for the study of p53 
pathway function. To model the p53-dependent response to oncogenic stress, we 
took advantage of a well-established genetically engineered mouse model of p53-
driven tumorigenesis: the KrasLA2-G12D/+; p53LSL/LSL; Rosa26-CreERT2 (KPR) 
mouse (Ventura et al. 2007; Feldser et al. 2010). In this mouse, p53 has been 
genetically inactivated by the insertion of a loxP-flanked transcription-translation 
STOP cassette into the first intron of both Trp53 alleles, leading the complete loss 
of p53 expression (Ventura et al. 2007). Additionally, KrasG12D (i.e. a constitutively 
active oncogenic mutant of Kras) is spontaneously activated in vivo through 
somatic recombination at a targeted KrasLA2-G12D allele. This leads to the 
heterozygous expression of KrasG12D in a subset of cells throughout the mouse 
(Johnson et al. 2001). Importantly, somatic TP53 and KRAS mutations are often 
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concurrent in many human cancers, especially in adenocarcinomas of the lung and 
other tissues, making this model of oncogenic stress clinically relevant (The Cancer 
Genome Atlas).  
Loss of p53 and gain of oncogenic KrasG12D leads to the rapid development 
of a spectrum of cancers in KPR mice, including lung adenocarcinomas, thymic 
lymphomas, and sarcomas (Johnson et al. 2001), from which cell lines can be 
established. Importantly, p53 expression can be restored in KPR mice or tumor-
derived cell lines by administering 4-hydroxytamxifen (Tam), which drives the 
nuclear translocation of CreERT2 expressed from the Rosa-26 locus, leading to the 
excision of the STOP cassette (Ventura et al. 2007; Feldser et al. 2010). Thus, the 
KPR mouse represents an ideal model for studying p53-dependent gene regulation 
and p53 pathway function downstream of oncogenic stress. The use of this model 
in probing p53 outcome-specificity is discussed further in Chapter 3. 
 
Genotoxic stress 
As Table 2.1 illustrates, p53 has been most extensively studied in the 
context of genotoxic stress. While this is undoubtedly an important area of 
research in its own right, this predominance is also likely in part due to the fact 
that many of the earliest insights into p53’s cellular functions were made in the 
context of the DNA damage response (Kastan et al. 1992; Lowe et al. 1993b; 
Brugarolas et al. 1995). MEFs exposed to various genotoxic insults (e.g. ionizing 
irradiation, UV, pharmacological compounds) represent a long-established in 
vitro system for studying novel components of the p53 pathway. As such, MEFs 
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have well-characterized p53 cellular responses and well-established assays for 
testing various p53 functions (Attardi et al. 2004; Lowe et al. 1994). MEFs exposed 
to the Doxorubicin (Doxo; a chemotherapeutic topoisomerase II inhibitor) served 
as a complementary in vitro system for probing the functions of multiple newly-
identified p53-activated lncRNAs within this work. 
 
Tools for the study of lncRNA loci 
As the study of lncRNAs matures as a field, it is becoming increasingly clear 
that experimental approaches to manipulate lncRNA expression must be tailored 
to the specific lncRNA locus under study, often more so than for protein coding 
genes. The following is a brief discussion of the merits and caveats of common 
lncRNA loss-of-function and gain-of-function strategies, many of which were 
employed in this work.   
 
LncRNA loss-of-function (LOF) 
While the ease of genetic manipulation has been greatly augmented in 
recent years by CRISPR-Cas9 technology, effective genetic inactivation of lncRNA 
loci is still challenging. This is due to the fact that our understanding of the RNA 
sequences important for lncRNA function remains imprecise. Genetic lncRNA 
knockouts have, by necessity, most often consisted of large-scale promoter or gene 
body deletions (Bassett et al. 2014; Kopp and Mendell 2018), unlike the targeting 
of protein coding genes which can be functionally inactivated by introducing small 
insertions and deletions that disrupt open reading frames (ORFs). One important 
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caveat of these large-scale deletion models is that potentially important DNA 
elements are also ablated along with lncRNA expression. Additionally, deletions 
targeting annotated promoters may not completely abrogate the use of alternative 
lncRNA transcription start sites. Thus, while large-scale deletions can be an 
effective LOF strategy for the initial characterization of a novel lncRNA locus, more 
precise genetic strategies are more ideal and, increasingly, more common. Two 
such strategies are inserting premature transcription termination signals or 
deleting more limited sequences (e.g. splice sites, DNA regulatory motifs). 
CRISPR-Cas9 based epigenetic inhibition (CRISPRi) (Gilbert et al. 2013) has also 
proven to be a useful alternative or complementary approach for stably 
inactivating lncRNA loci (Kopp and Mendell 2018).  
Another vital consideration for performing lncRNA LOF experiments is 
endogenous lncRNA localization. RNA interference (RNAi) is one common 
strategy for lncRNA LOF and has been historically used to target both cytoplasmic 
and nuclear lncRNAs. However, the efficacy of RNAi in targeting nuclear lncRNAs 
(or nuclear subpopulations of lncRNAs) has been called into question (Lennox and 
Behlke 2016), making the results of some of these lncRNA studies difficult to 
interpret. Antisense oligonucleotides (ASOs) are a commonly used alternative to 
RNAi and work to deplete RNA levels by triggering endogenous nuclear RNase H 
activity, leading to co-transcriptional RNA degradation and potentially premature 
transcriptional termination (Lai et al. 2020; Lee and Mendell 2020). Thus, 
depending on ASO design, ASO-mediated knockdown alone can be insufficient to 
determine whether an observed phenotype is through the loss of a lncRNA 
transcript or disrupted lncRNA biogenesis (i.e. perturbed transcription, splicing). 
46 
 
Nonetheless, ASOs function in the nucleus and thus can be an effective tool for 
knocking down both nuclear and cytoplasmic lncRNAs.  
A third developing technology for lncRNA knockdown is CRISPR-Cas13 
RNA targeting, Cas13 being a type VI CRISPR-associated RNA-guided RNase. A 
number of CRISPR-Cas13 platforms have recently been reported to be both more 
specific and more effective at knocking down both nuclear and cytoplasmic RNAs 
than position-matched shRNAs (Abudayyeh et al. 2017; Cox et al. 2017; 
Konermann et al. 2018). The ability to target nuclear lncRNAs in a genetically 
encodable system such as CRISPR-Cas13 would be invaluable, as ASOs are 
transient and thus less-suited for use in longer-term functional assays. However, 
CRISPR-Cas13 has not been widely adopted as a tool for RNA knockdown yet, 
likely due to still enigmatic gRNA design rules. Once a better understanding of 
what constitutes an effective Cas13 guide has been established, CRISPR-Cas13 is 
certain to greatly facilitate lncRNA characterization efforts. 
 
LncRNA gain-of-function (GOF) 
 The most commonly employed lncRNA GOF stratagem is transgene 
overexpression, in which full length or mutant lncRNA sequences are introduced 
into cells through either stable or transient means. However, it is important to note 
that such transgene overexpression systems can only be deemed true GOF (i.e. 
informative about the endogenous function of a lncRNA) for lncRNAs that act in 
trans. In fact, rescuing lncRNA LOF through the introduction of a lncRNA 
transgene is a crucial experiment in proving true trans lncRNA functionality. Such 
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approaches are less appropriate for the study of lncRNA-mediated cis-regulation, 
as cis-acting lncRNAs, by definition, exert their functions at their sites of 
expression. Driving lncRNA expression from elsewhere in the genome would not 
be expected to positively or negatively affect expression from its endogenous locus. 
To circumvent this issue, molecular tools to recruit ectopically expressed lncRNAs 
to their endogenous genomic loci have been developed (Shechner et al. 2015) but 
have not been as widely employed as means to locally manipulate gene regulation. 
One such approach is CRISPR-Cas9 based gene activation (CRISPRa) (Gilbert et 
al. 2013). CRISPRa is suitable for both trans- and cis-acting lncRNA GOF, as 
lncRNA upregulation is achieved by increasing the transcriptional activity of the 
endogenous lncRNA locus.  
 
 In summary, efficiently and specifically manipulating the expression of 
lncRNAs can be technically challenging. For lncRNA LOF in particular, it can be 
vital to employ multiple, orthogonal strategies in order to elucidate the functional 
feature(s) of a lncRNA locus. Additionally, the appropriateness of traditional (i.e. 
protein coding gene-oriented) LOF and GOF tools should be judiciously assessed 
on a lncRNA-by-lncRNA basis. In this work, multiple locus-specific strategies were 
employed to functionally characterize the many diverse lncRNAs under study. 






Table 2.1: Survey of genome-wide p53 ChIP-Seq and RNA profiling studies 
Ref RNA profiling Cell line(s) Stressor Category 
(Akdemir et al. 2014) RNA-seq hESCs Doxorubicin Geno 
(Catizone et al. 2019) RNA-seq IMR90 Etoposide Geno 
(Huarte et al. 2010) Microarray MEFs Doxorubicin Geno 
(Kenzelmann Broz et al. 
2013) 
RNA-seq MEFs Doxorubicin Geno 
(Lee et al. 2010) * Microarray mESCs Doxorubicin Geno 
(Li et al. 2012) Microarray mESCs Doxorubicin Geno 








(Smeenk et al. 2011) Microarray U2OS Actinomycin D Geno 
 
 
U2OS Etoposide Geno 
(Younger et al. 2015) RNA-seq MEFs; Human 
fibroblasts 
Doxorubicin Geno 
(Zhang et al. 2013b) * Microarray MEFs; mESCs Doxorubicin Geno 
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Chapter 3:  
Cis-regulatory lncRNAs in the p53 response to oncogenic 
stress 
  
Part of the work described in this chapter is being prepared as a manuscript for 
publication as follows: Tesfaye, E., Bendor, J., Martínez-Terroba, E., Zamudio, 
J., and Dimitrova, N. Core and outcome-specific signatures of p53 restoration in 
cancer modulated by cis-regulatory lncRNAs. Co-author contributions that 
have also been included in this thesis are specified in figure legends and/or text. 
 
Introduction 
The ability of p53 to sense and respond to oncogenic signaling is an important 
facet of its potent tumor suppressive capabilities (Brady et al. 2011; Kaiser and 
Attardi 2018). Yet, the p53 response to oncogenic stress is poorly understood, in 
part due to the dearth of global analyses comparing said response across diverse 
tumor types (discussed in Chapter 2; Table 2.1). Especially under-explored are 
the contributions of p53-activated lncRNAs to how p53 responds to oncogenic 
signalling across different cancer contexts. Detailed in this chapter is some of our 
work towards a more comprehensive understanding of the p53 transcriptional 
response to oncogenic stress and the regulatory roles previously described and 
novel lncRNAs play in it, achieved by performing a global survey of three different 
tumor types derived from the same genetically engineered mouse model of cancer. 
50 
 
Primarily discussed here are my main contributions to this project, namely the 
identification of stressor-specific, lineage-specific, and p53 outcome-specific 
transcriptional programs across our mouse model of cancer and the 
characterization of a cohort of newly-identified p53-activated lncRNAs (continued 
in Chapters 4 and 5).  
 
Results 
Genome-wide profiling of the p53 response to oncogenic stress  
In collaboration with Jesse Zamudio (J. Zamudio; UCLA), a quantitative 
biologist, we performed genome-wide p53 ChIP-seq and RNA-seq across a panel 
of lung adenocarcinoma (LA), sarcoma (SA), and lymphoma (LY)-isolated cell 
lines from the KPR mouse model of cancer, which is an established model for 
studying the p53 pathway (Ventura et al. 2007; Feldser et al. 2010) and described 
in detail in Chapter 2. In brief, in this model, oncogenic stress is derived from an 
activated KrasG12D allele, and p53 expression is inactivated by the homozygous 
insertion of a loxP-flanked transcriptional STOP cassette into the endogenous p53 
locus. Importantly, p53 expression can be restored by the addition of Tam, which 
removes the STOP cassette, thus allowing the analysis of events downstream of p53 
in the presence of oncogenic stress (Fig. 2A).  
We utilized a panel of six cell lines derived from three distinct KPR tumor 
types: two LA, two SA, and two LY. CreER-mediated recombination of the p53 
locus in these isolated cell lines was confirmed at 24h post Tam treatment by 
genotyping (Fig. 2B), and restoration of p53 expression was confirmed by qRT-
PCR (Fig. 2C). Following p53 restoration, p53 protein is stabilized by the presence 
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of oncogenic stress, as evidenced by immunoblotting (Fig. 2D) and the activation 
of transcriptional targets of p53, such as p21 (El-Deiry et al. 1993) (Fig. 2C, D).  
In addition to these molecular indicators of p53 restoration, KPR cell lines 
also displayed cellular outcomes consistent with previously described in vivo p53 
responses. p53 activation has been reported to lead to tumor regression via 
senescence in murine LA and SA tumors (Feldser et al. 2010; Ventura et al. 2007) 
and apoptosis in lymphoma (Ventura et al. 2007). Following p53 restoration, we 
observed induction of apoptosis in LY cells, but not LA and SA cells (Fig. 2D), and 
growth arrest in LA and SA cells, as expected. Positive staining for β-galactosidase 
activity at 168 hours post p53 restoration in LA and SA cells was consistent with 
these cells having underwent oncogene induced senescence (Serrano et al. 1997) 
(Fig. 2E). Thus, these data established KPR-derived cells as a suitable model to 
investigate oncogenic-stress specific, tumor type-specific, and p53 outcome-
specific transcriptional programs. 
We first queried where in the genome p53 binding occurred across the three 
tumor types by performing p53 ChIP-seq in one LA (LA2), one SA (SA1), and one 
LY (LY1) cell line. In parallel to our p53 ChIP-seq analysis, we analyzed RNA-seq 
data from the full panel of two LA (LA1 and LA2), two SA (SA1 and SA2) and two 
LY (LY1 and LY2) cell lines, allowing us to determine how p53 binding events 
related to transcriptional changes. Both p53 ChIP-seq and RNA-seq experiments 
were performed at 24 hours following mock treatment or Tam-mediated p53 
restoration by Nadya Dimitrova (N. Dimitrova). A schematic of this experimental 
pipeline can be found in (Fig. 2F). Bioinformatic analyses to identify regions bound 
by p53 and expressing transcripts differentially regulated in response to p53 
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restoration were performed by N. Dimitrova and J. Zamudio, yielding a list of 
peak-associated transcripts that N. Dimitrova and I interrogated further. 4,391 
p53-bound peaks were identified across the three tumor types, corresponding to 
4,745 individual peak-associated transcripts. Notably, 1,036 peaks did not have 
any detectable transcripts, consistent with previous reports of p53 frequently 
associating with intergenic regions, such as enhancers and repetitive elements 
(Léveillé et al. 2015; Wang et al. 2007). Overlap analysis of both transcript-
associated and intergenic peaks was performed by J. Zamudio and revealed that 
94% of p53 binding events were tumor type-specific, with only 44 sites (1%) being 
bound by p53 across all three tumor types, suggesting that p53 binding is perhaps 
driven more by cell- or tissue-specific factors than stressor type, as has been 
previously suggested (Tonelli et al. 2017; Catizone et al. 2019; Smeenk et al. 2011; 













Figure 2: Characterization of the p53 response to oncogenic stress. (A) Schematic of the 
KrasLA2-G12D/+; p53LSL/LSL; Rosa26-CreERT2 (KPR) mouse model and isolated tumor-derived cell 
lines. Tam-mediated p53 restoration (p53 “ON”) and subsequent p53 stabilization by oncogenic 
stress is indicated by a red nucleus. Six independent KPR cell lines, two per indicated tumor type, 
were used in this work. (B) Genotyping of indicated KPR cell lines and treatments. Expected bands: 
WT (p53 “ON”/restored) = 364 bp; LSL (p53 “OFF”/ unrestored) = 278 bp. (C) qRT-PCR analysis 
of p53 and p21 mRNA relative to endogenous control RNA Gapdh. Data show mean ±SEM (n=3 
biological replicates). *p <0.05, ** p<0.01, and **** p<0.0001, unpaired t test. (D) 
Immunoblotting for p53, p21, and CC3 protein. β-tubulin served as a loading control. (E) 
Senescence-associated β-galactosidase staining in indicated LA and SA KPR cells and treatments. 
(F) Diagram of p53 ChIP-Seq and RNA-seq experiments, including summary of identified p53-
bound peaks and de novo assembled transcriptome results. p53 ChIP-seq was performed in LA2, 
SA1, and LY1 cells, whereas RNA-Seq was performed in all KPR cell lines. p53-responsive 
transcripts were called based on log2FC (FDR >0.05). 
In (F), original ChIP-seq and RNA-seq experiments were performed by N. Dimitrova. 








Identification of core and senescence-specific p53 signatures 
Of the 4,745 peak-associated transcripts, 1,573 were differentially regulated 
in response to p53 restoration. 685 genes were upregulated >2-fold while 888 
genes were downregulated >2-fold across the three tumor types (Fig. 3A, C). 
Differentially regulated genes fell into three categories: 1) Tumor type specific (LA, 
SA, or LY-specific); 2) Outcome-specific (senescence or apoptosis); and 3) Core 
(common). In order to gain a better understanding of the make-up of the specific 
p53 transcriptional program(s) enacted in each category, and whether any unique 
signatures explained the different behaviors of each KPR tumor type, we 
performed gene set enrichment analysis (GSEA) on each category.  
Of the transcripts transcriptionally activated by p53, 61 were induced across 
all three tumor types, including many known p53 targets such as p21, Mdm2, 
Sesn2, and Bbc3 (Puma) (Fig. 3A). Unsurprisingly, GSEA of this core induced set 
of transcripts revealed significant enrichment for factors previously implicated in 
the p53 pathway and/or various processes regulated by p53, such as the DNA 
damage response and apoptosis (Fig. 3B). Moreover, in silico motif analysis of the 
p53 peaks associated with these transcripts performed by J. Zamudio via p53scan 
(Smeenk et al. 2008) revealed an enrichment for the canonical p53 response 
element (p53RE) (Fig. 3E), further supporting direct regulation by p53. Thus, we 
were able to identify a core set of genes regulated by p53 in response to oncogenic 
stress across multiple tumor contexts.  
In search for a potential apoptosis signature, we next investigated the 
transcripts upregulated uniquely in LY cells. However, while we did find 
enrichment for the p53 pathway itself (Fig. 3A), we found little overlap with 
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apoptosis gene sets and no enrichment of the p53RE (Fig. 3E), suggesting that 
other factors beyond transcriptional regulation by p53 may play a more important 
role in driving apoptosis in LY cells. Similar GSEA analysis of the 51 genes induced 
in LA and SA but not LY cells did not reveal any significantly enriched datasets, 
indicating the lack of a senescence-specific p53 activated signature. 
In contrast to the well-characterized role of p53 in gene activation, the 
functional importance of and mechanisms underlying p53-mediated gene 
repression are less clear (Vousden and Prives 2009; Fischer et al. 2014). By 
examining the 888 peak-associated transcripts which were downregulated >2-
fold, we noticed that a large proportion (35%) of these genes fell within the 
“senescence-specific” category (i.e. repressed only in both LA and SA cells) (Fig. 
3C). In contrast, only 3 genes were repressed across all three tumor types, none of 
which contained p53REs (Fig. 3C, F). These data suggested that p53-mediated 
transcriptional repression is likely not a dominant feature of the p53 
transcriptional network, at least in the context of oncogenic stress, but perhaps is 
a feature of outcome-specificity, specifically senescence.  
Indeed, GSEA of the 312 downregulated senescence-specific genes 
highlighted the repression of genes involved in the cell cycle, which is consistent 
with reduced proliferation during senescence (Fig. 3D). In addition, we discovered 
significant overlaps with E2F and DREAM targets (Fig. 3D), which is in line with 
a previously proposed model in which repression downstream of p53 is mediated 
by the p21/E2F/DREAM transcriptional complex (Engeland 2018; Uxa et al. 
2019). Only 17% of all p53 repressed genes contained a p53RE, compared to 30% 
of p53 induced genes (Fig. 3E, F), and this number was not further enriched in 
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senescence-repressed genes (Fig. 3F). However, as 56 of the 312 senescence-
repressed genes (18%) did contain recognizable p53REs, it remains possible that 
p53 binding may still be important for repression at some loci, whether through 
contributing to the localization of E2F/DREAM components or through other 
mechanisms. 
 In summary, these data indicated that senescence, but not apoptosis or the 
core p53 response to oncogenic stress, is distinctly characterized by pervasive p53-
mediated repression. Moreover, senescence-specific transcriptional repression 
may possibly be mediated through a repressive partner, such as the 







Figure 3: Pathway analysis of p53-responsive transcriptome reveals core and 
outcome-specific p53 signatures. (A) Venn diagram showing distribution of p53-induced 
(log2FC>1) transcripts across indicated KPR tumor types. Arrows designate results of GSEA of 
indicated gene category, with FDR q value shown. Highlighted gene categories: Core= LA, SA, and 
LY. Senescence= LA and SA. Apoptosis= LY. (B) GSEA of Core p53-induced category, using the H 
and C2 collections of MSigDB. Top ten enriched gene sets ranked by q values were plotted. Gene 
sets related to the p53 pathway are highlighted in red. (C) Venn diagram showing distribution of 
p53-repressed (log2FC<1) transcripts across indicated KPR tumor types. (D) GSEA of Senescence 
p53-repressed category, as described in (B). Gene sets related to cell cycle regulation are 
highlighted in red. (E-F) p53-responsive transcript distributions across indicated gene categories 
in relation to p53RE status as determined by p53scan on transcript-associated p53 peaks. (E) p53-
induced transcripts (F) p53-repressed transcripts. 
 




Many lncRNAs are activated by oncogenic stress following p53 
restoration 
We next focused on the identification and characterization of lncRNAs 
activated by p53 in our KPR model, wondering whether lncRNAs played an 
important role in the p53 response to oncogenic stress. Among the genes that were 
induced by p53 in KPR cells more than 2-fold, 21 lncRNAs were identified 
(described in Table 3.1). Interestingly, barring three transcripts which had 
previously been characterized as p53 targets, [lincRNA-p21 (Dimitrova et al. 2014; 
Huarte et al. 2010); Neat1 (Adriaens et al. 2016; Mello et al. 2017), and Pvt1 
isoform Pvt1b (Olivero et al. 2020)], the remaining lncRNAs were either novel or 
not previously associated with the p53 pathway. These novel lncRNAs were named 
as follows: antisense (as) according to genes overlapped in the antisense 
orientation, sense (s) respective to overlaps in the sense orientation, or long 
intergenic noncoding RNAs (lincRNAs) according to the nearest neighboring 
protein coding gene. Three lncRNAs, 2310008N11Rik (Zfp703 >150kb), Gm10801 
(Lrrc4c >1Mb), and Gm10721 (Alkbh8 >300kb) were located in gene deserts and 
were thus simply referred to by their MGI identifiers, unless otherwise noted. Of 
the 21 p53-induced lncRNAs, 13 were further identified by p53Scan to contain 
associated p53REs, providing a basis for direct regulation by p53 (Table 3.1).  
To confirm that these RNAs were truly noncoding, protein coding potential 
was assessed using the Coding Potential Assessment Tool (CPAT), which is a 
commonly employed, alignment-free algorithm for assessing the probability of a 
given nucleotide sequence containing a translated ORF (Wang et al. 2013). As 
expected, previously described lncRNAs lincRNA-p21, Airn, Neat1, Malat1, and 
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Pvt1 all had CPAT scores significantly lower than the protein-coding cut-off 
assigned to the mouse transcriptome (CPAT score >0.440), suggesting a lack of 
coding potential. Of the novel transcripts, all but one (Galnt2l-s) were similarly 
below the coding threshold, suggesting that these transcripts represent bona fide 
lncRNAs (Table 3.1). 
 
Table 3.1: LncRNAs activated by p53 during the oncogenic stress response  
# Name Class p53Scan CPAT score 
Coding 
label 
1 lincRNA-p21 Intergenic YES 0.246 NO 
2 Zmat3-as A.S overlap YES 0.176 NO 
3 Bahcc1-as A.S overlap YES 0.229 NO 
4 lincRNA-Spag9 Intergenic YES 0.046 NO 
5 lincRNA-Gadd45γ Intergenic YES 0.243 NO 
6 Airn A.S overlap  0.243 NO 
7 2310008N11Rik (lncRNA 7) Intergenic YES 0.044 NO 
8 lincRNA-Klhdc4 Intergenic YES 0.995 Yes 
9 Neat1 Intergenic  0.087 NO 
10 Malat1 Intergenic  0.056 NO 
11 Pvt1 Intergenic YES 0.119 NO 
12 Gm10801 Intergenic  0.064 NO 
13 lincRNA-Zfp945 Intergenic  0.122 NO 
14 Adamts9-as A.S overlap YES 0.124 NO 
15 Rhod-as A.S overlap YES 0.304 NO 
16 Sesn2-s S. overlap YES 0.050 NO 
17 Bfsp2-as A.S overlap YES 0.052 NO 
18 Anks1-as A.S overlap  0.213 NO 
19 Kdm4c-as A.S overlap  0.005 NO 
20 Gm10721 Intergenic  0.065 NO 
21 Ltc4s-as A.S overlap  YES 0.042 NO 
Bold= lncRNAs selected for further characterization 
  
Thirteen lncRNAs were selected for initial characterization experiments 
(bolded in Table 3.1). Criteria for selection included likelihood of direct regulation 
by p53, previous implication in the p53 pathway or other cancer-associated 
processes, and likely overall abundance as initially determined in our RNA-seq 
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data. p53-dependent induction of these select lncRNAs across the panel of KPR 
cancer cell lines was validated by qRT-PCR. In agreement with our RNA-seq 
analysis, 10/13 lncRNAs were induced >2-fold upon 24h Tam treatment in at least 
three of the six cell lines, barring Neat1, Malat1, and Ltc4s-as. 12/13 lncRNAs met 
this threshold of induction in at least one KPR cell line. Interestingly, we were 
unable to confirm p53-dependent induction of Neat1 at this early time point, 
implying a lack of direct regulation by p53 in contrast to previous studies (Fig. 4A). 
When a later time point (72h Tam) was examined, all 13 lncRNAs met this >2-fold 
threshold of induction, suggesting p53-regulated lncRNAs may be induced with 
different transcriptional dynamics (Fig. 4A). Of note, five lncRNAs (Pvt1b, Zmat3-
as, Bahcc1-as, 2310008N11Rik, and Rhod-as) were induced across all six KPR cell 
lines at both early (24h) and late (72h) time points, thus potentially encompassing 
a core set of oncogenic stress-specific, p53-activated lncRNAs.  
 
p53-activated lncRNAs are nuclear-enriched and co-regulated with 
their nearest neighboring mRNAs 
We next sought to determine the subcellular localization patterns of the 
selected lncRNAs using subcellular fractionation followed by qRT-PCR, assessing 
RNA levels in the cytoplasm (CP), nucleoplasm (NP), and at the chromatin 
interface (CHR) in an LA1-derived clonal cell line (LA1.1). As anticipated, control 
transcript Kcnq1ot1 was enriched in the chromatin fraction, whereas control 
transcripts Rn7sl and Gapdh were enriched in the cytoplasm (Fig. 4B). 
Furthermore, lncRNAs previously reported to be enriched in the nucleus 
(lincRNA-p21, Pvt1, Neat1, and Malat1) were similarly distributed in KPR cells as 
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well (Fig. 4B). Intriguingly, we determined that this nuclear-enrichment was 
common to all tested p53-activated lncRNAs, with most enriched specifically at the 
chromatin. These general patterns of subcellular localization also held true in wild 
type MEFs treated with Doxo, demonstrating that these subcellular localization 
patterns were conserved in the p53 response to genotoxic stress as well (Fig. 4C). 
Curious about the implications of this pervasive chromatin-enrichment, we 
next assessed the p53-responsiveness of each selected lncRNA’s overlapping 
and/or nearest neighboring protein coding genes, wondering whether lncRNA 
localization reflected lncRNA-mediated local gene regulation. As observed in the 
parental KPR cells, p53 restoration also induced lncRNA expression in LA1.1 cells 
(Fig. 4D). Strikingly, we found that most lncRNA-associated protein coding genes 
were also upregulated in response to p53 (Fig. 4D). These data suggested that 
lncRNAs that are activated by p53 in response to oncogenic stress are frequently 
transcriptionally co-regulated with nearby protein-coding genes. Notably, this 
correlation was positive for the majority of lncRNA-mRNA pairs investigated, with 
the only exception being Pvt1b, which showed a negative correlation with its 
upstream neighbor, Myc.  
 
Figure 4: LncRNAs activated by p53 in response to oncogenic stress are chromatin-
enriched and positively correlated with neighboring mRNAs. (A) qRT-PCR analysis of 
lncRNA levels relative to Gapdh in indicated KPR cell lines treated with 24h or 72h Tam, 
normalized to untreated cells. n.e.= not expressed. Data show mean ± SD (n=2 biological 
replicates). (B-C) Heat map representation of qRT-PCR analysis after subcellular fractionation. 
Rn7sl and Kcnq1ot1 served as fractionation controls for cytoplasmic and chromatin-associated 
fractions, respectively. Also shown is Gapdh mRNA, as an additional control. CP= cytoplasmic. NP= 
nucleoplasmic. CHR= chromatin-associated. (B) LA1.1 cells treated with 24h (left panel) or 72h 
(right panel) Tam. (C) Primary MEFs treated with 24h 0.5 µM Doxo. (D) Correlation plots of qRT-
PCR analysis of RNA induction upon 24h Tam treatment in LA1.1 cells. Represented are lncRNA 
and corresponding neighboring and/or overlapping mRNA levels relative to Gapdh, normalized to 
untreated LA1.1 cells. LincRNA-p21 plotted against p21 and Pvt1b plotted against Myc are 









To further examine the relationship between p53-activated lncRNAs and 
their neighboring mRNAs, we next sought to establish a genetic lncRNA LOF 
strategy. We turned to CRISPR-Cas9 mutagenesis of lncRNA-associated p53REs, 
reasoning that as p53 is a sequence-specific transcription factor, genetic 
disruptions of the DNA element recognized by p53 should specifically abrogate 
p53-dependent lncRNA induction. Of the 13 lncRNAs selected for validation, 11 
(excluding Neat1 and Malat1) had p53REs identifiable by p53scan (Tables 3.1, 
3.2). Most lncRNA-associated p53REs were located at or near promoter regions, 
with 8 out of 11 (73%) p53REs being found either upstream of a lncRNA’s TSS or 
within the lncRNA gene’s first exon or first intron, similar to what has been 
observed for protein coding p53 targets (Table 3.2) (Riley et al. 2008).  
To test the feasibility of our p53RE mutagenesis approach, we selected 7 
lncRNAs for which we were able to design gRNAs that were highly specific 
(specificity score by CRISPOR (Haeussler et al. 2016) >70/100) and predicted to 
direct Cas9 cleavage within or adjacent to a p53RE sequence. Introduction of Cas9 
and lncRNA p53RE-targeting (ΔRE) gRNAs into a clonal LA2-derived cell line, 
LA2.5 (cell lines generated by J. Bendor), abrogated the Tam-induced upregulation 
of 5 of the 7 targeted lncRNAs, confirming direct transcriptional regulation by p53 
(Fig. 5A). Two lncRNAs, 2310008N11Rik and Rhod-as, were not affected by this 
approach. This was likely due to the inefficient disruption of their p53REs by the 
designed gRNAs, as was revealed by Sanger sequencing individual alleles from 





Table 3.2: Descriptions of lncRNA-associated p53 response elements (p53REs)  
# LncRNA p53RE Location p53RE Sequence 
Suitable 
PAM? 
1 lincRNA-p21 Exon 1 AGGCAAGCCCGGGCAAGgCC YES 
2 Zmat3-as Promoter AGACATGCCTGGGCTTGTTT YES 
3 Bahcc1-as Down-stream 
GAACAAGCaT (GTAGACAGA) 
GcACATGTTC No 
4 lincRNA-Spag9 Intron 1 GGACTTGTTgGGACATGTCC YES 
5 lincRNA-Gadd45γ Exon 3 AGGCATGCCT (G) tGACATGCCT YES 
7 2310008N11Rik 
(lncRNA 7) Exon 1 AGACATGTCTGAGCAAGCCT *No 
11 Pvt1 Promoter tGACAAGTTTGGGCTTGTTC YES 
15 Rhod-as Intron 1 GAGCTAGCTC(TG)GcACATGgCa(GA)tGtCATGaaT *No 
16 Sesn2-s Promoter GGAtTTGCCT (GGACTTGAG) AcGCTcGCTT No 
17 Bfsp2-as Intron 5 GGACATGTAA (CGAAGGGCCTGCCC) GGGCATGTCC 
†No 
21 Ltc4s-as Intron 1 GGACTTGCCTGGACTTGCTC YES 
P53RE consensus sequence= RRRCWWGYYY(n)RRRCWWGYY; n=0-15 nt 
*Inefficient disruption of p53RE sequence experimentally determined (Fig. 5A) 
†Prohibitively low gRNA specificity score 
 
To assess the consequences of this p53RE mutagenesis on local gene 
expression and broader p53 pathway function, we turned to our LA1.1 cells, which 
are a better characterized model for LA function within the lab. As a positive 
control, we added lincRNA-p21 to our list of targeted p53-regulated lncRNA loci, 
and focused on lncRNA loci in which we were able to achieve efficient mutagenesis 
as determined by TIDE (Tracking of Indels by Decomposition) (Brinkman et al. 
2014) analysis of sequenced Con and ΔRE LA1.1 populations (Fig. 5C). Similar to 
what was observed in LA2.5 cells, lncRNA ΔRE-expressing LA1.1 cells exhibited 
significantly less lncRNA induction upon Tam-treatment compared to cells 
expressing control gRNAs (Fig. 5C). As expected, the downregulation of lincRNA-
p21 (73% knockdown) in cells expressing gRNA ΔRE-lincRNA-p21 was 
accompanied by a corresponding 24% decrease in p21 levels compared to control 
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cells, whereas Pvt1b downregulation (81%) in Tam-treated ΔRE-Pvt1b cells led to 
a 58% increase in Myc expression, confirming previously reported regulatory 
relationships at these loci (Dimitrova et al. 2014; Olivero et al. 2020).  
Intriguingly, we discovered that mutagenesis of the p53REs associated with 
three previously undescribed lncRNAs, Zmat3-as, lincRNA-Gadd45γ, and Ltc4s-
as, also resulted in reduced expression of their respective neighboring and/or 
overlapping genes, compared to control cells (Fig. 5C). Of note, for Ltc4s-as, which 
is transcribed antisense to two protein-coding genes (Ltc4s and Maml1), only Ltc4s 
was significantly reduced in ΔRE-Ltc4s-as-expressing cells, while Maml1 
expression was not significantly affected, suggesting that coregulation by p53 at 
this complex locus is tightly regulated. The regulatory relationship between Ltc4s-















Figure 5: LncRNA p53 response element (p53RE) mutagenesis reveals co-regulatory 
relationships. (A) Top- schematic of pilot CRISPR-Cas9 p53RE mutagenesis experiment. Vector 
shown= BRD001 (see supplementary table 1). Bottom- qRT-PCR of indicated lncRNA levels in 
LA2.5 cells expressing corresponding ΔRE-targeting gRNAs. Data shown as log2FC normalized to 
LA2.5 cells expressing non-targeting (Con) gRNA ±SD (n=2 biological replicates). (B) i. 
Schematics for indicated lncRNA/mRNA genomic loci and p53RE mutagenesis strategies. Green= 
p53RE location (asterisks), p53RE sequence (text). Brown= ΔRE gRNA targeted PAM. ii. 
Representative control and ΔRE mutated alleles identified by Sanger sequencing. Red= 
characterization of p53RE indels. (C) qRT-PCR detection of indicated lncRNAs and associated 
mRNAs in indicated LA1.1 cells and treatments, normalized to cells expressing control gRNAs. 
TIDE mutagenesis efficiencies (Mut.) are noted in red text. Data show mean ±SEM (n=3-5 
biological replicates). *p <0.05, ** p<0.01, ***p<0.001, and **** p<0.0001, ns= not significant, 













Novel p53 target lincRNA-Gadd45γ positively regulates Gadd45γ in cis  
 Given the role of lincRNA-p21 in promoting the expression of p21 and the 
role of Pvt1b in transcriptionally repressing Myc, we next wondered whether 
Zmat3-as, lincRNA-Gadd45γ, and Ltc4s-as might also influence the expression of 
their neighboring genes. Given the overlapping genomic contexts of Zmat3-as and 
Ltc4s-as, making functional dissociation of the lncRNA and mRNA transcripts 
more challenging, we initially chose to focus on lincRNA-Gadd45γ, which 
represents a discrete transcriptional unit located 125k b downstream of Gadd45γ 
(Growth arrest and DNA damage-inducible 45 gamma). Furthermore, Gadd45γ 
is a poorly characterized member of a family of proteins that are involved in cell 
cycle regulation and survival, some through the p53 pathway (E. Tamura et al. 
2012), though Gadd45γ is not thought to be directly regulated by p53 itself. Thus, 
multiple features of the lincRNA-Gadd45γ/Gadd45γ locus made it an attractive 
candidate for further study. 
 We next explored the possibility that lincRNA-Gadd45γ might play a 
functional role in promoting the expression of Gadd45γ, analogous to lincRNA-
p21 and p21. To determine whether loss of p53 binding at the lncRNA locus or loss 
of the lncRNA transcript itself contributed to the effects on Gadd45γ regulation 
observed in ΔRE- lincRNA-Gadd45γ cells, we turned to CRISPR-based epigenetic 
modulation of the lincRNA-Gadd45γ locus. First, we inhibited lincRNA-Gadd45γ 
expression via transcriptional interference by targeting Cas9 downstream of its 
TSS using a 12-nt dead RNA (dRNA), which allows the recruitment of catalytically 
active Cas9 without supporting nuclease activity (Fig. 6A-top) (Dahlman et al. 
2015). Importantly, this approach allowed us to abrogate lincRNA-Gadd45γ 
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expression in a manner removed from p53-dependent regulation at this locus. We 
observed a 50% decrease in lincRNA-Gadd45γ levels and a corresponding 30% 
decrease in Gadd45γ expression in Tam-treated LA1.1 cells expressing targeting 
dRNAs compared to controls (Fig. 6A-bottom). Thus, these data demonstrated 
that some aspect of lincRNA-Gadd45γ biogenesis or RNA positively regulates 
lincRNA-Gadd45γ expression in the p53-dependent response to oncogenic stress. 
 In the converse experiment, we used the CRISPR-Synergistic Activation 
Mediator (SAM) system to induce the expression of lincRNA-Gadd45γ in either 
the absence or presence of p53.  In this CRISPRa platform, catalytically active Cas9 
is recruited to a site upstream of the TSS using a dRNA fused to MS2 repeats, which 
in turn serve to recruit a complex of transcriptional activators fused to the MS2-
binding protein (MBP-HSF1-p65)(Fig. 6B-top) (Dahlman et al. 2015; Olivero et al. 
2020). In an experiment performed by E. Martínez-Terroba (who also developed 
the molecular reagents used in this specific CRISPRa platform), CRISPRa of 
lincRNA-Gadd45γ led to a 28-fold and 26-fold upregulation of lincRNA-Gadd45γ 
over control dRNAs in the absence and presence of p53, respectively. Importantly, 
p53-independent activation of lincRNA-Gadd45γ via CRISPR-SAM was marked 
by a 9-fold increase in Gadd45γ levels as well, further suggesting that transcription 
from the lncRNA locus is sufficient to promote Gadd45γ expression (Fig. 6B-
bottom). 
As a third orthogonal approach to depleting lincRNA-Gadd45γ levels, we 
employed antisense oligonucleotides (ASOs), which decrease target RNA levels 
through both RNase-H-dependent and transcription-based mechanisms (Lai et al. 
2020; Lee and Mendell 2020). Two independent lincRNA-Gadd45γ targeting 
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ASOs were designed and introduced into LA1.1 cells and RNA levels compared to 
a non-targeting control ASO (Con) (Fig. 6C-top). Interestingly, while both ASO1 
and ASO2 led to a significant decrease in lincRNA-Gadd45γ expression in Tam-
treated LA1.1 cells (96% and 93% knockdown, respectively), only ASO2 led to a 
corresponding 47% decrease in Gadd45γ levels (Fig. 6C-bottom). Curious as to 
whether this discrepancy stemmed from each ASO targeting a different 
complement of lincRNA-Gadd45γ isoforms, we designed an additional two qPCR 
primers against lincRNA-Gadd45γ. While primer pairs (1) and (2) revealed 
comparable levels of lincRNA-Gadd45γ knockdown for both ASO1 and ASO2, 
primer pair (3) showed that solely ASO2 yielded a significant 26% decrease in 
lincRNA-Gadd45γ, paralleling the effect observed on Gadd45γ (Fig. 6C-bottom). 
These data are suggestive of the presence of alternate lncRNA isoforms that 
differentially contribute to Gadd45γ regulation. 
Taken together, these data indicate that the production of lincRNA-
Gadd45γ is both necessary and sufficient to modulate Gadd45γ expression, 
analogous to other cis-regulatory lncRNAs, and expands the number of known cis-












Figure 6: LincRNA-Gadd45γ positively regulates Gadd45γ in cis. (A) Top- Design of 
lincRNA-Gadd45γ CRISPRi experiment. Bottom- qRT-PCR analysis of lincRNA-Gadd45γ and 
Gadd45γ levels relative to Gapdh in indicated LA1.1 cell lines and treatments. (B) Top- Design of 
lincRNA-Gadd45γ CRISPRa experiment. Bottom- qRT-PCR analysis of normalized lincRNA-
Gadd45γ and Gadd45γ levels relative to Gapdh in indicated LA1.2 cell lines and treatments. (C) 
Top- Diagram of lincRNA-Gadd45γ locus, indicating locations of ASOs (2) and qPCR primer pairs 
(3). Bottom- qRT-PCR detection of Gadd45γ and indicated lincRNA-Gadd45γ amplicons in LA1.1 
cells treated with indicated ASOs and Tam. Green asterisks indicate p53RE. Data show mean ±SEM 
(n=3 biological replicates). *p <0.05, ** p<0.01, ***p<0.001, and **** p<0.0001, ns= not 
significant, unpaired t test. 
 






Pvt1b-Myc co-regulation is necessary for p53’s anti-proliferative 
response to oncogenic stress 
Lastly, we examined whether genetic inhibition of the p53-activated 
lncRNAs lincRNA-p21, Pvt1b, Zmat3-as, lincRNA-Gadd45γ, and Ltc4s-as affected 
the antiproliferative outcome observed upon p53 activation in LA cell lines. To 
assess proliferation, we performed growth curve, BrdU incorporation, and colony 
formation assays with control, ΔRE-lincRNA-p21, ΔRE-Pvt1b, ΔRE-Zmat3-as, 
ΔRE-lincRNA-Gadd45γ, and ΔRE-Ltc4s-as cells. As expected, control cells 
underwent permanent cell cycle arrest following Tam-mediated p53 restoration 
and failed to grow or form colonies (Fig. 7A-D). We found that ΔRE-Pvt1b cells 
overcame in part the permanent growth arrest and formed colonies (Fig. 7A-D). In 
contrast, inhibition of either Zmat3-as, lincRNA-Gadd45γ, or Ltc4s-as did not 
significantly affect cellular proliferation and/or clonogenicity (Fig. 7A-D). While 
ΔRE-lincRNA-p21 cells did exhibit a slight growth advantage at earlier time points 
(Fig. 7B), likely reflecting the decreased levels of G1/S check point mediator p21 in 
these cells, this growth advantage was lost over time and ultimately did not 
contribute to defects in sustained growth arrest or increased colony formation 
capability.  
We also assessed the effects of lncRNA inhibition on apoptosis, which is not 
the normal p53 response initiated in LA cells but could theoretically be triggered 
by the loss of key p53 targets important for driving LA-specific p53 cell fate 
decisions. As expected, p53 restoration did not promote apoptosis or decrease 
viability in control cells, in contrast to positive control cells additionally treated 
with acute DNA damage (Fig. 7E, F). This resistance to cell death in response to 
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oncogenic stress was unaffected by the inhibition of lincRNA-p21, Pvt1b, Zmat3-
as, or lincRNA-Gadd45γ (Fig. 7E, F).  
Thus, these data demonstrate that, barring Pvt1b, loss of no individual p53-
activated lncRNA was sufficient to bypass oncogenic stress-mediated arrest, and 
that furthermore, lncRNAs are unlikely to significantly contribute to p53 cell fate 

















































Figure 7: Contributions of lncRNA-mRNA co-regulation to p53’s antiproliferative 
response to oncogenic stress. (A) Cumulative cell numbers of Tam-treated control (indicated 
in red) or lncRNA ΔRE gRNA-expressing LA1.1 cells over time. (B) BrdU incorporation in LA1.1 
cells expressing indicated gRNAs following 24h Tam and 2h BrdU treatment. Cells were scored for 
BrdU (FITC) incorporation by immunofluorescence and total number BrdU positive nuclei plotted 
over total scored nuclei per cell line. (C) Representative images of colony formation assays in Tam-
treated LA1.1 cells expressing indicated gRNAs. (D) Quantification of (C). (E) Immunoblotting for 
CC3 in LA1.1 cells expressing indicated gRNAs and indicated treatments (Doxo= 1 µM). (F) 
Viability assayed by Trypan blue exclusion in LA1.1 cells expressing indicated gRNAs and 
treatments (Doxo= 1 µM). Data in (A-D, F) represent mean values ±SEM (n=3-4 biological 
replicates). *p <0.05, ** p<0.01, and ***p<0.001, unpaired t test. 
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Data summary and conclusions 
Collectively, these data represent a comprehensive investigation of the p53 
response to oncogenic signaling and the gene networks that underlie common, 
tumor type-specific, and senescence- or apoptosis- specific p53 responses to this 
stress. Importantly, we uncovered a small core set of genes, including several novel 
lncRNAs, that were directly activated by p53 in all KPR tumor types, providing an 
important resource for future studies into the universal effects of p53 re-activation 
in cancer settings.  
Our data refutes the hypothesis that p53 decision-making is driven by the 
activation of unique, outcome-specific transcriptional networks, as we did not find 
any obvious senescence-specific of apoptosis-specific programs. These 
observations were initially surprising, given the striking, apparently stressor-
agnostic outcome-specificity of our KPR tumor-derived cell lines. However, this 
conclusion is consistent with an emerging model of p53 pathway function in which 
p53 is thought to activate a multifunctional and likely redundant core network, 
regardless of biological context (Andrysik et al. 2017; Verfaillie et al. 2016). In this 
model, context-specific p53 cellular responses would arise from cell- or stressor-
specific “interpretations” of this core p53 network, which could be p53-
independent. Interestingly, we did reveal a previously unappreciated connection 
between p53-mediated gene repression and oncogenic stress-induced senescence, 
but not apoptosis. The mechanism and importance of this repression remains to 
be explored further.  
This work also greatly expands the known catalogue of p53-activated 
lncRNAs, linking 16 previously undescribed lncRNAs to the p53 transcriptional 
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network, and specifically, the p53 response to oncogenic stress. Interestingly, a 
number of previously described lncRNAs induced by p53 in response to genotoxic 
stress (see Table 1.1), were not found in our work, suggesting significant species-
, cell line- or stress-dependent variability in the cohort of lncRNAs activated by 
p53. We found that most p53-activated lncRNAs remain at the chromatin, 
presumably at their sites of transcription (Werner and Ruthenburg 2015), and that 
many are co-regulated with their neighboring genes. These localization and 
regulatory patterns lead us to suppose that the primary role of p53-activated 
lncRNAs is cis-regulation, as exemplified by lincRNA-p21, Pvt1b, and two newly 
characterized lncRNAs: lincRNA-Gadd45γ (this chapter) and Ltc4s-as (discussed 
further in Chapter 5). Notably, the inhibitory function of Pvt1b appears to be 
unique in the p53 network and not a general mechanism by which p53 enacts gene 
repression as we did not find other examples of negative lncRNA-mRNA co-
regulation. This suggests that lncRNA-mediated cis activation, but not cis 
repression is a key feature of the p53 transcriptional network. 
Barring Pvt1b, loss of no individual tested p53-activated lncRNA was 
sufficient to bypass oncogenic stress-induced growth arrest. We interpret this to 
mean that the highly redundant nature of p53’s anti-growth response to oncogenic 
stress extends beyond just protein coding p53 targets and applies to lncRNA 
targets of p53 as well. Interestingly, these data also suggest that negative 
correlations between lncRNAs and neighboring protein coding genes, while 




Nevertheless, these data demonstrate the potential for p53-activated lncRNAs 
to contribute to p53 pathway regulation, and in the case of Pvt1b, the potential 
functional importance of cis-regulation in mediating p53 growth suppression. This 
concept of lncRNAs contributing to p53 regulated cellular responses, in possibly, 























Chapter 4:  




2310008N11Rik, hence-forth referred to as lncRNA 7, is one of the several 
previously undescribed p53-activated lncRNAs we identified in Chapter 3, and is 
an intergenic, spliced and poly-adenylated lncRNA of three exons located in a gene 
desert on chromosome 8 (Fig. 8A). This chapter is an in-depth characterization of 
this novel gene, which was chosen as an interesting p53-induced lncRNA for 
further study for several reasons, most notably its robust induction and expression 
profile across our KPR and genotoxic stress models, unique localization patterns, 
and possible conservation between mice and humans. Here, we investigate the role 
of lncRNA 7 in regulating p53-dependent cell cycle arrest and survival using 
exogenous overexpression and CRISPR-based epigenetic manipulations for 
lncRNA LOF and GOF. 
 
Results 
2310008N11Rik (lncRNA 7) is a previously undescribed lncRNA 
To confirm that this unstudied RNA was truly noncoding, protein coding 
potential was assessed in two ways. First, as discussed in Chapter 3, the Coding 
Potential Assessment Tool (CPAT) was employed. Full length lncRNA 7 had a 
CPAT score below the protein-coding threshold assigned to the mouse 
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transcriptome, suggesting a lack of coding potential (Table 3.1). Second, a 
number of recent publications have highlighted the potential of lncRNA loci to 
encode expressed and translated micropeptides. LncRNA-encoded micropeptides 
can be overlooked by both in silico coding assessment tools and mass proteomic 
analyses due to their small size (<100 amino acids) and potential non-canonical 
start codon usage, but are often identifiable by strong peaks of evolutionary 
conservation (Lewandowski et al. 2020; Anderson et al. 2015). As lncRNA 7 is 
found both in the nucleus and cytoplasm (Fig. 4B, C) and thus feasibly able to 
associate with the ribosome, manual binformatic analysis was performed to rule 
out the presence of any small but potentially translated ORFs within lncRNA 7 that 
may have been missed by CPAT. Using NCBI ORFinder, two putative small ORFs 
(sORFs) were identified, predicted to yield micropeptides of 13 (sORF1) and 21 
(sORF2) amino acids (Fig. 8B). However, comparing these putative peptides to 
publicly available protein databases yielded no significant matches within 
eukaryotes. Additional comparison of the RNA sequences of these putative 
peptides also revealed a lack of sequence conservation, further suggesting the 
absence of translated sORFs. In summary, lncRNA 7 was deemed unlikely to be 
micropeptide-encoding and thus represent a true novel lncRNA. 
 
LncRNA 7 is induced by oncogenic and genotoxic stress in a p53-
dependent manner 
In our original RNA-seq experiment in the panel of KPR cell lines, lncRNA 
7 was most robustly induced at 24h Tam treatment in the four independent lung 
adenocarcinoma (LA) and sarcoma (SA) cell lines, which undergo senescence upon 
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p53 restoration (LA1, LA2, SA1, SA2). In contrast, lncRNA 7 was less markedly 
upregulated at this time point in the two lymphoma (LY) cell lines (LY1, LY2), 
which undergo p53-dependent apoptosis. This observation was confirmed by qRT-
PCR in the same panel of six KPR cell lines (Fig. 8C), firmly establishing lncRNA 7 
as being induced in a p53-dependent manner under conditions of oncogenic stress 
and hinting at senescence-specific regulation.  
Intriguingly, lncRNA 7 shares synteny, if not primary sequence similarities, 
with a lncRNA located in the corresponding region on human chromosome 8, 
LINC01605 (Fig. 8A). Looking through publicly available data on p53 binding 
throughout the human genome (Wei et al. 2006), we noticed that p53 bound near 
LINC01605 in human colorectal cancer cells treated with 5-fluorouracil, leading us 
to wonder whether LINC01605 represented a putative human orthologue of 
lncRNA 7. Supporting this hypothesis, we saw that in human osteosarcoma (U2OS) 
cells with in-tact p53, LINC01605 was upregulated upon Nutlin-3 treatment, 
which stabilizes p53 protein through antagonizing interactions with MDM2 (Nag 
et al. 2013), signifying p53-dependent regulation of this human lncRNA (Fig. 8D). 
Moreover, LINC01605 has been recently reported to play a role in human colon 
cancer, indicating another link between this locus and cancer signaling pathways 
(Forrest et al. 2018). Thus, lncRNA expression from this region under conditions 
of oncogenic stress may be conserved in mice and humans.  
Further characterization revealed that lncRNA 7 was also induced under 
conditions of p53 stabilization in other cellular contexts. As discussed in Chapter 
2, MEFs treated with Doxo represent a well-established in vitro system to study 
p53-dependent processes downstream of genotoxic stress (Attardi et al. 2004).  
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LncRNA 7 upregulation was observed in Doxo-treated primary MEFs at as early as 
8h post-treatment, comparable to direct p53 target p21, and reached an average of 
5-fold induction at 24h (Fig. 8E). To further establish that this induction was 
directly through p53, lncRNA 7 levels were also assessed in p53LSL/LSL; Rosa26-
CreERT2 (p53-restorable) MEFs. In these MEFs, p53 is constitutively inactivated 
by the homozygous insertion of a LoxP-flanked STOP cassette into the endogenous 
p53 locus. Upon treatment with Tam, Cre-mediated excision of the STOP cassette 
restores p53 expression (Ventura et al. 2007). While treatment with Doxo had 
negligible effects on lncRNA 7 and p21 induction in the absence of Tam, significant 
induction was observed in p53-restorable MEFs upon Tam and Doxo treatment, 
indicating that induction relied on p53-proficiency (Fig. 8F). Of note, a milder 
induction of both lncRNA 7 and p21 was also observed in Tam only treated cells 
(Fig. 8F), likely reflecting a milder p53 response triggered by the stress naturally 
accumulated over time in cells lacking p53 (Ventura et al. 2007). 
 In further support of direct regulation by p53, lncRNA 7 was found to 
harbor a p53 response element (p53RE) within its first exon. The sequence of this 
p53RE perfectly matches the consensus p53RE motif and contains two directly 
juxtaposed half sites, both of which are features associated with high affinity 
p53REs (Riley et al. 2008). Indeed, p53 ChIP-qPCR confirmed p53 binding at this 






Figure 8: LncRNA 7 (2310008N11Rik) is a novel, p53-regulated lncRNA. (A) Schematic 
of lncRNA 7 locus, with nearest neighboring genes indicated in relation to distance from lncRNA 
7’s TSS. Asterisk indicates p53RE location. Shading marks region of shared genic synteny with 
human chromosome 8, centered around LINC01605. (B) Full length lncRNA 7 sequence and ORF 
analysis. Two putative sORFs identified by NCBI ORFinder are highlighted in orange. Results of 
peptide and nucleotide sequence conservation analysis are noted below. (C) qRT-PCR analysis of 
lncRNA 7 relative to endogenous control RNA Gapdh in the indicated KPR cell lines and 
treatments. Data show mean ±SEM (n=3 biological replicates). *p <0.05 and ** p<0.01, unpaired 
t test. (D) qRT-PCR analysis of LINC01605 relative to GAPDH in U2OS cells and indicated 
treatment (Nutlin= 5 µM). Data show mean ±SD (n=3 technical replicates). (E) qRT-PCR analysis 
of lncRNA 7 and p21 relative to Gapdh in primary MEFs treated with 0.5 µM Doxo, normalized to 
untreated control. Data show mean ±SEM (n=3 biological replicates). ** p<0.01, unpaired t test. 
(F) qRT-PCR analysis of lncRNA 7 and p21 relative to Gapdh in p53LSL/LSL; Rosa-CreERT2(p53-
restorable) MEFs treated as indicated (Doxo= 0.5 µM). Data show mean ±SD (n=2 biological 
replicates). (G) Top= lncRNA 7 p53RE sequence compared to consensus sequence. Bottom= 
Enrichment of p53 binding at lncRNA 7’s p53RE or a control region (gene desert) by ChIP followed 
by qRT-qPCR. Data show mean ±SD (n=3 technical replicates). 






Taken together, these data established that lncRNA 7 is a novel lncRNA 
directly activated by p53 in multiple biological contexts and suggested that lncRNA 
7 may play a significant role in the p53 pathway, either contributing to p53’s cell 
fate decision making in response to oncogenic stress or as a more general regulator 
of p53 activity. To test these hypotheses, we next set out to establish efficient, 
locus-appropriate LOF and GOF tools. Subcellular fractionation revealed that 
although lncRNA 7 is nuclear-enriched, a sizeable (~40%) fraction is also found in 
the cytoplasm in both KPR cells and primary MEFs (Fig. 4B, C). As discussed in 
Chapter 3, this cytoplasmic localization pattern was revealed to be somewhat 
unique to lncRNA 7 amongst the p53-responsive lncRNAs identified in our study. 
With this localization pattern and lncRNA 7’s status as an intergenic lncRNA in 
mind, the following GOF and LOF approaches were employed in order to 
interrogate lncRNA 7 function.  
  
Exogenous overexpression of lncRNA 7 yields no discernable effects on 
p53 pathway function 
As lncRNA 7 was initially identified as being preferentially upregulated in 
cells that undergo senescence, we first tested whether over-expressing lncRNA 7 
might affect cellular proliferation. While transgene overexpression (OE) is 
unsuitable for studying locally acting lncRNAs, the large fraction of endogenous 
lncRNA 7 found in the cytoplasm prompted as to investigate a potential trans-
acting role by first taking an exogenous lncRNA OE approach. Full-length lncRNA 
7 cDNA was stably introduced into cells using a retroviral vector, with an empty 
vector (EV) construct serving as a negative control. High levels of lncRNA 7 OE 
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were achieved in both KPR cells (LA1, LA2, SA1, SA2) and primary MEFs, reaching 
levels several hundred-fold beyond those achieved via endogenous activation upon 
either Tam or Doxo treatment, respectively (Fig. 9A).  
With these two in vitro models established, cellular proliferation was 
assessed in both the absence and presence of p53, rationalizing that if lncRNA 7 
works as a downstream target of p53, its OE might be able to recapitulate some 
aspect(s) of p53 activity in lieu of activation of the rest of the p53 network. 
However, lncRNA 7 OE had no significant effect on proliferation rates in either 
normally growing early passage primary MEFs, p53-deficient MEFs (i.e. p53-
restorable MEFs -Tam), or p53-deficient KPR cells. These data suggested that 
exogenous OE of lncRNA 7 does not promote senescence or cell cycle arrest in these 
diverse biological contexts (Fig. 9B). To test whether lncRNA 7 was perhaps indeed 
a necessary component of p53’s antiproliferative response but not sufficient to 
drive growth arrest in the absence of a competent p53 pathway, proliferation was 
also assessed in p53-proficient, p53-restorable MEFs. As predicted, Tam-treated 
p53-restorable MEFs grew at a slightly slower rate than un-restored, p53-deficient 
cells, reflecting a p53-dependent antigrowth response to stress accumulated in 
these cells prior to p53-restoration. However, this growth rate was comparable 
between lncRNA-7- and EV-expressing control cells, suggesting that exogenous OE 
of lncRNA 7 does not promote growth arrest in the presence of a competent p53 
network but no additional stress (Fig. 9B).  
Primary MEFs exposed to low levels of DNA damage undergo senescence, 
as detected through morphological changes (enlarged nuclei, enlarged and 
flattened cellular shape) and positive senescence-associated β-galactosidase (SA-β 
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gal) staining (Campisi and d’Adda di Fagagna 2007). To test whether exogenous 
OE of lncRNA 7 modulated this stress-induced senescence in MEFs, SA-β gal 
activity was monitored in lncRNA 7- and EV-expressing primary MEFs treated 
with low levels of Doxo for one week. MEFs over-expressing lncRNA 7 were as 
proficient at undergoing senescence as EV-expressing cells (Fig. 9C). LncRNA 7 
exogenous OE similarly had no significant effect on growth arrest in Tam-treated 
LA and SA KPR cells (Fig. 9D). Thus, transgene OE of lncRNA 7 did not appear to 
have any discernable effects on cellular proliferation in multiple independent cell 
lines, nor in response to either genotoxicity-induced or oncogene-induced growth 
arrest.  
Next, we tested whether lncRNA 7 might not promote cellular arrest, but 
rather prevent the initiation of an alternative cell fate upon p53 activation. 
Increased resistance to pro-apoptotic signals is a commonly observed feature in 
senescent cells (Childs et al. 2014; Soto-Gamez et al. 2019). Curious as to whether 
lncRNA 7 might play a pro-survival role, we assessed the effects of lncRNA 7 
exogenous OE on apoptosis in our primary MEF and LA and SA KPR models.  
While primary MEFs are predisposed to undergo p53-dependent cell cycle 
arrest in response to genotoxic stress, acute exposure to high levels of DNA damage 
can drive apoptosis (Attardi et al. 2004; Kastan et al. 1992). In the absence of Doxo, 
exogenous lncRNA 7 OE had no effect on viability in primary MEFs (Fig. 9E). 
Under pro-apoptotic conditions (i.e. treatment with 1 µM Doxo), apoptosis as 
measured by cleaved caspase 3 (CC3) was detectable in both lncRNA 7- and EV-
expressing cells. However, no significant differences were observed between the 
two conditions, indicating lncRNA 7 OE did not modulate the apoptotic response 
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to genotoxic stress in primary MEFs (Fig. 9E). E1A-expressing MEFs also undergo 
apoptosis in response to DNA damage in a specifically p53-dependent manner, and 
thus represent a widely-employed model to study components of the p53 pathway 
that contribute to apoptosis (Lowe et al. 1993a). Aiming to refine our investigation 
of lncRNA 7’s role in modulating apoptosis downstream of p53, control- or E1A-
expresssing p53-restorable MEFs were stably infected with EV or lncRNA 7 and 
treated with Tam to restore p53 and Doxo to induce apoptosis. Similar to what was 
observed in primary MEFs, lncRNA 7 OE did not have any effect on the extent of 
apoptosis observed in E1A-sensitized MEFs exposed to genotoxic stress (Fig. 9F).  
Also investigated were the effects of lncRNA 7 OE on viability in LA and SA 
KPR cells, which preferentially undergo p53-dependent senescence rather than 
apoptosis. As expected, EV-expressing control LA cells did not undergo 
appreciable apoptosis, either in the absence (-Tam) or presence (+Tam) of p53, 
confirming that p53-restoration is insufficient to drive apoptosis in these cells. 
This phenotype was not altered by lncRNA 7 OE (Fig. 9G). Hypothesizing that 
lncRNA 7 OE may confer cytoprotective effects solely under pro-apoptotic 
conditions, apoptosis was assessed in p53-restored LA and SA KPR cells treated 
with high levels of acute genotoxic stress (1 µM Doxo). While Doxo treatment was 
indeed able to drive SA cells to undergo apoptosis, lncRNA 7 OE had no significant 
effect on the extent of this apoptosis (Fig. 9H). Thus, these data altogether suggest 
that exogenous lncRNA 7 OE does not alter p53 outcome-specificity or pathway 





Figure 9: LncRNA 7 exogenous OE does not affect cellular proliferation or apoptosis 
under genotoxic or oncogenic stress. (A) qRT-PCR analysis of lncRNA 7 in primary MEF and 
KPR cell lines expressing either lncRNA 7 overexpression (OE; L7) or empty vector (EV) control 
and treatments (Doxo= 0.5 µM). Data show mean ±SEM (n=3 biological replicates). *p <0.05 and 
** p<0.01, unpaired t test. (B) Growth curves in indicated EV and L7 cell lines and treatments 
passaged over time. For primary MEF experiments, data represent mean ±SEM (n=3 biological 
replicates), unpaired t test at each passage. For p53-restorable and KPR cell lines, data are 
representative. (C) Senescence-associated β-galactosidase staining in indicated cell lines and 
treatment. (D) Cumulative cell numbers over time in indicated Tam-treated EV and L7 KPR cell 
lines. (E) Left= Representative immunoblot for CC3 protein in indicated cell lines and treatments. 
α-tubulin served as a loading control. Right= Densitometry analysis of CC3 levels relative to loading 
control, normalized to EV. Data show mean ±SEM (n=3 biological replicates). ns=not significant, 
unpaired t test. (F) Immunoblotting for CC3 protein in indicated cell lines treated with 48h Tam 
and 24h 0.5 µM Doxo. α-tubulin served as a loading control. (G) Representative FACS plots of EV 
and L7 LA KPR cells, untreated or treated with 48h Tam prior to Annexin V/PI analysis. (H) 
Immunoblotting for CC3 protein in indicated cell lines treated with 48h Tam and 24h 0.5 µM Doxo. 






Epigenetic downregulation of lncRNA 7 may affect cellular 
proliferation during specifically the oncogenic stress response 
Next in our efforts to characterize lncRNA 7 was to develop strategies to 
manipulate the endogenous expression of lncRNA 7, starting with a suitable LOF 
approach. While CRISPR-Cas9 mutagenesis of lncRNA-associated p53REs proved 
to be highly effective for the molecular dissection of several other p53-activated 
lncRNAs (see Chapter 3), the lack of compatible PAM sites precluded the use of 
this genetic strategy for lncRNA 7 (Fig. 5A, B). Instead, we turned to CRISPR-
inhibition (CRISPRi) to epigenetically silence the lncRNA 7 locus. CRISPRi was 
achieved by recruiting nuclease-deficient Cas9 fused to the transcriptionally 
repressive Krüppel- associated box domain of Kox1 (dCas9-KRAB) (Gilbert et al. 
2013) to lncRNA 7’s TSS. With this approach, we aimed to take advantage of the 
fact that lncRNA 7 resides in a gene desert, thus minimizing the likelihood of 
CRISPR-based modulation of the locus directly interfering with the expression of 
other nearby genes.  
A panel of eight lncRNA 7-targeting gRNAs were designed, selected for high 
specificity (score >70/100 via CRISPOR) and TSS proximity. gRNAs were screened 
for efficacy in p53-restorable MEFs engineered to stably express dCas9-KRAB 
(Fig. 10A, B). Remarkably, all tested guides were able to knockdown lncRNA 7 
levels by 70-85% compared to a non-targeting control (Con) gRNA (Fig. 10B). 
Three of the most efficient gRNAs (gRNAs #7, #9, #10) were selected for further 
functional investigation of the consequences of lncRNA 7 loss on p53 pathway 
function in MEFs. Despite achieving high levels of lncRNA 7 knockdown, no overt 
effects on cellular proliferation were observed, as assayed through either growth 
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curve analysis (Fig. 10C-left) or BrdU incorporation (Fig. 10C-right). Similarly, no 
consistent effects on DNA damage-induced apoptosis were observed (Fig. 10D). 
Taken together, these data suggested that lncRNA 7 is dispensable for the p53 







Figure 10: Epigenetic silencing of lncRNA 7 locus does not affect p53 pathway 
function in p53-restorable MEFs. (A) Diagram of PAM locations of designed lncRNA 7-
targeting gRNAs. Ex1= exon 1. (B) qRT-PCR detection of dCas9-KRAB in engineered p53-
restorable-dCas9-KRAB MEFs and lncRNA 7 levels in indicated gRNA-expressing cells and 
treatments, relative to Gapdh (Doxo= 0.5 µM). C= nontargeting control gRNA. Data show mean 
±SD (n=3 technical replicates). (C) Left= Growth curves in indicated cell lines and treatments. 
Right= BrdU incorporation in indicated cell lines following 24h Tam and 4h BrdU treatment. Cells 
were scored for BrdU (FITC) incorporation by immunofluorescence and total number BrdU 
positive nuclei plotted over total scored nuclei per cell line. (D) Two representative immunoblots 





Next we assessed the effects of lncRNA 7 LOF in our KPR oncogenic stress 
model, hypothesizing that lncRNA 7 may be induced by p53 across many different 
contexts but only functionally important in certain cell-type- and/or stressor-
specific settings, as has been previously suggested for other p53 targets (Mello et 
al. 2017; Kastenhuber and Lowe 2017). Surprisingly, screening the same lncRNA 
7-targeting gRNAs in LA1.1 cells stably expressing dCas9-KRAB revealed that 
dCas9-KRAB-mediated CRISPRi yielded 40-60% lncRNA 7 knockdown compared 
to non-targeting control gRNA-expressing cells, in contrast to the 70-85% 
knockdown observed in MEFs (Fig. 11A-left). These differences in CRISPRi efficacy 
may reflect cell-intrinsic differences in chromatin state at this locus. The three top 
LA1.1 performing gRNAs were subsequently introduced into parental LA1 cells 
engineered to express a Doxycycline (Doxy)-inducible dCas9-KRAB construct, 
which would facilitate more precise timing of LOF experiments (Fig. 11A-right). Of 
the three gRNAs tested, only one guide (gRNA #12) appeared to confer a slight 
growth defect, despite all three guides yielding comparable levels of lncRNA 7 
knockdown (Fig. 11A, B). This phenotype was initially encouraging and explored 
further in experiments detailed in Chapter 5, in which the role of lncRNA 7 and 
several other senescence-associated lncRNAs is more finely examined. 
 
Modest transcriptional activation of endogenous lncRNA 7 does not 
affect cellular proliferation in LA KPR cells 
 As discussed in Chapter 1 and Chapter 3, lncRNAs can very broadly be 
grouped as functioning near (cis-acting) or distal to (trans-acting) their sites of 
transcription, with each category having unique constraints on the types of suitable 
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LOF and GOF approaches. Considering the results of our exogenous lncRNA 7 OE 
experiments, we wondered whether the apparent lack of an appreciable phenotype 
stemmed from lncRNA 7 indeed playing a local, cis-regulatory role. In that 
scenario, a transgenic OE GOF approach would not be expected to have a 
phenotype, as transgenic lncRNA 7 would not be properly localized to its 
endogenous site of function. To experimentally address this hypothesis, we turned 
to CRISPRa as an alternative GOF strategy. Specifically, we employed gRNA-
mediated recruitment of nuclease-dead Cas9 fused to four copies of the 
transcription activator VP16 (dCas9-VP64) (Gilbert et al. 2013) to promote the 
transcriptional upregulation of lncRNA 7 from its endogenous locus. 
Three gRNAs targeting lncRNA 7’s TSS (gRNAs #9, #10, #12; annotated in 
Fig. 10A) were tested in LA1.1 and LA1 cells engineered to constitutively express 
dCas9-VP64. gRNA #12 did not yield lncRNA 7 upregulation in either LA1.1 or LA1 
cells. In contrast, gRNAs #9 and #10 led to the upregulation of lncRNA 7 levels to 
4x and 8x above a nontargeting control gRNA (Con) in un-restored LA1.1 cells, 
reaching roughly 22% and 50% of the lncRNA 7 levels observed upon full p53 
restoration. In p53-restored LA1.1 cells, gRNAs #9 and #10 activated lncRNA 7 to 
2x and 4x above control, respectively (Fig. 11C-Left). LncRNA 7 CRISPRa was 
slightly more efficient in LA1 cells, with gRNA #9 yielding 5x upregulation (24% 
full lncRNA 7 induction) and gRNA #10 yielding 11x upregulation (55% full 
lncRNA 7 induction) in un-restored cells, and 6x and 5x upregulation, respectively, 
upon Tam-treatment (Fig. 11C-Right). Thus, recruitment of dCas9-VP64 to 
lncRNA-7’s TSS was able to drive modest induction of lncRNA 7 for two of the three 
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gRNAs tested, suggesting that CRISPRa efficacy positively correlates with 
proximity to TSS, as has been previously reported (Konermann et al. 2014). 
Next, the effects of lncRNA 7 CRISPRa on cellular proliferation were 
assayed, both in the absence and presence of p53. Upregulation of endogenous 
lncRNA 7 had no effect on cellular proliferation in the absence of p53, as measured 
by growth curve analyses in both LA1 and LA1.1 cells (Fig. 11D). This was despite 
gRNA #10 driving lncRNA 7 expression in un-restored cells to levels approaching 
that seen in control gRNA-expressing cells upon p53 activation (Fig. 11D). 
Similarly, lncRNA 7 activation did not significantly affect growth arrest upon p53 
restoration in either Tam-treated LA1.1 or LA1 cells (Fig. 11E). Taken together, 
these CRISPRa data suggested that locally-acting lncRNA 7 may not contribute to 
p53’s antiproliferative response to oncogenic stress, despite lncRNA 7 being 
activated by p53 in such conditions. Alternatively, a threshold of lncRNA 7 
transcription might be required for function, and the levels of activation achieved 
using solely the recruitment of dCas9-VP64 may be insufficient. The functional 
consequences of significantly higher endogenous lncRNA 7 activation are further 












Figure 11: Assessing lncRNA 7 CRISPRi and CRISPRa in KPR LA cells. (A) qRT-PCR 
detection of dCas9-KRAB in LA1.1 and LA1 cells engineered to stably express dCas9-KRAB and 
lncRNA 7 levels in indicated gRNA-expressing cells and treatments, relative to Gapdh. Data show 
mean ±SD (n=3 technical replicates). (B) Cumulative cell numbers over time in indicated Tam-
treated LA1-dCas9-KRAB cell lines. (C) qRT-PCR detection of dCas9-VP64 in LA1.1 and LA1 cells 
engineered to stably express dCas9-VP64 and lncRNA 7 levels in indicated gRNA-expressing cells 
and treatments, relative to Gapdh. Data show mean ±SD (n=3 technical replicates). (D) Growth 
curves in indicated cell lines and treatments. (E) Cumulative cell numbers over time in indicated 












Data summary and conclusions 
These data firmly establish lncRNA 7 as a novel lncRNA directly activated 
by p53 in multiple cellular and stressor contexts. Moreover, we confirm the 
presence of a syntenic human lincRNA (LINC01605) that is also p53-responsive in 
Nutlin 3-treated human osteosarcoma cells, suggesting conserved p53 regulation, 
though the importance of this p53 regulation in human cells is an intriguing 
unknown. 
Although we found that lncRNA 7 was strongly induced by DNA damage in 
MEFs, we were unable to find any evidence for lncRNA 7 significantly contributing 
to cellular proliferation, senescence, or apoptosis in this context. Similarly, 
exogenous OE of lncRNA 7 did not influence the p53 outcomes of LA and SA cells, 
despite the preferential induction of lncRNA 7 in these four senescing KPR cell 
lines. These data suggest that lncRNA 7 does not function in trans to modulate 
oncogenic stress-driven cellular senescence. It is also unlikely that trans-acting 
lncRNA 7 has cytoprotective effects against either genotoxic or oncogenic stress, at 
least in LA and SA cells and MEFs, which are naturally resistant apoptosis. Thus, 
we conclude that lncRNA 7 is unlikely to exert any functions in trans downstream 
of p53 activation, despite its cytoplasmic localization.  
The effects of lncRNA 7 LOF and GOF in KPR cells is explored further in 








Chapter 5:  
Senescence-associated lncRNAs in p53 pathway function 
  
Introduction 
The underlying drivers of p53 cell fate decision making, or why certain 
cellular conditions lead to one p53 stress response versus another, remain poorly 
understood (see Chapters 1 and 2). Senescence is an irreversible state of 
proliferative arrest that can be triggered by a number of stress stimuli and is 
characterized by distinct morphological, epigenetic, molecular, and secretory 
phenotypes (Campisi and d’Adda di Fagagna 2007). Cellular senescence is thought 
to act as a safeguard against the persistent growth of cells that have accumulated 
irreparable DNA damage. As such, senescence has been implicated in numerous 
homeostatic processes, including tissue repair and immune clearance, as well as 
several age-associated pathologies, such as neurodegeneration, chronic 
inflammation, tissue degeneration, and cancer (Muñoz-Espín and Serrano 2014; 
Campisi 2013). In cancer, senescence can be both tumor suppressive and 
oncogenic, largely due to the pleiotropic effects of the proinflammatory SASP 
(senescence-associated secretory phenotype) (Muñoz-Espín and Serrano 2014; 
Collado and Serrano 2010). Nonetheless, p53 is known to be an important 
upstream activator of oncogene-induced senescence (Serrano et al. 1997; Campisi 
and d’Adda di Fagagna 2007) and p53-dependent senescence can be an important 
barrier to tumor progression in vivo (Xue et al. 2007; Ventura et al. 2007; Feldser 
et al. 2010; Li et al. 2014). 
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In this chapter, we address the long-standing question of why p53 elicits 
senescence in certain tumor types while apoptosis is initiated in others (Ventura et 
al. 2007; Symonds et al. 1994). Specifically, we investigate the importance of p53-
activated lncRNAs that are preferentially expressed during oncogene-induced 
senescence over oncogene-driven apoptosis. While a handful of lncRNAs have 
previously been associated with senescence (Abdelmohsen et al. 2013; Hu et al. 
2014; Ghanam et al. 2017), the broader importance of lncRNAs in establishing or 
maintaining senescence driven by oncogenic stress is incompletely understood. 
 
Results 
Identification of senescence-associated lncRNAs 
To identify candidate lncRNA loci that may contribute to p53 outcome-
specificity, we leveraged a key feature of the KPR mouse model in which cell lines 
derived from distinct tumor types respond differently to Tam-mediated p53 
restoration (Fig. 2). Namely, lung adenocarcinoma cell lines (LA1, LA2) and 
sarcoma cell lines (SA1, SA2) undergo senescence with no appreciable apoptosis, 
thus representing an ideal in vitro system to identify novel factors contributing to 
p53-mediated senescence across four independent cell lines representing two 
independent tissue contexts. As detailed in Chapter 3, 21 lncRNAs were found via 
genome-wide p53 ChIP-seq and RNA-seq analyses to be activated by p53 across 
various KPR cell lines (Table 3.1). Amongst these 21 lncRNAs, closer examination 
of expression patterns across the six KPR cell lines revealed that several lncRNAs 
were preferentially upregulated in LA and SA cells upon p53-restoration, 
compared to the two independent lymphoma cell lines (LY1, LY2) (Fig. 12A).  
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Curious as to whether these apparent senescence-specific expression 
patterns reflected a shared function, four of these oncogenic-stress induced 
lncRNAs were selected for further study (2310008N11Rik [lncRNA-7], Bfsp2-as, 
Ltc4s-as, and Neat1), first confirming the expression patterns observed in our 
RNA-seq dataset via qRT-PCR across the six KPR cell lines (Fig. 12B). All four 
lncRNAs were also induced in primary MEFs exposed to acute DNA damage, as 
would be expected of direct targets of p53 (Fig. 12C). Interestingly, lncRNA-7, 
Bfsp2-as, Ltc4s-as, and Neat1 levels also accumulated in MEFs under sustained 
exposure to low levels of DNA damage, which also promotes senescence (Fig. 12D). 
Indeed, lncRNA expression patterns paralleled those of key mediators of 
senescence, p21 and p16 (Serrano et al. 1997), which also accumulated over 
exposure time as is characteristic of cells undergoing senescence (Lin et al. 1998; 
Campisi and d’Adda di Fagagna 2007) (Fig. 12D). 
In searching for other p53-regulated lncRNAs that may also have outcome-
specific expression patterns, a striking senescence-specificity was revealed for 
9230114K14Rik (henceforth referred to as lincRNA-RAPT1). While lincRNA-
RAPT1 did not meet our stringent filtering criteria to be called as an oncogenic 
stress-responsive, p53-activated lncRNA in our genome-wide KPR dataset, it had 
previously been implicated as a target of p53 (Guttman et al. 2009) and clearly 
demonstrated p53-dependent induction in Tam-treated KPR cells (Fig. 12B) and 
DNA damage-treated MEFs (Fig. 12C, D). Thus, lncRNA-7, Bfsp2-as, Ltc4s-as, 
Neat1, and lincRNA-RAPT1 were determined to be induced by both oncogenic 





Figure 12: Several p53-activated lncRNAs have senescence-associated expression 
patterns. (A) RNA-seq values (log2 FC) in indicated KPR cell lines treated with 24h Tam 
normalized to untreated samples. (B) qRT-PCR analysis of indicated lncRNAs relative to Gapdh in 
indicated KPR cell lines. Fold change were calculated by normalizing to untreated cells. Data show 
mean ±SEM (n=3 biological replicates). *p <0.05, ** p<0.01, and *** p<0.001, unpaired t test. (C) 
qRT-PCR detection of indicated lncRNAs in primary MEFs treated with 24h mock or 24h 0.5 µM 
Doxo. Data show mean ±SEM (n=3 biological replicates). *p <0.05, ** p<0.01, and *** p<0.001, 
unpaired t test. (D) qRT-PCR detection of indicated lncRNAs and p21 and p16 mRNA in primary 
MEFs treated as indicated. Data show mean ±SD (n=3 technical replicates). 









Characterization of lincRNA-RAPT, a novel p53-activated lncRNA 
LincRNA-RAPT1 was selected for functional characterization first, due in 
part to the availability of powerful genetic tools developed and initially 
characterized in our lab by N. Dimitrova, and several unique features of this 
lncRNA locus (described shortly). 
 LincRNA-RAPT1 is a polyadenylated, 9.1 kb-long transcript comprised of 
four exons. While lincRNA-RAPT1 had previously come up as a transcript that was 
induced by DNA damage in a p53-dependent manner in one of the earliest 
genome-wide lincRNA datasets (Guttman et al. 2009), it had not been functionally 
followed up on nor established to be a true direct target of p53. Our own 
investigation of the lincRNA-RAPT1 locus revealed the presence of multiple p53 
response elements (p53REs) within lincRNA-RAPT1’s first intron (Fig. 13A), 
providing evidence for direct regulation by p53 and a basis for the p53-dependent 
induction patterns observed in our two in vitro model systems (Fig. 12B, C). In the 
UCSC genome browser, lincRNA-RAPT1 is annotated as RIKEN cDNA 
9230114K14Rik, with several variants reflecting alternative splicing patterns and 
multiple TSSs and termination sites (Fig. 13A). Deep RNA-sequencing of primary 
MEFs performed by N. Dimitrova provided further evidence for the presence of 
multiple transcript variants, while also revealing that full length (FL) lincRNA-
RAPT1 in fact extends 8 kb beyond the last annotated termination site (Fig. 13A).  
Intriguingly, early sequence analysis performed by N. Dimitrova also 
identified a short (15 nt) region of complementarity between lincRNA-RAPT1 and 
p53 mRNA’s 5’ untranslated region (5’ UTR) (Fig. 13B). Of note, this region of 
complementarity, which fell within the extended lincRNA-RAPT1 exon four, 
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corresponded to a region of p53 mRNA also predicted to base-pair with its own 3’ 
UTR. Such 5’UTR-3’UTR interactions had previously been shown to be important 
for promoting the translation of human p53 under conditions of stress (Chen and 
Kastan 2010; Chen et al. 2012). Thus, we were intrigued by the possibility that 
lincRNA-RAPT1 may contribute to either p53 outcome-specificity or general p53 
pathway robustness, potentially though RNA-RNA interactions with p53 itself.  
In order to further interrogate the role of lincRNA-RAPT1 in the p53 
network, two complementary genetic mouse models were developed prior to my 
taking on the project and will be briefly described here. Care was taken to design a 
knockout strategy that would abolish p53-dependent lincRNA-RAPT1 expression 
without affecting the expression of Dhx15, which is a protein coding gene that 
lincRNA-RAPT1 shares a promoter with (Fig. 13A). Dhx15 (also known as Prp43) 
is a DEAD/DEAH box RNA helicase implicated in ribosome biogenesis and 
spliceosome disassembly (Combs et al. 2006). Unlike lincRNA-RAPT1, Dhx15 did 
not appear to be significantly regulated by p53 (Fig. 13E). While it is unclear how 
two genes sharing a promoter can be differentially regulated as such, it is possible 
that the intronic location of lincRNA-RAPT1’s p53REs provide an explanation. 
Importantly, Dhx15 has not been previously implicated in senescence. Thus, we 
concluded that lincRNA-RAPT1 and Dhx15 are unlikely to be functionally linked.  
To avoid disrupting the shared promoter while designing a conditional 
knockout (KO) allele, loxP sites were inserted within the first and second introns 
of lincRNA-RAPT1. This allele will be referred to as the floxed (fl) allele (Fig. 13C-
top). The lincRNA-RAPT1 constitutive KO (null; -) allele was subsequently 
generated by crossing lincRNA-RAPT1fl/fl mice to transgenic mice constitutively 
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expressing Cre recombinase, leading to the generation of mice in which the region 
between the two loxP sites has been excised. Importantly included in this excised 
region are lincRNA-RAPT1’s p53REs (Fig. 13C-bottom).  
The following lincRNA-RAPT1 characterization experiments were 
performed in early passage primary MEFs of two complementary lincRNA-RAPT1 
genetic backgrounds: (1) lincRNA-RAPT1fl/fl; Rosa26-CreERT2 or (2) lincRNA-
RAPT1-/- vs lincRNA-RAPT1+/+. For conditional KO experiments, lincRNA-
RAPT1fl/fl; Rosa26-CreERT2 MEFs were isolated from homozygous crosses 
between lincRNA-RAPT1fl/fl; Rosa26-CreERT2 mice. In these cells, the addition of 
Tam facilitates in vitro CreER-mediated recombination of the floxed allele and loss 
of lincRNA-RAPT1 expression. Mock treatment served as a control, allowing 
isogenic comparisons of wild type (WT) and KO cells (Fig. 13D- top). Importantly, 
this strategy led to a 95% decrease in lincRNA-RAPT1 levels, effectively abolishing 
p53-dependent induction, whereas Dhx15 expression was not significantly affected 
(Fig. 13E). For constitutive KO experiments, littermate lincRNA-RAPT1+/+ and 
lincRNA-RAPT1-/- MEFs were isolated from crosses of lincRNA-RAPT1+/- 








Figure 13: LincRNA-RAPT1 (9230114K14Rik) locus and development of knockout 
mouse models. (A) Top= UCSC genome browser view (mm10) of Riken cDNA 9230114K14Rik, 
henceforth referred to as lincRNA-RAPT1. Bottom= Schematic of Dhx15 / lincRNA-RAPT1 locus, 
including previously unannotated region of lincRNA-RAPT1 exon 4 identified by RNA-seq. p53REs 
are marked by asterisks. (B) Schematic of 15 nt region of complementarity between lincRNA-
RAPT1 and p53 mRNA 5’ UTR (highlighted in blue). Also illustrated is predicted complementarity 
between p53 mRNA 5’ UTR and 3’ UTR. (C) Schematic of floxed (fl) and null (-) lincRNA-RAPT1 
alleles, with important features labeled as indicated. p53UCS= p53 UTR complementary sequence. 
(D) Matings and in vitro drug treatments for generating primary MEF cell lines of indicated 
genotypes. (E) qRT-PCR detection of lincRNA-RAPT1 and Dhx15 in primary MEFs of indicated 
genotypes and treatments relative to Gapdh, normalized to WT untreated cells (Doxo=0.5 µM). 
Data show mean ±SEM (n=2 biological replicates). ** p<0.01 and *** p<0.001, ns= not significant, 
unpaired t test. 
In (A), lincRNA-RAPT1 unannotated region indicated was identified by N. Dimitrova via RNA-seq 
(data not shown). In (B), 15 nt p53UCS was identified by N. Dimitrova. Mouse alleles/genetic 
models described above and in text were developed by N. Dimitrova, though all characterization 





To determine whether loss of lincRNA-RAPT1 led to any changes in 
proliferation, growth curve analyses were performed in lincRNA-RAPT1 WT and 
KO MEFs. Despite the drastic reduction in lincRNA-RAPT1 levels achieved, no 
significant differences in proliferation rate were observed (Fig. 14A). As lincRNA-
RAPT1-deficient MEFs appeared to grow normally, suggesting lincRNA-RAPT1 
did not regulate growth arrest downstream of p53, we next wondered whether 
lincRNA-RAPT1 may regulate other aspects of p53 activity. A few p53-activated 
lncRNAs have been reported to regulate p53 activity in positive feedback loops (see 
Table 1.1), though none have been reported to interact with p53 mRNA. Given 
lincRNA-RAPT1’s short region of complementarity with p53 mRNA’s 5’ UTR, we 
questioned whether the loss of lincRNA-RAPT1 affected p53 RNA and/or protein 
levels. In constitutive KO MEFs, p53 mRNA levels were not significantly altered 
compared to WT MEFs in either the presence or absence of DNA damage (Fig. 
43B). This was also true in conditional KO MEFs (Fig. 14D), implying that 
lincRNA-RAPT1 did not influence p53 mRNA transcription and/or stability. 
Given that cellular stress promotes the translation of p53 mRNA (Takagi et 
al. 2005) and p53 protein stabilization (Horn and Vousden 2007), we next 
questioned whether lincRNA-RAPT1 promoted p53 protein levels during stress. 
Increases in p53 protein were detectable in both WT and lincRNA-RAPT1 KO 
MEFs at as early as 6h Doxo treatment (Fig. 14C). However, in comparing 
littermate WT and constitutive KO MEFs, significant variability in p53 protein 
levels was consistently observed, even amongst independent littermate WT 
controls (Fig. 14C). Considering this apparent variability in p53 protein levels, 
which could stem from heterogeneity in basal p53 levels or handling stress, we 
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decided to focus on our conditional lincRNA-RAPT1 KO model, which allows 
isogenic comparisons. Similar experiments in lincRNA-RAPT1 conditional KO (i.e. 
Tam-treated) and WT (i.e. mock-treated) MEFs demonstrated no consistent effect 
on p53 protein levels at either 6h or 24h Doxo treatment (Fig. 14E). Given the 
accumulation of lincRNA-RAPT1 under pro-senescent conditions (Fig. 12B, D), we 
also tested whether lincRNA-RAPT1 loss affected p53 levels under conditions in 
which MEFs undergo senescence and did not see a significant difference compared 
to control MEFs (Fig. 14F), though substantial variability in p53 protein levels 
across biological replicates was observed.  
Curious about potential biological explanations for this persistent 
phenotypic variability, in which several experiments in multiple independently-
derived cell lines suggested some level of positive correlation between lincRNA-
RAPT1 and p53 protein levels, we next performed more experiments further 
characterizing our lincRNA-RAPT1 KO allele. Single molecule RNA FISH (smRNA 
FISH) of WT and KO MEFs treated with DNA damage (Doxo) to induce lincRNA-
RAPT1 expression revealed the persistence of cytoplasmic lincRNA-RAPT1 signal 
in KO cells, albeit at drastically reduced levels (Fig. 14G-top). These data were 
consistent with the endogenous localization pattern of WT lincRNA-RAPT1 as 
determined by subcellular fractionation (Fig. 14G-bottom), as well as our qRT-PCR 
data showing highly efficient (>90%) but not complete lincRNA-RAPT1 
knockdown in KO cells.  
In order to better characterize the RNA products of this persistent 
transcription from the lincRNA-RAPT1 locus in KO cells, we designed a series of 
qRT-PCR primers spanning lincRNA-RAPT1, aiming to capture transcript variants 
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utilizing the locus’ many alternate start, splice, and termination sites (Fig. 14H-
top). Surprisingly, absolute transcript abundance analysis using these primers in 
WT and KO MEFs exposed the presence of quantifiable amounts of lincRNA-
RAPT1 in KO MEFs (Fig. 14H-bottom), leading us to conclude that the lincRNA-
RAPT1 KO allele is in fact a hypomorph. 
 In summary, our work establishes lincRNA-RAPT1 as a direct target of p53, 
though its contributions to downstream processes regulated by p53 and possibly 



















Figure 14: Characterization of lincRNA-RAPT1. (A) Growth curves in primary MEFs of 
indicated genotypes. Data represent mean cell numbers ±SEM (n=4 biological replicates), unpaired 
t test at each passage. (B) qRT-PCR analysis of lincRNA-RAPT1 and p53 mRNA in primary MEFs 
of indicated genotypes and treatments relative to Gapdh (Doxo=0.5 µM). Data show mean ±SEM 
(n=3 biological replicates). * p<0.05, ns= not significant, unpaired t test. (C) Immunoblotting for 
p53 protein in indicated cells and treatments. HSP90 served as a loading control. (D) qRT-PCR 
analysis of lincRNA-RAPT1 and p53 mRNA in primary MEFs of indicated genotypes and 
treatments relative to Gapdh, normalized to untreated WT MEFs (Doxo=0.5 µM). Data show mean 
±SEM (n=3 biological replicates). *** p<0.001 and **** p<0.0001, ns= not significant, unpaired t 
test. (E, F) Left= Representative immunoblot for p53 protein in indicated cells and treatments 
(Doxo in (E) =0.5 µM). HSP90 served as a loading control. Right= Densitometry analysis of p53 
protein levels relative to loading control. Data show mean ±SEM (n=3 biological replicates). ns=not 
significant, paired t test. (G) Top= smRNA-FISH of lincRNA-RAPT1 in indicated cells treated with 
24h 0.5 µM Doxo. Note- background signal in nuclei from Doxo autofluorescence. Bottom= qRT-
PCR detection of controls (Rn7sl= cytoplasm; Kcnq1ot1= chromatin) and lincRNA-RAPT1 after 
subcellular fractionation in WT primary MEFs treated with 24h 0.5 µM Doxo. CP= cytoplasmic. 
NP= nucleoplasmic. CHR= chromatin-associated. (H) Top= Diagram indicating locations of qRT-
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PCR primers across lincRNA-RAPT1 exons. Bottom= Copy number calculations for lincRNA-
RAPT1 as detected by qRT-PCR with indicated primer pairs in WT and KO MEFs 
 
Description of oncogenic stress-induced, senescence-associated 
lncRNAs 
In order to determine whether additional lncRNAs contributed to p53 
cellular decision making in our KPR model, we selected four candidates from our 
list of oncogenic stress-induced lncRNAs that were found to have senescence-
associated expression patterns (Fig. 12). The lncRNAs selected were: 
2310008N11Rik (lncRNA 7), Bfsp2-as, Ltc4s-as, and Neat1. Of these four 
lncRNAs, only Neat1 had been previously studied and is a monoexonic intergenic 
lncRNA located on chromosome 19 (Fig. 15A-iv). Interestingly, Neat1 has recently 
been implicated in the p53 response to oncogenic stress (Mello et al. 2017) 
(discussed further in Chapter 1).  
The three other senescence-associated lncRNA candidates had not been 
previously studied, nor linked to the p53 pathway. LncRNA 7 is an intergenic 
lncRNA located on chromosome 8 (Fig. 15A-i) and is discussed more in Chapter 
4, which is an in-depth characterization of this novel lncRNA.  
Ltc4s-as (RIKEN cDNA AK157916) is a 1.2 kb spliced and polyadenylated 
transcript of three exons (Fig. 15A-ii). As touched upon in Chapter 3, Ltc4s-as is 
transcribed antisense to two protein-coding genes, Ltc4s and Maml1. Ltc4s 
(Leukotriene C4 synthase) encodes an enzyme involved in the conversion of 
arachidonic acid to cysteinyl leukotrienes, which are important lipid inflammatory 
mediators. Although it has not been previously implicated in the p53 pathway, 
Ltc4s has been linked to anaphylaxis and other inflammatory responses in humans 
107 
 
(Funk 2001; Lam and Frank Austen 2002). Maml1 (Mastermind-like protein 1) is 
a transcriptional co-activator in the Notch signaling pathway and, interestingly, 
has been reported to also interact with p53 protein and promote p53 
transactivation in human breast cancer cells (Zhao et al. 2007; Yun et al. 2015). In 
contrast to Ltc4s-as and Ltc4s, which were found to be transcriptionally activated 
in multiple LA and SA KPR cells lines upon Tam treatment, Maml1 expression was 
not significantly altered by either p53 restoration or mutagenesis of Ltc4s-as’ 
p53RE (Fig. 5C), suggesting that Maml1 is not regulated in a p53-dependent 
manner. 
Bfsp2-as (RIKEN cDNA 5830418P13Rik) is a polyadenylated transcript 2.2 
kb in size, comprised of six exons, and is transcribed antisense to the gene Bfsp2 
(Beaded filament structural protein 2) (Fig. 15A-iii). Bfsp2 is an ocular lens-
specific intermediate filament important for eye development (Perng et al. 2007). 
While Bfsp2 did emerge as a p53-responsive gene in a previously published 
genome-wide dataset (Tonelli et al. 2017), it has never been studied in the context 
of the p53 stress response nor implicated in any known p53-regulated cellular 
processes.  
 
Functional investigation of the role of lncRNAs in mediating p53 
outcome-specificity in response to oncogenic stress  
Candidate loci determined, we elected to take CRISPR-based approaches to 
epigenetically down or up-regulate lncRNA expression, which is a strategy that has 
been employed to functionally interrogate noncoding loci with great success in 
recent years (Liu et al. 2017; Joung et al. 2017; Fulco et al. 2016). For senescence-
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associated lncRNA LOF, we employed CRISPR-based transcriptional 
interference/inhibition (CRISPRi). In this system, catalytically inactive Cas9 fused 
to the KRAB (dCas9-KRAB) was recruited to the TSSs of target loci in a gRNA-
directed manner (Fig. 15B). We anticipated that both steric transcriptional 
interference from dCas9 and epigenetic repression from KRAB-mediated 
recruitment of repressive chromatin modifiers would lead to the knockdown of 
target lncRNA expression (Gilbert et al. 2014; Thakore et al. 2015). Two TSS-
targeting gRNAs were designed for each senescence-associated lncRNA, with care 
being taken to design guides with high specificity (scores >70/100 via CRISPOR) 
and suitability for both CRISPRi and CRISPRa manipulations (Fig. 15A- right). 
In order to interrogate the effects of lncRNA loss on either the 
establishment or maintenance of senescence in LA and SA KPR cells, a Doxy-
inducible dCas9-KRAB system was selected, which would allow more temporal 
control over lncRNA LOF. LA1 and SA1 cell lines stably expressing (TRE)dCaS9-
KRAB were established and confirmed to undergo senescence upon Tam-mediated 
p53 restoration with dynamics comparable to parental LA1 and SA1 cells (Fig. 16A, 
B). Individual lncRNA TSS-targeting gRNAs were stably introduced into LA1-
dCas9-KRAB or SA1-dCas9-KRAB cells and cells were Doxy-treated for 5-10 days 
to induce dCas9-KRAB expression and allow sufficient time for KRAB-mediated 
epigenetic repression (Kearns et al. 2014). Knockdown efficacy was assessed by 
qRT-PCR, using the average lncRNA expression levels in cell lines expressing two 
independent, non-targeting gRNAs as controls. Surprisingly, no knockdown was 
observed across our panel of lncRNA-targeting gRNAs in SA1-dCas9-KRAB cells, 
even when gRNAs validated to facilitate efficient CRISPRi in other, non-SA cell 
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lines were assessed. Thus, our data reinforces the notion that both gRNA-specific 




Figure 15: CRISPRi and CRISPRa strategies of senescence-associated lncRNA LOF 
and GOF. (A) Locus schematics for four (i-iv) candidate senescence-associated lncRNAs. Light 
blue boxes show PAM locations of designed lncRNA TSS-targeting gRNAs. (B) Details of CRISPRi 
strategy and two-vector system for introducing necessary components: (1) dCas9-KRAB; (2) gRNA. 
(C) Details of CRISPRa (VP64 CRISPR-SAM) strategy and two-vector system for introducing 




Of the four senescence-associated lncRNAs targeted in LA1-dCas9-KRAB 
cells, we were able to robustly knockdown Ltc4s-as and lncRNA 7. For Ltc4s-as, 
gRNA 1 yielded a 53% knockdown and gRNA 2 yielded a 23% knockdown, 
compared to the average of two independent control gRNAs (Fig. 16C). For lncRNA 
7, gRNA 1 led to a 48% decrease in lncRNA 7 levels, while gRNA 2 led to a 13% 
knockdown (Fig. 16C), compared to control average levels. One gRNA targeting 
Bfsp2-as, gRNA 2, strangely led to a significant increase in Bfsp2-as RNA levels 
(Fig. 16C). However, a closer examination of cells expressing this gRNA revealed 
the dysregulation of several other p53-regulated genes, suggesting that this gRNA 
had off-target effects and was not worth investigating further. Neat1 levels were 
not significantly reduced in LA1-dCas9-KRAB cells. 
We next asked whether the observed decreases in Lct4s-as and lncRNA 7 
levels influenced cellular proliferation or survival in LA1-dCas9-KRAB cells. As 
both lncRNAs are very lowly expressed in the absence of p53, most of the following 
experiments were performed in p53-restored cells. However, we did determine 
that epigenetic repression of either loci had no significant effect on the ability of 
LA1-dCas9-KRAB cells to form colonies in the absence of p53 (Fig. 16D), 
suggesting the unlikelihood of these lncRNA loci contributing to p53-independent 
functions related to proliferation and/or survival.  
In p53-proficient cells, knockdown of either Ltc4s-as or lncRNA 7 had no 
effect on growth rate (Fig. 16E) or the establishment of senescence (Fig. 16F). 
Moreover, colony formation was similarly unaffected (Fig. 16G), suggesting that 
lncRNA loss did not significantly disrupt the maintenance of senescence. Lastly, 
we examined whether lncRNA CRISPRi modulated either resistance or sensitivity 
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to apoptosis, both of which have been observed in human cells of various 
backgrounds that have undergone senescence (Marcotte et al. 2004; Childs et al. 
2014). As was observed in parental LA and SA cells, LA1-dCas9-KRAB cells did not 
undergo apoptosis upon p53-restoration, as measured by cleaved caspase 3 (CC3) 
levels, and this was unaffected by Ltc4s-as or lncRNA 7 reduction (Fig. 16H-i). On 
average, treatment with 24h 1 µM Doxo drove p53-proficient LA1-dCas9-KRAB to 
undergo apoptosis to comparable levels in control gRNA-expressing and lncRNA 
targeting gRNA-expressing cells, though considerable variability in CC3 levels was 
observed even amongst control cells (Fig. 16H). More tellingly, CC3 levels did not 
correlate with lncRNA knockdown efficiencies. Thus, we concluded that loss of 





Figure 16: CRISPRi of lncRNA 7 or Ltc4s-as does not affect proliferation or survival 
in LA KPR cells. (A, B) Left= qRT-PCR detection of p53 mRNA and dCas9-KRAB in engineered 
LA1 (A) and SA1 (B) cell lines treated as indicated. Data show mean ±SD (n=3 technical replicates). 
Right= Senescence-associated β-galactosidase staining in indicated cell lines and treatments. (C) 
qRT-PCR analysis of indicated lncRNAs in Tam-treated LA1-dCas9-KRAB cells expressing noted 
gRNAs. Data show RNA levels relative to Gapdh, normalized to the average of two non-targeting 
control gRNAs. Mean values ±SEM (n=3 biological replicates). * p<0.05, **p<0.01, and 
****p<0.0001, unpaired t test. (D) Representative images of colony formation assays in untreated 
LA1-dCas9-KRAB cells expressing indicated gRNAs. (E) Cumulative cell numbers in Tam-treated 
LA1-dCas9-KRAB cells expressing indicated gRNAs after 3d. Data show mean values ±SEM (n=3 
biological replicates), one-way ANOVA= no significant differences. (F) Quantification of SA β-gal 
assays in indicated cell lines and treatment. Data show mean ±SD (n=10 technical replicates). (G) 
Representative images of colony formation assays in Tam-treated LA1-dCas9-KRAB cells 
expressing indicated gRNAs. (H) Immunoblots for CC3 (i, ii) and cPARP (iii) protein levels in 







In Chapter 4, we discovered that recruitment of the CRISPR-SAM module 
to lncRNA 7’s TSS in p53-deficient LA1 cells was able to upregulate lncRNA 7 
expression 5-11x fold over a non-targeting control gRNA, reaching 24%-55% of the 
levels of lncRNA 7 induction observed upon p53-restoration in these cells (Fig. 
11C). While this level of CRISPRa did not yield an observable effect on cellular 
proliferation, we wondered whether this perhaps stemmed from an insufficient 
amount of upregulation. Thus, in order to interrogate the functional consequences 
of Ltc4s-as and lncRNA-7 GOF in our LA1 and SA1 systems, we revisited the 
CRISPR-SAM system described in Chapter 4 and made the following 
modifications to see if we could maximize CRISPRa even further: in place of 
shortened ‘dead’ RNAs and nuclease-proficient Cas9, full length gRNAs and 
nuclease-dead Cas9 fused with four copies of the transcriptional coactivator VP16 
(dCas9-VP64) were employed, as the recruitment of this combination of 
coactivators has been reported to even further improve the synergistic activating 
effects of CRISPR-SAM (Konermann et al. 2014) (Fig. 15C). dCas9-VP64-
expressing LA1 and SA1 cell lines were established, and as expected, p53-
restoration in both cell lines led to the acquisition of features of senescence, such 
as senescence-associated morphological changes and β-Gal staining (Fig. 17A, B).  
Using the same two independent gRNAs per lncRNA employed for 
CRISPRi, we assessed the efficacy of this improved dCas9-VP64 CRISPR-SAM 
system in transcriptionally activating Ltc4s-as and lncRNA 7. Two non-targeting 
gRNAs served as controls. Although we did not observe significant p53-dependent 
induction of Ltc4s-as in control LA1-dCas9-VP64 cells treated with Tam for 24h, 
we were able to achieve roughly 4x (gRNA 1) and 2x (gRNA 2) upregulation of this 
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lncRNA in both untreated and Tam treated cells, thus reaching levels of Ltc4s-as 
induction greater than those induced by p53 at this time point (Fig. 17C-left). 
Ltc4s-as was more highly expressed in SA1-dCas9-VP64 cells, induced 3-4x upon 
24h p53-restoration in control gRNA-expressing cells (Fig. 17D-left). Interestingly, 
Ltc4s-as CRISPRa was also more effective in this cell line, achieving 9x (gRNA 1) 
and 3x (gRNA 2) upregulation over controls in untreated cells, or 304% (gRNA 1) 
and 85% (gRNA 2) of the levels of Ltc4s-as seen upon p53-mediated induction in 
these cells (Fig. 17D-left). 
 dCas9-VP64 CRISPR-SAM of lncRNA 7 was also highly efficient. In 
unrestored LA1-dCas9-VP64 cells, gRNA 1 led to a 16x upregulation of lncRNA 7, 
and gRNA 2 led to a 290x upregulation, compared to nontargeting control gRNAs. 
Notably, this level of activation in p53-deficient cells represented 65% and 1184% 
of the lncRNA 7 levels achieved upon p53-restoration in these same cells (Fig. 17C-
right). As was seen for Ltc4s-as, lncRNA 7 CRISPRa was even more effective in 
SA1-dCas9-VP64 cells, where gRNA 1 promoted 77x upregulation and gRNA 1 433x 
upregulation of lncRNA 7, driving lncRNA 7 expression to at or 600% p53-driven 
induction levels (Fig. 17D-right). Thus, dCas9-VP64 CRISPR-SAM of Ltc4s-as and 
lncRNA 7 was highly efficient in transcriptionally upregulated these two 
senescence-associated lncRNAs to levels reaching or considerably exceeding 
endogenous, p53-dependent activation levels.  
Given the association between Ltc4s-as and lncRNA 7 induction and 
senescence-onset, we next asked whether promoting the transcriptional 
upregulation of these loci affected this process. In the absence of p53, Ltc4s-as and 
lncRNA-7 upregulation did not have any appreciable effects on LA1-dCas9-VP64 
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and SA1-dCas9-VP64 proliferation (Fig. 17E), suggesting that expression of these 
lncRNA loci in themselves was not sufficient to initiate cellular arrest. Colony 
formation assays in p53-restored LA1-dCas9-VP64 further supported this 
conclusion, with no differences observed in the number of colonies formed in 
lncRNA upregulated cells compared to controls, though cells in which lncRNA 7 
had been upregulated appeared to form morphologically distinct colonies (Fig. 
17F). Furthermore, neither Ltc4s-as nor lncRNA 7 upregulation affected sensitivity 
to Doxo-induced apoptosis in either LA1-dCas9-VP64 or SA1-dCas9-VP64 cells 
(Fig. 17G). Taken altogether, these CRISPRi and CRISPRa data suggested that 
Ltc4s-as and lncRNA 7 are not integral to either the establishment or maintenance 
of senescence in response to oncogenic stress and are unlikely to individually 






Figure 17: CRISPRa of lncRNA 7 or Ltc4s-as does not affect proliferation or survival 
in LA and SA KPR cells. (A, B) Left= qRT-PCR detection of p53 mRNA and dCas9-VP64 in 
engineered LA1 (A) and SA1 (B) cell lines treated as indicated. Data show mean ±SD (n=3 technical 
replicates). Right= Senescence-associated β-galactosidase staining in indicated cell lines and 
treatments. (C, D) qRT-PCR analysis of indicated lncRNAs in Tam-treated LA1-dCas9-VP64 (C) 
or SA1-dCas9-VP64 (D) cells expressing noted gRNAs. Data show RNA levels relative to Gapdh, 
normalized to untreated control gRNA 1. Mean values ±SD (n=3 technical replicates). (E) Growth 
curves of indicated cell lines in the absence of Tam. (F) Representative images of colony formation 
assays in Tam-treated LA1-dCas9-VP64 cells expressing indicated gRNAs. (G) Immunoblots for 
CC3 and cPARP protein levels in indicated cell lines and treatments (Doxo= 1.0 µM). HSP90 served 









Given this lack of an obvious senescence phenotype in our CRISPRi and 
CRISPRa systems and our discovery of a broader cis-regulatory lncRNA signature 
in the p53 transcriptional response to oncogenic stress (Chapter 3), we lastly 
asked whether Ltc4s-as and lncRNA 7 may instead exert more local functions 
regulating gene expression. In multiple KPR cell lines tested, lncRNA 7 was the 
only p53-responsive gene within a window encompassing 250 kb upstream of its 
TSS and 700 kb downstream of its termination site, assessing a generous window 
given lncRNA 7 being located in an otherwise gene-depleted region of chromosome 
8 (Fig. 8A). As no other genes were either induced or repressed >2-fold upon p53 
restoration in this region, we concluded that lncRNA 7 expression was unlikely to 
be tied to that of any of its neighbors.  
In contrast, Ltc4s-as expression positively correlated with that of Ltc4s, but 
not Maml1, in multiple KPR cell lines. Furthermore, p53RE mutagenesis 
experiments performed in Chapter 3 demonstrated that Ltc4s-as and Ltc4s were 
co-regulated by p53, independent of Maml1. Curious about the effects of 
transcriptionally silencing or upregulating Ltc4s-as on its associated protein 
coding genes, we assessed Ltc4s and Maml1 levels in our LA1 CRISPRa and 
CRISPRi cell lines. Consistent with our p53RE mutagenesis data, we saw a strong 
positive correlation (R=0.85) between Ltc4s-as and Ltc4s levels and no correlation 
between Ltc4s-as and Maml1 (R=0.00) (Fig. 18A).  
Given the proximity and potential overlap of Ltc4s-as’ and Ltc4s’ 
promoters, raising the possibility that CRISPR-based epigenetic manipulations of 
one could directly affect the other, we decided to take an alternative approach to 
reduce Ltc4s-as levels by designing an antisense oligonucleotide (ASO) targeting 
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its third exon. Introducing this ASO into LA1.1 cells led to a roughly 30% decrease 
in Ltc4s-as RNA, both in the presence (+Tam) and absence (-Tam) of p53, 
compared to a non-targeting control ASO (Con) (Fig. 18B). Ltc4s levels were also 
reduced in these cells, by 27% and 41% in unrestored and p53 restored cells, 
respectively. As this ASO targeted a unique (i.e. non-overlapping) region of Ltc4s-
as more than 50 kb downstream of either its or Ltc4s’ TSS, it is unlikely that the 
observed Ltc4s knockdown stemmed from direct ASO-mediated interference of 
the protein coding gene’s transcription. Notably, ASO depletion of Ltc4s-as did not 
significantly affect Maml1 (Fig. 18B), consistent with the results of our other Ltc4s-
as LOF and GOF experiments. Taken altogether, these data led us to conclude that 
either Ltc4s-as’ transcription or RNA is important for optimal expression of Ltc4s, 
but not Maml1, firmly establishing the Ltc4s-as locus as an additional, previously 































Figure 18: Ltc4s-as positively regulates Ltc4s, but not Maml1, in cis. (A) Correlation 
plot of Ltc4s-as levels against Ltc4s and Maml1 levels, as detected by qRT-PCR upon 24h Tam 
treatment in CRISPRa and CRISPRi experiments performed in LA1 cells. RNA values relative to 
Gapdh were calculated and normalized to control gRNAs within each respective experiment before 
plotting normalized values. Simple linear regression analyses were performed on Ltc4s-as vs Ltc4s 
and Ltc4s-as vs Maml1 levels. Lines of best-fit, goodness of fit values, and significance of slopes are 
indicated on graph. (B) qRT-PCR analysis of Ltc4s-as, Ltc4s, and Maml1 in mock or Tam-treated 
LA1.1 cells transfected with indicated ASOs. RNA values relative to Gapdh were normalized to 
control (Con) ASO-treated cells in each Tam condition. Data show mean ±SEM (n=4 biological 











Data summary and conclusions 
 Broadly, the research detailed in this chapter explores the hypothesis that 
lncRNA expression patterns can be reflective of functional significance. In the case 
of p53-dependent senescence driven by oncogenic stress (or in the case of 
lincRNA-RAPT1, genotoxic stress), we were unable to find evidence for lncRNAs 
significantly contributing to cellular senescence, despite these lncRNAs being 
transcriptionally activated in a senescence-specific manner. For lincRNA-RAPT1, 
further work (utilizing alternative LOF approaches) will be necessary to determine 
whether this senescence-associated lncRNA contributes to p53 pathway function 
in other ways. Of the two lncRNAs we were able to efficiently knockdown in our 
KPR model systems, lncRNA 7 and Ltc4s-as, we did not observe any phenotypes 
related two key aspects of the senescent state, proliferation and survival, 
suggesting that these lncRNAs are not necessary for the establishment or 
maintenance of oncogene-induced senescence. Furthermore, transcriptional 
upregulation of these lncRNAs did not alter the cell fates of LA and SA cells, 
demonstrating that induction of these lncRNAs is not sufficient to initiate or 
accelerate senescence.   
 One interpretation of these data is that outcome-specific lncRNA expression 
patterns are the consequence and not the cause of specific cell fates. It is possible 
that the same yet-to-be determined factors that determine the outcome-specificity 
of KPR cells also influence the outcome-specific expression patterns of lncRNAs, 
which are as a class known to be more cell- or tissue-specific than mRNAs (Cabili 
et al. 2011). This is a meaningful conclusion, as questions regarding the biological 
significance of these oft-observed associations between lncRNA expression 
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patterns and cellular states are longstanding in the field. Here, we have tested one 
such correlation in a biological system perfectly set-up to do so.  
It is also possible that senescence-specific lncRNAs do functionally 
contribute to senescence but do so in incremental and/or redundant ways that 
would not be uncovered by individual lncRNA LOF experiments. Importantly, it is 
exceedingly rare for the loss of individual protein coding targets of p53 to have 
dramatic effects on pathway function or tumorigenesis (discussed further in 
Chapter 6). Thus, it remains possible that a network of senescence-associated 
p53-activated lncRNAs work in concert to ensure a robust, sustained 
antiproliferative response to oncogenic stress.  
Cis-acting lncRNAs, such as the ones we describe in Chapter 3 and here, 
would be well-suited to finely regulate a broad, flexible network of genes not 
directly regulated by p53 themselves towards this end. The Ltc4s-as locus 
illustrates how gene-specific this lncRNA-mediated cis-regulation can be, in which 
we see that Ltc4s but not Maml1 expression is modulated by Ltc4s-as expression, 
despite the lncRNA overlapping both protein coding genes. Ltc4s’ role in 
proinflammatory signaling, which is a phenotype associated with senescence in 
vivo, also raises the possibility of a model in which the functional importance of 






Chapter 6: Summary and Perspectives 
Our research expands our understanding of the ways in which lncRNAs 
contribute to the regulation of gene networks, as well as provides new insights into 
gene regulation by the central tumor suppressor p53. LncRNAs have garnered a 
significant amount of attention over the past decade or so as a largely untapped 
pool of potentially important biomolecules, including within the p53 pathway 
where many have been implicated as important effectors of p53 function (see 
Chapter 1). But the extent to which lncRNAs contribute to the p53 pathway 
remains ambiguous. This is in part due to cross-study comparisons of individual 
lncRNA studies often being complicated by variability in approaches taken or 
biological conditions under which the p53 pathway was studied. For example, 
whether lncRNAs contribute to the p53 response in a stress-specific manner is 
largely unknown. Here, we have employed a powerful in vitro model of p53-driven 
tumorigenesis and multiple state-of-the art lncRNA LOF and GOF tools to address 
several important questions about the role of p53-activated lncRNAs within the 
p53 response to oncogenic stress. 
As sequencing technologies have become more sensitive and robust, so too 
has the catalogue of known lncRNA genes and associated transcripts grown (Fang 
et al. 2018; Uszczynska-Ratajczak et al. 2018). Understandably, determining what 
fraction of these many thousands of uncharacterized transcripts represent 
biologically important RNAs has been a pressing challenge in the study of 
lncRNAs. The operational definition of lncRNA and an incomplete understanding 
of the relationship between lncRNA primary sequence and lncRNA function have 
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made a priori predictions of importance impractical. Instead, various approaches 
to further subdivide lncRNAs based on observed expression patterns have often 
served as starting points for functional studies. These expression pattern-based 
associations have been especially provocative in the context of cancer, where 
lncRNAs have been noted to be transcriptionally regulated in ways that exquisitely 
parallel various aspects of cancer pathophysiology [e.g. tissue of origin or 
metastatic vs nonmetastatic disease (Iyer et al. 2015; Ji et al. 2003; Gupta et al. 
2010)]. Our work adds to this wealth of cancer-associated lncRNA data by greatly 
expanding the number of known lncRNAs regulated by p53. Importantly, our work 
provides evidence for direct regulation by p53 for many of these previously 
undescribed lncRNAs, thus giving a more complete picture of the total p53-
regulated lncRNA transcriptome. 
An additionally important facet of our work is that these lncRNAs are 
induced by p53 in response to oncogenic stress and may thus represent a stressor-
specific cohort of lncRNAs. This is supported by the observation that many 
lncRNAs that have previously been shown to be activated by p53 in the context of 
genotoxic stress (Table 1.1) did not come up in our list of lncRNAs. While it is 
possible that this is a reflection of cell type-specific differences rather than stress 
stimuli, it is worth noting that our KPR model allowed us to assess the p53 
response to oncogenic stress across six unique cell lines and three distinct 
tumors/tissue types of origin, thus permitting us to sample a breadth of cellular 
contexts. Importantly, we identified five lncRNAs (Pvt1b, Zmat3-as, Bahcc1-as, 
2310008N11Rik, and Rhod-as) which were significantly upregulated by p53 across 
all cell lines and tumor types. Prior to this study, none of these five Core-induced 
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lncRNAs, nor the majority of the other lncRNAs we identified as p53-activated in 
our KPR model had been previously linked to the p53 pathway. Thus, these data 
suggest that our work has in fact identified a set of lncRNAs linked to specifically 
p53 regulation in the context of oncogenic stress and support a previously 
proposed model in which the transcriptional networks enacted by p53 in response 
to acute genotoxic stress and oncogenic stress are at least partially distinct from 
each other (Brady et al. 2011; Kastenhuber and Lowe 2017). 
Surprisingly, we found an extremely limited overlap between the lncRNAs 
identified in our work and previously published p53-activated lncRNAs, restricted 
to only lincRNA-p21 and Neat1, which are established direct targets of p53 (Huarte 
et al. 2010; Mello et al. 2017), and Malat1, which has been reported to be regulated 
by a distal p53 bound enhancer (Melo et al. 2016). Thus, even lncRNAs that have 
been demonstrated to be p53-responsive in other in vitro models of oncogenic 
stress were not identified as such in our KPR model. For some lncRNAs, such as 
the human-specific lncRNA PANDA, our data simply confirm previously noted 
absences of orthologous mouse genes. For others (e.g. GUARDIN, LED, Linc-Pint), 
it is possible that our results reflect species-specific differences in p53 network 
activation. However, it is important to note that most studies of human lncRNAs 
in the context of the p53 response to oncogenic stress have been performed in a 
limited number of human cancer cell lines, thus making cell line-specific 
differences in p53 regulation an equally likely possibility. Notably, our 
identification of a p53-responsive human lncRNA at the genomic location syntenic 
to 2310008N11Rik (lncRNA 7) in this work and our lab’s previous description of 
an orthologous human PVT1B isoform (Olivero et al. 2020) demonstrate that at 
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least two of the five lncRNAs we found to be activated by p53 across all KPR tumor 
types are also regulated by p53 in human cells, under at least some stress 
conditions. The full extent of human conservation of our newly identified catalogue 
of p53-regulated lncRNAs remains to be explored in future studies.  
Our work also considerably increases our understanding of the broader p53 
transcriptional response to oncogenic stress. It is clear that transcriptional 
regulation is a key aspect of p53-mediated tumor suppression (Brady et al. 2011; 
Jiang et al. 2011), but the full set of specific p53 targets that underlie said tumor 
suppression are elusive. Moreover, p53 suppresses tumorigenesis through a 
variety of cellular processes, two important examples being apoptosis and cellular 
senescence, though by what mechanisms these different cellular processes are 
initiated in different tumor types is less clear. By characterizing the p53 response 
across multiple tumor types facing the same oncogenic stressor, we shed new light 
onto these fundamental questions of p53 regulation in several ways. First, we 
identified a set of target genes activated by p53 in LA, SA, and LY KPR cells, 
suggesting that this small but robustly-activated group of genes may be critical for 
p53 sensing and/or responding to oncogenic signaling. These Core genes included 
important mediators of central p53 processes, such as cell cycle regulation and 
apoptosis, as well as genes involved in autophagy, metabolism, and tumor 
microenvironment signaling, which are more recently appreciated p53-regulated 
processes that have been associated with tumor suppression (Kaiser and Attardi 
2018). As expected, many of these genes represented known p53 targets that are 
activated by p53 in other stress conditions as well. This was in contrast to the panel 
of lncRNAs we uniquely identified as p53 targets for the first time in this work. 
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Thus, it may be the case that p53-activated lncRNAs are more stressor-specific 
than protein coding p53 target genes.  
Additionally, our data strongly suggest that tumor type-specific differences 
in the cellular consequences of p53 stabilization do not stem from significant 
differences in p53 transcriptional activation. This is in contrast to some postulated 
models of p53 decision-making, in which the expression of clearly delineated 
outcome-specific gene networks is proposed to underlie outcome-specificity 
(Weinberg et al. 2005; Schlereth et al. 2010). Instead, our data is in line with more 
recent reports where genomic p53 binding patterns (Nikulenkov et al. 2012; 
Botcheva and McCorkle 2014) and p53 network activation correlated more with 
cell identity than stress stimuli or ultimate cellular outcome enacted in a number 
of human and mouse cell lines (Tonelli et al. 2017; Catizone et al. 2019; Zhang et 
al. 2013b). These cell identity-specific factors may be related to p53-dependent 
functions but have fate-determining patterns of regulation that are either partially 
p53-independent or pre-exist p53 pathway activation. “Mitochondrial priming” is 
one example of this, in which a given cell type’s characteristic ratio of 
mitochondrially-localized pro-apoptotic versus anti-apoptotic BCL-2 family 
member proteins can determine whether said cell type is inherently apoptosis-
resistant or apoptosis-prone (Chonghaile et al. 2011; Liu et al. 2013a). However, it 
is indisputable that the p53 network is regulated at multiple, intricately-woven 
levels. We acknowledge that stimuli-specific inputs such as the nature of the stress 
encountered can also influence p53 pathway activation in some settings, for 
example by dictating where in the genome p53 binds (Menendez et al. 2013) or by 
altering the dynamics of p53 protein stabilization (Purvis et al. 2012). Our work 
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joins this dialogue to provide additional, novel perspective on this fundamental 
question regarding how inputs into the p53 network modulate network activation.  
Interestingly, we uncovered an unexpected association between p53-
mediated gene repression and senescence. In contrast, gene repression 
downstream of p53 was not a feature of the core transcriptional response to 
oncogenic stress, nor apoptosis. How p53 represses this senescence-specific gene 
network remains to be determined, as experimental evidence for direct gene 
repression by p53 is very limited (Vousden and Prives 2009). P53’s role in indirect 
repression is clearer, as p21 activation downstream of p53 is important for gene 
repression by the E2F/DREAM complex (Engeland 2018). Intriguingly, a recent 
cross-species metanalysis of orthologous human and mouse genes regulated by 
p53 found that p53-repressed genes were more likely to be similarly regulated 
across the two species than p53-activated genes (Fischer 2019), raising the 
fascinating question of whether a link between p53-dependent gene repression and 
senescence is also conserved. The functional importance of this p53 gene 
repression in senescence is largely unknown, though our work does provide one 
specific example by demonstrating that Pvt1b/Myc negative co-regulation is 
necessary for the maintenance of growth arrest in LA KPR cells. However, our 
lncRNA data suggest that most p53-dependent gene repression is not 
accomplished through lncRNA cis-regulation. Further exploring the mechanisms 
by which p53 gene repression is established and the biological importance of 
repressive p53 regulation are important avenues of inquiry for future work. 
Similar to other genome-wide profiles of the p53 network, we found that key 
protein coding p53 targets involved in cell cycle arrest and apoptosis were activated 
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by oncogenic stress in an outcome-agnostic manner. This in part led us to explore 
whether lncRNAs, which did exhibit outcome-specific activation in our data, could 
underlie outcome-specificity. LncRNAs have previously been hypothesized to be 
drivers of cell fate due to their cell identity- or state-specific expression patterns 
(Cabili et al. 2011; Derrien et al. 2012). However, our lncRNA GOF and LOF studies 
did not yield any evidence for any individual lncRNA contributing to the 
establishment of cellular senescence in LA and SA KPR cells, even when lncRNA 
expression patterns were highly correlated with senescence and anticorrelated 
with apoptosis in our KPR model. Thus, while examples of lncRNAs demonstrably 
regulating cell fate decisions do exist (Kretz et al. 2013; Grote et al. 2013; 
Lewandowski et al. 2019), our research joins an growing body of literature 
(Goudarzi et al. 2019) encouraging caution when interpreting correlative lncRNA 
associations as functional in the absence of experimental validation. It is possible 
that our panel of senescence-associated lncRNAs are not drivers of senescence but 
are rather transcriptional read-outs of specific cellular characteristics that are 
unique to cells primed to undergo senescence in response to p53 activation. 
Alternatively, it is also possible that these lncRNAs function at a longer time-scale 
than investigated in this work and contribute to the long-term maintenance of 
senescence, which is a uniquely stable biological state.  
However, our single lncRNA LOF data are also consistent with the 
functional redundancy of the p53 network hinted at in our KPR transcriptome 
profiling data and other studies. In this paradigm of p53 network function, the loss 
of expression of one or even several p53 target genes can be compensated for by 
others to maintain a robust p53 response. For example, in one recent shRNA 
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screen for p53 targets important for mediating growth arrest in human 
osteosarcoma cells, the only significant hit identified was p53 itself (Andrysik et al. 
2017), suggesting that even the loss of key protein coding mediators of growth 
arrest can be insufficient to bypass p53-directed growth arrest. Importantly, there 
has not been a single p53 target gene to date in which genetic knockout in vivo is 
able to recapitulate the dramatic spontaneous tumorigenesis observed in p53 
knockout mice, including mice lacking key drivers of p53-dependent cell cycle 
arrest [p21 (Brugarolas et al. 1995); Gadd45α (Hollander et al. 1999); PML (Gang 
Wang 1998)], apoptosis [Puma; Noxa (Villunger 2003); Perp (Ihrie et al. 2006); 
Bax (Knudson et al. 2001)], or combinations of target genes important for these 
processes (Michalak et al. 2008; Valente et al. 2013). Nevertheless, these protein 
coding genes demonstrably contribute to p53-dependent anti-growth responses in 
various in vitro settings (perhaps reflecting tissue- or cell type-specific functions) 
and/or in the context of specific in vivo cancer models. Thus, many of the lncRNAs 
we have found to be activated by p53 in response to oncogenic stress may also play 
subtle, redundant, or context-specific roles in the p53 pathway that collectively 
support the overall robustness of this tumor suppressive stress response. This 
functional subtlety and/or redundancy seems to be likely true for many lncRNAs 
in other tightly regulated biological processes as well, such as development 
(Goudarzi et al. 2019). 
Our research strongly suggests that cis-regulatory lncRNAs predominate 
within the p53 network. While we cannot formally exclude trans activities for all 
identified lncRNAs, the vast majority of lncRNAs found in this study were enriched 
at the chromatin, relatively low in abundance, and transcriptionally linked to the 
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expression of their neighboring genes, all of which are features associated with cis-
regulation. Moreover, our thorough locus investigation of one of the more 
abundant, partially cytoplasmically-localized lncRNAs, 2310008N11Rik (lncRNA 
7), did not reveal a trans phenotype. Thus, our research adds to a growing body of 
work suggesting that most p53-activated lncRNAs function in the nucleus to 
regulate the transcriptional output of the p53 network (reviewed in Chapter 1).  
We demonstrate that lncRNA locus-mediated cis-regulation is a much more 
common mechanism by which lncRNAs achieve this than previously appreciated. 
As our characterization of the lincRNA-Gadd45γ locus demonstrates, this cis-
regulation can tie-in protein coding genes not directly regulated by p53 into the 
broader p53 transcriptional network. Our LOF characterization of several other 
lncRNA loci suggests that this positive cis-regulation is not unique to this locus. 
Conversely, our work also demonstrates that Pvt1b’s regulation of Myc represents 
an exceptional example of cis-repression within the p53 network, suggesting that 
lncRNAs do not significantly contribute to p53-mediated gene repression. Thus, 
we show that lncRNAs can fine-tune p53’s transcriptional response on a locus-by-
locus basis, with likely locus-specific RNA-dependent and RNA-independent 
mechanisms. 
Furthermore, our discovery of Pvt1b’s importance in mediating growth 
arrest in LA KPR cells demonstrates that lncRNA-mediated cis-regulation can be 
important for p53 pathway function downstream of oncogenic stress. Our data 
suggest that this phenotype is not driven through changing the cell fate of LA cells, 
which remained resistant to apoptosis, but rather through Pvt1b’s effect on Myc 
levels. Indeed, other work from our lab further supports the conclusion that the 
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cellular consequences of Pvt1b loss are solely mediated through Myc derepression 
(Olivero et al. 2020). Myc is a universal regulator of cellular growth, thus it is not 
surprising that dysregulating Myc levels would have profound effects on cellular 
proliferation. The functional consequences of disrupted cis-regulation at other 
p53-activated lncRNA loci may be more context-specific in a manner related to the 
normal functions of the protein coding genes under regulation.  
The senescence-associated Ltc4s-as locus and its positive reinforcement of 
Ltc4s expression may represent an example of this scenario. Ltc4s is an enzyme 
involved in the catalysis of leukotrienes, which are important lipid 
proinflammatory molecules (Funk 2001). One hallmark of senescence is the 
secretion of a variable suite of proinflammatory and ECM remodeling molecules 
that drive senescence-associated autocrine and paracrine signaling (i.e. 
senescence-associated secretory phenotype; SASP), which can be oncogenic or 
tumor suppressive (Campisi 2013; Collado and Serrano 2010). Leukotriene 
signaling has recently been shown to be a part of the SASP of several senescent 
human cell lines and linked to senescence-associated lung fibrosis (Wiley et al. 
2019). Thus, we imagine that Ltc4s-as-dependent cis-regulation of Ltc4s could be 
important for phenotypes associated with cellular senescence or inflammation 
more broadly in contexts beyond the in vitro stress models we assessed in this 
work. 
Lastly, we do not claim that all lncRNA-mRNA co-regulatory relationships 
are indicative of direct cis regulation. Rather, they are demonstrative of linked gene 
regulation within the p53 network and provide a conceptual platform for potential 
secondary, fine-tuning transcriptional inputs from lncRNA loci downstream of the 
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primary input from p53 at these lncRNA-mRNA transcriptional units. Prior to our 
work, direct lncRNA-mediated cis-activation within the p53 network had only been 
demonstrated for lincRNA-p21; we expand this to two novel lncRNAs chosen from 
our identified catalogue of co-regulated loci. Support for Ltc4s-as and lincRNA-
Gadd45γ being representative examples of a wider cis-activating cohort of p53-
induced lncRNAs includes the fact that co-regulation in addition to chromatin 
enrichment has been shown to be predictive of cis-regulation in other cellular 
systems (Werner et al. 2017). Whether true, lncRNA locus-driven cis-activation 
contributes to the positive co-regulation observed at the other loci we uncovered 
will be work for future investigation. 
As for cis-repression, we speculate that the presence of a negative co-
regulatory relationship is likely to be predictive of true lncRNA mediated cis-
regulation, especially when negative co-regulation involving intergenic (i.e. non-
overlapping) lncRNA loci is observed. This is based on the rationalization that 
lncRNA cis-activation may more readily evolve through either the simple act of a 
lncRNA locus being transcribed or through the modulation of pre-existing 
transcription-activating signals at a given locus. For example, the transcription of 
a lncRNA locus may be sufficient to promote the recruitment of positive 
transcriptional regulators or RNA pol II itself to another genomic region as well, if 
said region is in close proximity to the lncRNA locus in either linear or three 
dimensional genomic space, in much the same way enhancers are thought to 
function. In contrast, cis-repression is likely to necessitate additional molecular 
inputs that are able to overcome and reverse these activating inputs (e.g. the 
recruitment of repressive epigenetic machinery by XIST). Furthermore, the rarity 
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of such negative co-regulatory relationships compared to positive ones in our data 
and in other genome-wide surveys of lncRNA regulatory patterns (Basu and 
Larsson 2018) further suggests that sites of negative lncRNA-mRNA co-regulation 
arise from an evolutionary trajectory distinct from those of positive co-regulation. 
Pvt1b’s activation by p53 and cis-repression of Myc (a transcription factor in its 
own right) suggest that such negative cis-regulatory relationships may be most 
likely to emerge at key nodes in transcriptional networks, functioning to adjust 





















Mammalian genomes are complex, both in organization and in regulation. 
It’s long been appreciated that lncRNAs can significantly contribute to both of 
these features, but our understanding of the importance of lncRNAs in complex 
regulatory networks remains incomplete. One emerging regulatory theme our 
work expands upon is that of lncRNA-mediated cis-regulation [e.g. (Dimitrova et 
al. 2014; Olivero et al. 2020; Joung et al. 2017; Werner et al. 2017; Engreitz et al. 
2016)], namely its previously underappreciated prevalence in the centrally 
important tumor suppressive p53 pathway. Unlike transcription factors or other 
nuclear-acting proteins, which are invariably translated distally from their sites of 
action, lncRNA loci are uniquely positioned to rapidly respond to stimuli by 
engaging with and modulating the expression of other nearby genes. Within the 
p53 transcriptional network, we find at least one example of lncRNA-mediated cis-
regulation being important for tumor suppression in the context of oncogenic 
stress and speculate that lncRNA local regulation may contribute to the highly 
tissue- and stimuli-specific nature of the p53 stress response in other settings as 
well. The ability of cis-acting lncRNA loci to dynamically and flexibly fine-tune 
transcriptional outputs may be especially important in stress responses in general, 
warranting closer examination of this mode of lncRNA-mediated gene regulation 




Chapter 7: Materials and Methods 
Cell lines and treatments: KPR cell lines were previously established from 
spontaneously arising primary lung adenocarcinoma (LA1, LA2), sarcoma (SA1, 
SA2), or lymphoma (LY1, LY2) tumors isolated from KrasLA2-G12D/+ ; p53LSL/LSL; 
Rosa-CreERT2 mice (Feldser et al. 2010). Puromycin-sensitive LA1 cells (LA1.1) 
were previously described (Olivero et al. 2020). In brief, LA1 cells were transiently 
transfected with a guide RNA targeting the ORF of puromycin to inactivate the 
puromycin-resistance gene expressed from the Rosa-CreERT2 allele, followed by 
clonal expansion. gRNAs were introduced cloned downstream of a U6 promoter in 
a lentiviral vector co-expressing SpCas9 and GFP (BRD004; gift from the Broad 
Institute, MIT). Puromycin-sensitive LA2 cells (LA2.5) were similarly generated. 
Primary WT mouse embryonic fibroblasts (MEFs) were isolated from embryos at 
E13.5 from timed matings of WT C57BL/6J mice. LincRNA-RAPT1fl/fl; Rosa26-
CreERT2 MEFs were isolated at E13.5 from timed homozygote matings, while 
littermate lincRNA-RAPT1+/+ and lincRNA-RAPT1-/- MEFs were isolated from 
lincRNA-RAPT1+/- (heterozygote) matings. All primary MEF experiments were 
performed at passages 2-10. p53LSL/LSL; Rosa-CreERT2 (p53-restorable) MEFs 
were previously described (Ventura et al. 2007).  
LA and SA cells were maintained in DMEM (GIBCO) supplemented with 
10% FBS, 50 U/mL pen/strep, 2 mM L-glutamine, 0.1 mM non-essential amino 
acids, and 0.055 mM β-mercapatoethanol. LY cells were cultured in IMDM 
(GIBCO) supplemented with 10% FBS, 50 U/mL pen/strep, and 0.055 mM β-
mercapatoethanol. MEFs were cultured in DMEM supplemented with 15% FBS, 
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50 U/mL pen/strep, 2 mM L-glutamine, 0.1 mM non-essential amino acids, and 
0.055 mM β-mercapatoethanol. All cells were grown at 37°C in a humidified 
incubator with 5% CO2.  
To excise the LSL cassette and restore p53 expression, KPR cells and p53-
restorable MEFs were treated with 0.5 µM 4-hydroxytamoxifen (Tam, Cayman 
Chemical Company) at time points indicated in text and figure legends. To ablate 
lincRNA-RAPT1 expression in the conditional knockout system, lincRNA-
RAPT1fl/fl; Rosa26-CreERT2 MEFs were treated with 0.5 µM Tam for 72-96h. To 
induce DNA damage, cells were treated with Doxorubicin (Doxo, Sigma-Aldrich), 
at dosage concentrations and lengths indicated in text and figure legends. To 
activate Tetracycline-dependent gene expression in LA1-TRE-dCas9-KRAB and 
SA1-TRE-dCas9-KRAB cell lines, cells were treated with 2 µg/mL Doxycycline 
(Doxy, Sigma-Aldrich) for lengths of time indicated in text and figure legends. 
 
Viral transductions: Lentivirus was produced in 293 cells by co-transfecting 
lentiviral constructs with pCMV-Δ8.2 (Addgene plasmid #8455) and pCMV-VSV-
G (Addgene plasmid #8454) viral packaging constructs. Fresh virus-containing 
supernatants supplemented with 4 µg/mL polybrene (Millipore Sigma) were used 
to infect cells in 2-3 consecutive lentiviral infections, collected and delivered at 24h 
intervals. For retroviral transduction experiments, virus was produced in Phoenix 
cells transfected with retroviral constructs. Viral supernatant was collected at four 
consecutive 12h intervals, supplemented with 4 µg/mL polybrene, and 
immediately used to infect cells. Following infections, cells were selected with 
Puromycin (2 µg/mL for MEFs, 5 µg/mL for KPR cell lines), hygromycin (400 
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µg/mL for MEFs, 800 µg/mL for KPR cell lines), neomycin (400-600 µg/mL), or 
blasticidin (5-10 µg/mL), as appropriate. All viral constructs and gRNA/dRNA 
sequences used in this work can be found in Supplementary Tables 1 and 2. 
 LncRNA p53RE mutagenesis: CRISPR-Cas9 mutagenesis was performed by 
infecting LA1.1 or LA2.5 cells with site-specific gRNAs cloned downstream of an 
hU6 promoter in BRD001, a lentiviral vector co-expressing SpCas9 and an IRES-
driven puromycin-resistance gene (gift from the Broad Institute, MIT). dTomato-
targeting gRNA served as a negative control. Mutagenesis efficiency was assessed 
by Sanger sequencing using PCR and sequencing primers in Supplementary Table 
2 and quantified using the TIDE (Tracking of Indels by Decomposition) webtool 
(Brinkman et al. 2014). For sequencing of individual mutated alleles, PCR products 
were subsequently cloned into the pCR-Blunt II-TOPO vector (Invitrogen) and 
individual clones submitted for Sanger sequencing. 
LincRNA-Gadd45γ CRISPRi and CRISPRa: CRISPRi was performed by 
expressing 15-mer ‘dead RNAs’ (dRNAs) (Dahlman et al. 2015) from BRD001, 
targeting a region downstream of the transcription start site of lincRNA-Gadd45γ 
or a non-targeting control region (Con). For CRISPRa experiments, an SpCas9-
IRES-GFP-expressing stable cell line was first generated by introducing lentiviral 
vector BRD004 (gift from the Broad Institute, MIT) into LA1 cells and selecting for 
GFP expression by FACS. CRISPRa of lincRNA-Gadd45γ was subsequently 
achieved by the CRISPR-SAM system employed in (Olivero et al. 2020). In brief, 
MS2-tagged gRNAs and HSF-p64-MBP (SAM module) were stably introduced into 
LA1-SpCas9-GFP cells via a single vector co-expressing both, lenti SAM Hygro 
(generated by E. Martínez-Terroba), followed by hygromycin selection. 
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LncRNA 7 exogenous overexpression and E1A MEF sensitization: Full-
length lncRNA 7 cDNA was synthesized as a gene block (IDT) and cloned into 
MSCVpuro and pWZL Hygro (Addgene# #18750) retroviral vectors. Empty 
vectors (EV) served as controls. MSCVpuro was used to deliver lncRNA 7 into 
primary MEFs, while pWZL Hygro was used for LA and SA KPR cells, followed by 
puromycin or hygromycin selection, respectively. For E1A sensitization 
experiments, pLPC 12S E1A puro (Addgene plasmid #18740) or EV control 
retroviral constructs were introduced into control or lncRNA 7-overexpressing 
p53-restorable MEFs and puromycin selection applied. 
LncRNA 7 and senescence-associated lncRNAs CRISPRi and CRISPRa: For 
lncRNA 7 CRISPRi experiments in p53-restorable MEFs and LA1.1 cells, stable 
dCas9-KRAB cell lines were first generated by introducing pHR-SFFV-dCas9-BFP-
KRAB (Addgene plasmid #46911) into cells via lentiviral transduction and 
selecting for BFP expression by FACS. gRNAs targeting lncRNA 7’s TSS were 
subsequently delivered to cells by BRD003, a lentiviral vector for expressing hU6-
driven SpCas9 gRNAs (gift from the Broad Institute, MIT), and cells selected for 
puromycin resistance. CRISPRi efficacy was assessed in comparison to dTomato-
targeting Con gRNA. For lncRNA 7 CRISPRa experiments performed in Chapter 
4, dCas9-VP64-expressing cell lines were generated by introducing Lenti dCas-
VP64_Blast (Addgene plasmid #61425) into LA1.1 and LA1 cells and selecting for 
blasticidin resistance. gRNAs were lentivirally delivered by either BRD003 for 
LA1.1 cells or pLenti BsmBI sgRNA hygro (Addgene plasmid #62205) for LA1 cells, 
due to the latter’s puromycin resistance. After the appropriate selection regimes, 
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lncRNA 7 CRISPRa was assessed compared to the same dTomato-targeting Con 
gRNA. 
For CRISPRi experiments performed in Chapter 5, Doxy-inducible dCas9-
KRAB cell lines were generated by introducing Phage TRE-dCas9-KRAB (Addgene 
plasmid #50917) into LA1 and SA1 cells and selecting for neomycin/G418 
resistance. gRNAs were introduced into cells by lentiviral delivery in pLenti BsmBI 
sgRNA hygro, followed by hygromycin selection. For CRISPRa experiments 
performed in Chapter 5 (VP64-SAM), dCas9-VP64 cell lines were generated by 
introducing Lenti dCas-VP64_Blast into LA1 and SA1 cell lines. MS2-tagged 
gRNAs and HSF-p64-MBP were subsequently introduced into cells by lenti SAM 
Hygro, followed by hygromycin selection. For calculations of CRISPRi and 
CRISPRa efficiencies, RNA values relative to an endogenous control gene (Gapdh) 
were individually calculated for two independent non-targeting control gRNAs and 
averaged, yielding a control average relative expression value. LncRNA TSS-
targeting gRNA relative expression values were then normalized to this control 
average relative expression value. 
 
RNA isolation and qRT-PCR: For RNA analysis of MEF samples, RNA was 
isolated with the RNeasy Mini Kit (Qiagen). For RNA analysis of KPR samples, 
RNA was isolated using TRIzol reagent (Invitrogen). 1.0 µg total RNA was reverse 
transcribed using the High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems). SYBR Green PCR master mix (Kapa Biosystems) was used for 
quantitative PCR in triplicate reactions. Primers sequences are listed in 
Supplementary Table 3. RNA expression levels relative to the housekeeping gene 
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Gapdh were calculated using the ddCt method and normalized to control samples 
when noted. 
 
Genotyping: KPR cells were lysed in 1 M Tris-HCl pH 8.0, 0.5 M EDTA pH 8.0, 
20% SDS, 5 M NaCl supplemented with 1 mg/mL Proteinase K at 55 °C. Total 
genomic DNA was extracted by isopropanol precipitation, and genotyping was 
performed by PCR with primers listed in Supplementary Table 3. 
 
Immunoblotting: Cells were lysed in 2x Laemmli buffer (100 mM Tris-HCl 
pH6.8, 200 mM DTT, 3% SDS, 20% glycerol) at 1x104 cells/µL. Samples were 
heated at 95°C for 7 minutes and passed through an insulin syringe. Protein from 
1x105 cells was separated on 12% SDS-polyacrylamide gels and transferred to 
nitrocellulose membranes (Bio-Rad). After blocking (5% milk-PBST), membranes 
were incubated overnight at 4°C in primary antibody, then 1hr at RT in secondary 
antibody. The following antibodies were used: anti-p53 (1C12) (1:1,000, 2524S, 
Cell Signaling Technology), anti-p21(F-5) (1:250, sc-6246, Santa Cruz 
Biotechnology), anti-cleaved caspase 3(Asp175) (1:250, 9661, Cell Signaling 
Technology), anti-cleaved PARP (Asp214)(7C9) (1:500, 9548S, Cell Signaling 
Technology), anti-α tubulin (DM1A) (1:1000, 3873S, Cell Signaling Technology), 
anti-β tubulin (9F3) (1:1000, 2128S, Cell Signaling Technology), anti-Hsp90 
(C45G5) (1:1,000, 4877S, Cell Signaling Technology), goat anti-mouse secondary 
antibody (1:50000,1706516, Bio-Rad), and donkey anti-rabbit secondary antibody 
(1:50000, 711-035-152, Jackson ImmunoResearch). Protein bands were visualized 
using Amersham ECL Prime Western Blotting Detection Reagent (GE Healthcare). 
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Quantitative densitometry analysis was performed using background adjusted 
volume intensities normalized to loading control on Image Lab software (Bio-
Rad). 
 
Gene set enrichment analysis (GSEA): GSEA was performed on p53-induced 
and p53-repressed gene sets identified by RNA-seq analysis using the Molecular 
Signature Database (MSigDB) (Subramanian et al. 2005).  
 
Antisense oligonucleotide (ASO) knockdown: For lincRNA-Gadd45γ 
knockdown, 1 µM lncRNA-targeting (ASO1, ASO2) or control (CON) antisense 
LNA Gapmers (Exiqon, QIAGEN) were transfected into 1x106 LA1.1 cells treated 
with Tam for 48h using the Amaxa Primary Mammalian Epithelial Cells 
Nucleofector Kit (Lonza, VPI-1005) and the Nucleofector 2b Device (Lonza). 
Knockdown of lincRNA-Gadd45γ and subsequent effects on Gadd45 γ expression 
were assayed by qRT-PCR at 24h post-transfection (72h Tam treatment). For 
Ltc4s-as knockdown, 1 µM lncRNA-targeting (ASO) or control (Con) antisense 
LNA Gapmers were transfected into 3x105 LA1.1 cells using Attractene transfection 
reagent (Qiagen). Ltc4s-as, Ltc4s, and Maml1 expression was assessed by qRT-
PCR at 24h post-transfection, in mock- or Tam-treated cells. ASO sequences are 
listed in Supplementary Table 2. 
 
Subcellular fractionation: Subcellular fractionation was performed as 
previously described (Conrad and Ørom 2017) with some modifications. Briefly, 
cells were harvested by trypsinization, rinsed once in PBS, and re-suspended in 
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PBS-1 mM EDTA. Half of this cell suspension was set aside for whole cell (WC) 
RNA isolation using TRIzol reagent. The remaining cells were lysed in 0.4 mL cell 
lysis buffer for 5 min on ice. Lysis buffer composition for primary MEFs= 10 mM 
TrisHCl pH 7.5, 0.15% NP-40, 150 mM NaCl, 100 U/mL RNase-IN (Promega); for 
LA1.1 cells= 10 mM TrisHCl pH 7.5, 0.20% NP-40, 150 mM NaCl, 100 U/mL 
RNase-IN. Lysate was layered on a sucrose cushion (24% w/v sucrose, 150 mM 
NaCl, 10 mM TrisHCl pH 7.5,100 U/mL RNase-IN) and centrifuged for 10 min at 
3500g for primary MEFs and at 3000g for LA1.1 cells, yielding the cleared 
cytoplasmic fraction (supernatant) and pelleted nuclei. Nuclear pellets were 
washed once in PBS-1 mM EDTA, re-suspended in 0.25 mL glycerol buffer (50% 
glycerol, 20 mM Tris-HCl pH 7.5, 75 mM NaCl, 0.5 mM EDTA, 0.85 mM DTT, 100 
U/mL RNase-IN), and lysed by the immediate addition of an equal volume nuclear 
lysis buffer (10 mM HEPES pH 7.6, 7.5 mM MgCl2, 0.2 mM EDTA, 300 mM NaCl, 
1% NP-40, 1 mM DTT, 1M Urea, 100 U/mL RNase-IN) with 2 min incubation on 
ice. Centrifugation for 2 min at 18800g yielded the nucleoplasmic and chromatin-
associated fractions in the supernatant and pellet, respectively. Chromatin pellets 
were washed once in PBS-1 mM EDTA and solubilized in 1 mL TRIzol reagent by 
syringing. RNA was extracted from the cytoplasmic and nucleoplasmic fractions 
using TRIzol-LS (Invitrogen) and from the chromatin-associated fraction using 
TRIzol, following the manufacturer’s protocols. Subcellular RNA enrichment was 
determined by qRT-PCR, normalizing fraction Ct values to WC Ct values. 
Cytoplasmically-enriched RNA Rn7s1 and chromatin-enriched RNA Kcnq1ot1 
served as fractionation quality controls. Primers sequences can be found in 
Supplementary Table 3. 
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Single-molecule RNA FISH (smRNA-FISH): smRNA-FISH was performed 
as previously described (Olivero et al. 2020). In brief, cells were grown on 
coverslips and fixed for 10 min at RT in 4% methanol-free formaldehyde (Thermo 
Scientific). Cells were permeabilized overnight at 4°C in 70% EtOH-DEPC H2O. 
Coverslips were then transferred to a hybridization chamber, equilibrated in Wash 
Buffer A (Stellaris, LGC Biosciences) supplemented with formamide (Millipore 
Sigma), and incubated overnight at 30°C with probes diluted 1:50 in Hybridization 
Buffer (Stellaris, LGC Biosciences) with formamide. The following day, cells were 
washed twice for 30 min at 30°C in Wash Buffer A, incubated for 5 min at RT in 
Wash Buffer B (Stellaris, LGC Biosciences), and mounted in Vectashield Mounting 
medium with DAPI (Vector Laboratories). LincRNA-RAPT1 spanning probes were 
labeled with Quasar® 570 (LGC Biosearch Technologies). Images were captured 
using an Axio Imager 2 microscope with a PlanApo 63x 1.4 oil DIC objective lens 
(Zeiss) and edited using Adobe Photoshop. 
 
Senescence-associated β-gal assay: Primary MEFs were cultured in 0.1 µM 
Doxo for 168 hours to induce senescence. LA and SA KPR cells were grown in 
normal media or media supplemented with Tam for 168 hours. Cells were fixed for 
15 min at RT in 0.5% glutaraldehyde diluted in PBS, washed 3 times in 1 mM MgCl2 
in PBS (not pH adjusted) and once in 1 mM MgCl2 in PBS (pH 5.5 for MEFs and 
LA cells; pH 5.0 for SA cells). Cells were then stained in β-gal staining solution (5 
mM potassium ferrocyanide, 5 mM potassium ferricyanide, 1 mg/mL X-gal, 1 mM 





Proliferation and colony formation assays: Growth curves were generated 
for various transgenic and genetically engineered primary MEF lines, p53-
restorable MEFs, and mock-treated (no Tam) KPR cell lines by passaging cells, 
counting cumulative cell numbers, and calculating population doublings over time.  
p53-proficient growth or growth arrest bypass was assessed by plating cells 
in Tam-supplemented media and counting cells at intervals of indicated lengths, 
changing media every three days. Cumulative cell numbers over time were plotted 
as the average of three independent experiments, when appropriate. For p53-
proficient colony formation assays, 4x105 cells/6 cm dish were grown in Tam-
supplemented media and monitored for colony growth. For p53-deficient (-Tam) 
colony formation assays, 1x105 cells/6 cm dish were plated and grown in normal 
media. After 7-10 days, dishes were washed with PBS, fixed in 0.5% Crystal Violet; 
25% methanol for 10 minutes, and thoroughly washed in ddH2O prior to colony 
counting. Whenever shown, averages represent three independent experiments.   
 
BrdU incorporation: Cells were grown on coverslips to roughly 50% confluency 
in Tam-supplemented media. At 22h post-Tam treatment, cells were labeled with 
10 µM 5-bromo-2-deoxyuridine (BrdU; Sigma-Aldrich) for 2h for KPR cells or 4h 
for p53-restorable MEFs, washed once in PBS, and fixed overnight at -20 °C in 
Fixation Buffer (75% ethanol, 25% 0.05 M glycine pH 2.2). Fixed cells were then 
washed in PBS and incubated for 10 min at RT in 4N HCL, followed by three PBS 
washes. In a covered humidified chamber, coverslips were blocked in PBG (0.5% 
w/v BSA [Sigma A-2153], 0.2% w/v cold water fish gelatin [Sigma G-7765] in PBS) 
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and stained with FITC-conjugated anti-BrdU antibody diluted 1:100 in PBG for 45 
min at RT. Coverslips were washed three times in PBG and mounted in Vectashield 
Mounting medium with DAPI before imaging. Nuclei were scored for BrdU 
positivity and data presented as fraction BrdU positive over negative. 
 
Apoptosis assays: Cleaved caspase 3 (CC3) levels, as assessed by 
immunoblotting, were used as a read out for apoptosis induced by oncogenic and 
genotoxic stressors, with the appropriate Tam and/or Doxo treatments indicated 
in text and figure legends. Pro-apoptotic genotoxicity was induced in MEFs and 
KPR cells by treating cells with 1 µM Doxo for 24h. Apoptosis was also monitored 
in LA1 and LA2 cells using the Alexa Fluro 488® Annexin V/Dead Cell Apoptosis 
kit (Invitrogen), following the manufacturer’s protocol, and analyzed on a FACS 
Aria III sorter equipped with FACS DIVA software (BD Biosciences). 
 
Statistical Analysis: Statistical tests and sample sizes used for each analysis are 
indicated in figure legends. Analyses were performed using GraphPad Prism 8. 
p<0.05 was considered statistically significant, with the following significance 











Supplementary Table 1: Key plasmids used in this work 
 
Name Details Source 
pCMV-dR8.2 lentiviral packaging Addgene plasmid #8455 
pCMV-VSV-G lentiviral packaging Addgene plasmid #8454 
BRD001 lentiviral; SpCas9; hU6-gRNA; Puro Broad Institute gift 
BRD003 lentiviral; hU6-gRNA; Puro Broad Institute gift 
BRD004 lentiviral; SpCas9; hU6-gRNA; GFP Broad Institute gift 




MSCV Puro retroviral mammalian expression; Puro  
pWZL Hygro retroviral mammalian expression; Hygro Addgene plasmid 
#18750 
pLPC 12S E1A 
puro  




lentiviral; constitutive dCas9-BFP-KRAB; BFP 
Addgene plasmid #46911 
Lenti dCas-
VP64_Blast  



























Supplementary Table 2: gRNA, dRNA, and ASO information 
 
SpCas9 gRNAs 
Name Target Sequence *Score 
gRNA-Control 1 (Con) dTomato GGCCACGAGTTCGAGATCGA -- 
gRNA-Control 2  mCherry GTATTACTGATATTGGTGGG -- 
    
ΔRE-Zmat3-as lncRNA p53RE CATGCTCCCAAGACATGCCT  88 
ΔRE-lincRNA-Spag9 lncRNA p53RE CTGCTGTGCTTGGACTTGTT 84 
ΔRE-lincRNA-Gadd45γ lncRNA p53RE GTGACATGCCTGTCCCCGAC 91 
ΔRE-Ltc4s-as lncRNA p53RE TCTGAGGCCTGGGACTTGCC 70 
ΔRE-2310008N11Rik lncRNA p53RE GGTCCACATTGCAGTTCTTC 90 
ΔRE-Pvt1b lncRNA p53RE ATATGGGCAGTGACAAGTTT 87 
ΔRE-lincRNA-p21 lncRNA p53RE GATGCAACCGAAGGCAAGCC 90 
ΔRE-Rhod-as lncRNA p53RE TCAGAGCTAGCTCTGGCACA 81 
    
gRNA #7 lncRNA 7 TSS (+43) TGCTCAGACATGTCTAAGCC 91 
gRNA #8 lncRNA 7 TSS (+68) GGTCCACATTGCAGTTCTTC 90 
gRNA #9; 
lncRNA 7 gRNA 1 
lncRNA 7 TSS (-10) AAACACAGTGCCTTCGCTCT 94 
gRNA #10; 
lncRNA 7 gRNA 2 
lncRNA 7 TSS (-123) AGCTATAGATCTGTCAGTAC 91 
gRNA #12 lncRNA 7 TSS (-340) AGTCACCAGCTTTGGCGCCC 92 
gRNA #13 lncRNA 7 TSS (-180) TACATGGTACTCATGACCCT 90 
gRNA #14 lncRNA 7 TSS (-120) GCTTTCTGGCTTAACATGTA 90 
    
Ltc4s-as gRNA 1 TSS (-134) CGGGCTACACCGGCTCGCTA 99 
Ltc4s-as gRNA 2 TSS (-46) CCCACCCTTTGAGCGGCGTT 98 
Bfsp2-as gRNA 1 TSS (-65) AGCTATAGATCTGTCAGTAC 90 
Bfsp2-as gRNA 2 TSS (-19) TGCAGCTGTCTCAGCGACAT 78 
Neat1 gRNA 3 TSS (-78) TCCTGATGGCTTTTGCACCC 92 
Neat1 gRNA 4 TSS (-130) GGCCATGACCCGCCCCTCGT 86 
    
SpCas9 dRNAs 
Name Target Sequence -- 
dRNA-Control (dCon) dTomato gCGAGTTCGAGATCGA -- 
dRNA-A1 lincRNA-Gadd45γ TSS (-10) GACCTACCGCGGCTC  -- 
dRNA-I1 lincRNA-Gadd45γ TSS (+3) CTCAGAAGAGTGACT  -- 
    
ASOs 
Name Target Sequence -- 
Con N/A GCTCCCTTCAATCCAA -- 
ASO 1 lincRNA-Gadd45γ GGTCAAATCGGTGCAG -- 
ASO 2 lincRNA-Gadd45γ ACCATTACTCCTCAAT -- 
ASO (Ltc4s-as) Ltc4s-as TGTCGGTTAGTAGATG  















Supplementary Table 3: qRT-PCR, PCR, and sequencing primer information 
 
qRT-PCR primers (mouse); 5’ 3’ 
Gene Forward sequence Reverse sequence 
Gapdh AGCTTGTCATCAACGGGAAG TTTGATGTTAGTGGGGTCTCG 
p53 ACGCTTCTCCGAAGACTGG AGGGAGCTCGAGGCTGATA 
p21 TCCACAGCGATATCCAGACA GGACATCACCAGGATTGGAC 
p16 CATCTGGAGCAGCATGGAGTC TACGACCGAAAGAGTTCGGGG 
Rn7s1 CTGTAGTGCGCTATGCCGA   GTTCACCCCTCCTTAGGCAA   
Kcnq1ot1 GGCCAGAAGCAGAGGTGATT CCGAGCCGTAACTGCAAAAC 
Zmat3-as AGCCTACCCTGAAAGCGATG TTCCAATGTCTTTGGGCGGA 
Bahcc1-as AAGGCCGCTTGATGAAAGGA TGGCCTGATTCAATCGCGTA 
lincRNA-Spag9 GCCTCATGAGACCTGCTGAA GCCCCTGTGTAGCAATCACT 
lincRNA-Gadd45γ GCTCCGTTCCACGAAGTTTT TGGGCTAGGCAGGTTAGGTA 
lincRNA-Gadd45γ (2) CTCAGAAGAGTGACTCGGCG AGGCAATAACTCCAGCTCTTTGA 
lincRNA-Gadd45γ (3) ACTCTTATCAGCACACTCCAGC CAGGCATGAGGGTCTGTGTC 
Ltc4s-as CCTTGGCTGACACCCGAACC CCGAGTTCGAGCGCGTCTTC 
2310008N11Rik (lncRNA 7) AGGAAAGAAGCGACTGAACACT GATGACGAAGGTGAGGCACA 
Neat1 GGTTGACGCCTACACAGTGA CTGCTGCCATTCATGCATCC 
Malat1 AACCAGTTTCCCCAGCTTTT CTACATTCCCACCCAGCACT 
Pvt1a ACTTAGCATTCCCAGAGCCC TGGAGGGCATCTTCTTACCG 
Pvt1b CCATGACTGGGAAAAACCTCG TGGAGGGCATCTTCTTACCG 
Rhod-as GGCAAGTTCTGAAGCCCACA CCTGGGGGATTTCTCATCAGC 
Sesn2-as GGTCCGAGTGCTTTATGGGT TTGCTCTGTTCCCACACCAC 
Bfsp2-as TTGGCTATGGGTGCTTCGGC AGCCGGGACTCTATCCATCC 
lincRNA-p21 CCTGTCCCACTCGCTTTC GGAACTGGAGACGGAATGTCTC 
Zmat3 TGTCACCTTGAACTCCGCTC GCACAGCTTACAGTAGTCATTCT 
Bahcc1 GGGATTCATGGGATTGCCCT GGCCAGCACATCCTCATCTT 
Spag9 GAATGGGTCGTGAGGTGGAG TCTGCACGAGCTTTCCTGAG 
Gadd45γ GTGGCCAGGATACAGTTCCG CAGGGTCCACATTCAGGACTT 
Ltc4s CCCTCGTGGGAGTTCTGTTG GCGTATAGGGGAGTCAGCCT 
Maml1 ACACAAAGCACCTTCCCACA GAGGACAGCTGGAGTTGGAC 
Myc TTCATCTGCGATCCTGACGAC CACTGAGGGGTCAATGCACTC 
Sytl12 ACAGCAATGAGGGCAAAGGA GCTGGATCCACCAAACTGGA 
Rhod GCTCCTCTGCTTCGATGTGAC TGAGAGCCACTTCTGCTGCTT 
Sestrin2 CACTGCGTCTTTGGCATCAG GGTCGTCTTCTCAGGGTAGC 
Bfsp2 GGAAAACAGCTTGCACGACG TGAGGTTCTTCAGACGTCACC 
Thap1 CCAGAAGGATGGTGCAGTCC GGGCGAGTAAGAGGAAACTTGT 
Zfp703 CCAATTGAGCTGGACGCCAA CGGAGTTGAGCTTGGATGAG  
Erlin2 CTGGAGGGACAGCCTGGATA ACAGCTGAGAAGAGAGATGCA 
Rnf170 AGCTAGGTAGTCCCCGGAAA CTTAGACGCCCTAAGCTCG 
LincRNA-RAPT1 [aka (2)] ACAGCTGGCAAGTGGCAAAGCA CCACCCACCTGCTTCTGTGTCC 
Dhx15  CAGCCCAGGAGAGTGGCTGC ACGCTCCAGAAGGGGATCGTTCA 




LincRNA-RAPT1 (8) AGCTTCTCAGGACCTCTCTGCA AGCTATACTTTCCTGAACCCAGAC
GA 
LincRNA-RAPT1 (2kb) GCCTGATAGACTGAGAGGCAC CTAGGCAAGTGTGAGTGGTGAA  
LincRNA-RAPT1 (4kb) TGACCCCATCCACATCAGTC  GTATGGAGCCCCGATTGAGA  
LincRNA-RAPT1 (6kb) TACCAAAACTCAGGGTAAGGGAA  AAGGCATCCGTGAGGTTGATGG  
LincRNA-RAPT1 (8kb) TATGGCTGAATAGTGTCTCTGCT  CCCTTCTCACTCTACGCTCGTG 
 
qRT-PCR primers (human); 5’ 3’ 
Gene Forward sequence Reverse sequence 




Genotyping PCR primers; 5’ 3’ 
Name Sequence 
p53 LSL-1 CTT GGA GAC ATA GCC ACA CTG 
p53 LSL-2 CAA CTG TTC TAC CTC AAG AGC C 
SD5 AGC TAG CCA CCA TGG CTT GAG TAA GTC TGC A 
 
Mutagenesis efficiency PCR primers; 5’ 3’ 
Name Forward sequence Reverse sequence 
Zmat3-as PCR GAGCTTCCCTGTCTGTGATGA  ATCCTTCGTGTCTGCCATCG 
lincRNA-Gadd45γ PCR CTTGCAGACCCGTCTTGAGT CAGGCATGAGGGTCTGTGTC 
lincRNA-p21 PCR ATTGGCTAACCCCATGAGCAC CTCTTCTTGCAGAAAGCCGCA 
Pvt1b PCR ATTGCGTTCCTGTGTTCGTG AGGCAAAACAACAAGGCAGTC 
Ltc4s-as PCR GCAGCTGGACAGATAGATACC GCTAACAACCACAGTGCAGG 
 
TIDE sequencing primers; 5’ 3’ 
Name Sequence 
Zmat3-as seq CAACTACCCGTATCTCTGGAAAC  
lincRNA-Gadd45γ seq CTGACTCCAGTTCTACCACAAG  
lincRNA-p21 seq GCCCTCTCTCCATCCTCAATG  
Pvt1b seq CTGCTCTTGTGTTTTTAAGGGG 


















Abdelmohsen K, Panda A, Kang M-J, Xu J, Selimyan R, Yoon J-H, Martindale JL, De S, 
Wood WH, Becker KG, et al. 2013. Senescence-associated lncRNAs: senescence-
associated long noncoding RNAs. Aging Cell 12: 890–900. 
Abudayyeh OO, Gootenberg JS, Essletzbichler P, Han S, Joung J, Belanto JJ, Verdine V, 
Cox DBT, Kellner MJ, Regev A, et al. 2017. RNA targeting with CRISPR-Cas13. 
Nature 550: 280–284. 
Adriaens C, Standaert L, Barra J, Latil M, Verfaillie A, Kalev P, Boeckx B, Wijnhoven 
PWG, Radaelli E, Vermi W, et al. 2016. p53 induces formation of NEAT1 lncRNA-
containing paraspeckles that modulate replication stress response and 
chemosensitivity. Nat Med 22: 861–868. 
Akdemir KC, Jain AK, Allton K, Aronow B, Xu X, Cooney AJ, Li W, Barton MC. 2014. 
Genome-wide profiling reveals stimulus-specific functions of p53 during 
differentiation and DNA damage of human embryonic stem cells. Nucleic Acids Res 
42: 205–23. 
Allen MA, Andrysik Z, Dengler VL, Mellert HS, Guarnieri A, Freeman JA, Sullivan KD, 
Galbraith MD, Luo X, Kraus WL, et al. 2014. Global analysis of p53-regulated 
transcription identifies its direct targets and unexpected regulatory mechanisms. 
Elife 3: e02200. 
Amândio AR, Necsulea A, Joye E, Mascrez B, Duboule D. 2016. Hotair Is Dispensible for 
Mouse Development. ed. G.S. Barsh. PLoS Genet 12: e1006232. 
Anderson DM, Anderson KM, Chang CL, Makarewich CA, Nelson BR, McAnally JR, 
Kasaragod P, Shelton JM, Liou J, Bassel-Duby R, et al. 2015. A micropeptide 
encoded by a putative long noncoding RNA regulates muscle performance. Cell 
160: 595–606. 
Anderson KM, Anderson DM, McAnally JR, Shelton JM, Bassel-Duby R, Olson EN. 
2016. Transcription of the non-coding RNA upperhand controls Hand2 expression 
and heart development. Nature 539: 433–436. 
Andrysik Z, Galbraith MD, Guarnieri AL, Zaccara S, Sullivan KD, Pandey A, MacBeth M, 
Inga A, Espinosa JM. 2017. Identification of a core TP53 transcriptional program 
with highly distributed tumor suppressive activity. Genome Res 27: 1645–1657. 
Arun G, Diermeier S, Akerman M, Chang K-C, Wilkinson JE, Hearn S, Kim Y, MacLeod 
AR, Krainer AR, Norton L, et al. 2016. Differentiation of mammary tumors and 
reduction in metastasis upon Malat1 lncRNA loss. Genes Dev 30: 34–51. 
Attardi LD, de Vries A, Jacks T. 2004. Activation of the p53-dependent G1 checkpoint 
response in mouse embryo fibroblasts depends on the specific DNA damage 
inducer. Oncogene 23: 973–980. 
Bartkova J, Rezaei N, Liontos M, Karakaidos P, Kletsas D, Issaeva N, Vassiliou L-VF, 
Kolettas E, Niforou K, Zoumpourlis VC, et al. 2006. Oncogene-induced senescence 
is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 
444: 633–7. 
Bassett AR, Akhtar A, Barlow DP, Bird AP, Brockdorff N, Duboule D, Ephrussi A, 
151 
 
Ferguson-Smith AC, Gingeras TR, Haerty W, et al. 2014. Considerations when 
investigating lncRNA function in vivo. Elife 3: e03058. 
Basu S, Larsson E. 2018. A catalogue of putative cis-regulatory interactions between long 
non-coding RNAs and proximal coding genes based on correlative analysis across 
diverse human tumors. G3 Genes, Genomes, Genet 8: 2019–2025. 
Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, 
Boehm JS, Dobson J, Urashima M, et al. 2010. The landscape of somatic copy-
number alteration across human cancers. Nature 463: 899–905. 
Botcheva K, McCorkle SR. 2014. Cell context dependent p53 genome-wide binding 
patterns and enrichment at repeats. PLoS One 9: e113492. 
Brady CA, Jiang D, Mello SS, Johnson TM, Jarvis LA, Kozak MM, Broz DK, Basak S, 
Park EJ, McLaughlin ME, et al. 2011. Distinct p53 transcriptional programs dictate 
acute DNA-damage responses and tumor suppression. Cell 145: 571–583. 
Brinkman EK, Chen T, Amendola M, van Steensel B. 2014. Easy quantitative assessment 
of genome editing by sequence trace decomposition. Nucleic Acids Res 42: e168. 
Brown CJ, Ballabio A, Rupert JL, Lafreniere RG, Grompe M, Tonlorenzi R, Willard HF. 
1991. A gene from the region of the human X inactivation centre is expressed 
exclusively from the inactive X chromosome. Nature 349: 38–44. 
Brugarolas J, Chandrasekaran C, Gordon J, I., Beach D, Jacks T, Hannon G, J. 1995. 
Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 377: 
552–557. 
Cabili MN, Dunagin MC, McClanahan PD, Biaesch A, Padovan-Merhar O, Regev A, Rinn 
JL, Raj A. 2015. Localization and abundance analysis of human lncRNAs at single-
cell and single-molecule resolution. Genome Biol 16: 20. 
Cabili MN, Trapnell C, Goff L, Koziol M, Tazon-Vega B, Regev A, Rinn JL. 2011. 
Integrative annotation of human large intergenic noncoding RNAs reveals global 
properties and specific subclasses. Genes Dev 25: 1915–27. 
Campisi J. 2013. Aging, Cellular Senescence, and Cancer. Annu Rev Physiol 75: 685–
705. 
Campisi J, d’Adda di Fagagna F. 2007. Cellular senescence: when bad things happen to 
good cells. Nat Rev Mol Cell Biol 8: 729–740. 
Carrieri C, Cimatti L, Biagioli M, Beugnet A, Zucchelli S, Fedele S, Pesce E, Ferrer I, 
Collavin L, Santoro C, et al. 2012. Long non-coding antisense RNA controls Uchl1 
translation through an embedded SINEB2 repeat. Nature 491: 454–457. 
Catizone AN, Good CR, Alexander KA, Berger SL, Sammons MA. 2019. Comparison of 
genotoxic versus nongenotoxic stabilization of p53 provides insight into parallel 
stress-responsive transcriptional networks. Cell Cycle 18: 809–823. 
Chaudhary R, Gryder B, Woods WS, Subramanian M, Jones MF, Li XL, Jenkins LM, 
Shabalina SA, Mo M, Dasso M, et al. 2017. Prosurvival long noncoding RNA PINCR 
regulates a subset of p53 targets in human colorectal cancer cells by binding to 
Matrin 3. Elife 6. 
Chen C-K, Blanco M, Jackson C, Aznauryan E, Ollikainen N, Surka C, Chow A, Cerase A, 
152 
 
McDonel P, Guttman M. 2016. Xist recruits the X chromosome to the nuclear 
lamina to enable chromosome-wide silencing. Science (80- ) 354: 468–472. 
Chen J, Guo K, Kastan MB. 2012. Interactions of nucleolin and ribosomal protein L26 
(RPL26) in translational control of human p53 mRNA. J Biol Chem 287: 16467–76. 
Chen J, Kastan MB. 2010. 5’-3’-UTR interactions regulate p53 mRNA translation and 
provide a target for modulating p53 induction after DNA damage. Genes Dev 24: 
2146–56. 
Chen M-T, Lin H-S, Shen C, Ma Y-N, Wang F, Zhao H-L, Yu J, Zhang J-W. 2015. PU.1-
Regulated Long Noncoding RNA lnc-MC Controls Human Monocyte/Macrophage 
Differentiation through Interaction with MicroRNA 199a-5p. Mol Cell Biol 35: 
3212–24. 
Childs BG, Baker DJ, Kirkland JL, Campisi J, van Deursen JM. 2014. Senescence and 
apoptosis: dueling or complementary cell fates? EMBO Rep 15: 1139–1153. 
Cho SW, Xu J, Sun R, Mumbach MR, Carter AC, Chen YG, Yost KE, Kim J, He J, Nevins 
SA, et al. 2018. Promoter of lncRNA Gene PVT1 Is a Tumor-Suppressor DNA 
Boundary Element. Cell 173: 1398-1412.e22. 
Chonghaile TN, Sarosiek KA, Vo TT, Ryan JA, Tammareddi A, Moore VDG, Deng J, 
Anderson KC, Richardson P, Tai YT, et al. 2011. Pretreatment mitochondrial 
priming correlates with clinical response to cytotoxic chemotherapy. Science (80- ) 
334: 1129–1133. 
Clemson CM, Hutchinson JN, Sara SA, Ensminger AW, Fox AH, Chess A, Lawrence JB. 
2009. An Architectural Role for a Nuclear Noncoding RNA: NEAT1 RNA Is 
Essential for the Structure of Paraspeckles. Mol Cell 33: 717–726. 
Collado M, Serrano M. 2010. Senescence in tumours: Evidence from mice and humans. 
Nat Rev Cancer 10: 51–57. 
Combs DJ, Nagel RJ, Ares M, Stevens SW. 2006. Prp43p Is a DEAH-Box Spliceosome 
Disassembly Factor Essential for Ribosome Biogenesis. Mol Cell Biol 26: 523–534. 
Conrad T, Ørom UA. 2017. Cellular fractionation and isolation of chromatin- associated 
RNA. Methods Mol Biol 1468: 1–9. 
Cox DBT, Gootenberg JS, Abudayyeh OO, Franklin B, Kellner MJ, Joung J, Zhang F. 
2017. RNA editing with CRISPR-Cas13. Science 358: 1019–1027. 
Cunnington MS, Santibanez Koref M, Mayosi BM, Burn J, Keavney B. 2010. 
Chromosome 9p21 SNPs Associated with Multiple Disease Phenotypes Correlate 
with ANRIL Expression ed. G. Gibson. PLoS Genet 6: e1000899. 
Dahlman JE, Abudayyeh OO, Joung J, Gootenberg JS, Zhang F, Konermann S. 2015. 
Orthogonal gene knockout and activation with a catalytically active Cas9 nuclease. 
Nat Biotechnol 33: 1159–1161. 
Davidovich C, Zheng L, Goodrich KJ, Cech TR. 2013. Promiscuous RNA binding by 
Polycomb repressive complex 2. Nat Struct Mol Biol 20: 1250–1257. 
Derrien T, Johnson R, Bussotti G, Tanzer A, Djebali S, Tilgner H, Guernec G, Martin D, 
Merkel A, Knowles DG, et al. 2012. The GENCODE v7 catalog of human long 
noncoding RNAs: Analysis of their gene structure, evolution, and expression. 
153 
 
Genome Res 22: 1775–1789. 
Di Micco R, Fumagalli M, Cicalese A, Piccinin S, Gasparini P, Luise C, Schurra C, Garre’ 
M, Giovanni Nuciforo P, Bensimon A, et al. 2006. Oncogene-induced senescence is 
a DNA damage response triggered by DNA hyper-replication. Nature 444: 638–
642. 
Dimitrova N, Zamudio JR, Jong RM, Soukup D, Resnick R, Sarma K, Ward AJ, Raj A, 
Lee JT, Sharp PA, et al. 2014. LincRNA-p21 activates p21 in cis to promote 
Polycomb target gene expression and to enforce the G1/S checkpoint. Mol Cell 54: 
777–90. 
Djebali S, Davis CA, Merkel A, Dobin A, Lassmann T, Mortazavi A, Tanzer A, Lagarde J, 
Lin W, Schlesinger F, et al. 2012. Landscape of transcription in human cells. Nature 
489: 101–108. 
Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA, Butel JS, Bradley. 
1992. Mice deficient for p53 are developmentally normal but susceptible to 
spontaneous tumours. Nature 356: 215–221. 
E. Tamura R, F. de Vasconcellos J, Sarkar D, A. Libermann T, B. Fisher P, F. Zerbini L. 
2012. GADD45 Proteins: Central Players in Tumorigenesis. Curr Mol Med 12: 634–
651. 
El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer 
WE, Kinzler KW, Vogelstein B. 1993. WAF1, a potential mediator of p53 tumor 
suppression. Cell 75: 817–825. 
Engeland K. 2018. Cell cycle arrest through indirect transcriptional repression by p53: I 
have a DREAM. Cell Death Differ 25: 114–132. 
Engreitz JM, Haines JE, Perez EM, Munson G, Chen J, Kane M, McDonel PE, Guttman 
M, Lander ES. 2016. Local regulation of gene expression by lncRNA promoters, 
transcription and splicing. Nature 539: 452–455. 
Faghihi MA, Zhang M, Huang J, Modarresi F, Van der Brug MP, Nalls MA, Cookson MR, 
St-Laurent G, Wahlestedt C. 2010. Evidence for natural antisense transcript-
mediated inhibition of microRNA function. Genome Biol 11: R56. 
Fang S, Zhang L, Guo J, Niu Y, Wu Y, Li H, Zhao L, Li X, Teng X, Sun X, et al. 2018. 
NONCODEV5: a comprehensive annotation database for long non-coding RNAs. 
Nucleic Acids Res 46: D308–D314. 
Fatica A, Bozzoni I. 2014. Long non-coding RNAs: new players in cell differentiation and 
development. Nat Rev Genet 15: 7–21. 
Feldser DM, Kostova KK, Winslow MM, Taylor SE, Cashman C, Whittaker CA, Sanchez-
Rivera FJ, Resnick R, Bronson R, Hemann MT, et al. 2010. Stage-specific sensitivity 
to p53 restoration during lung cancer progression. Nature 468: 572–5. 
Fischer M. 2017. Census and evaluation of p53 target genes. Oncogene 36: 3943–3956. 
Fischer M. 2019. Conservation and divergence of the p53 gene regulatory network 
between mice and humans. Oncogene 38: 4095–4109. 
Fischer M, Steiner L, Engeland K. 2014. The transcription factor p53: Not a repressor, 
solely an activator. Cell Cycle 13: 3037–3058. 
154 
 
Forrest ME, Saiakhova A, Beard L, Buchner DA, Scacheri PC, LaFramboise T, Markowitz 
S, Khalil AM. 2018. Colon Cancer-Upregulated Long Non-Coding RNA lincDUSP 
Regulates Cell Cycle Genes and Potentiates Resistance to Apoptosis. Sci Rep 8: 1–
12. 
Fulco CP, Munschauer M, Anyoha R, Munson G, Grossman SR, Perez EM, Kane M, 
Cleary B, Lander ES, Engreitz JM. 2016. Systematic mapping of functional 
enhancer–promoter connections with CRISPR interference. Science 354: 769–773. 
Funk CD. 2001. Prostaglandins and Leukotrienes: Advances in Eicosanoid Biology. 
Science (80- ) 294: 1871–1875. 
Gang Wang Z. 1998. Role of PML in Cell Growth and the Retinoic Acid Pathway. Science 
279: 1547–1551. 
Ghanam AR, Xu Q, Ke S, Azhar M, Cheng Q, Song X. 2017. Shining the light on 
senescence associated lncRNAs. Aging Dis 8: 149–161. 
Gil N, Ulitsky I. 2020. Regulation of gene expression by cis-acting long non-coding 
RNAs. Nat Rev Genet 21: 102–117. 
Gilbert LA, Horlbeck MA, Adamson B, Villalta JE, Chen Y, Whitehead EH, Guimaraes C, 
Panning B, Ploegh HL, Bassik MC, et al. 2014. Genome-Scale CRISPR-Mediated 
Control of Gene Repression and Activation. Cell 159: 647–661. 
Gilbert LA, Larson MH, Morsut L, Liu Z, Brar GA, Torres SE, Stern-Ginossar N, 
Brandman O, Whitehead EH, Doudna JA, et al. 2013. CRISPR-Mediated Modular 
RNA-Guided Regulation of Transcription in Eukaryotes. Cell 154: 442–451. 
Goff LA, Rinn JL. 2015. Linking RNA biology to lncRNAs. Genome Res 25: 1456–65. 
Gong C, Maquat LE. 2011. lncRNAs transactivate STAU1-mediated mRNA decay by 
duplexing with 3′ UTRs via Alu elements. Nature 470: 284–288. 
Goudarzi M, Berg K, Pieper LM, Schier AF. 2019. Individual long non-coding RNAs have 
no overt functions in zebrafish embryogenesis, viability and fertility. Elife 8. 
Groff AF, Sanchez-Gomez DB, Soruco MML, Gerhardinger C, Barutcu AR, Li E, Elcavage 
L, Plana O, Sanchez L V., Lee JC, et al. 2016. In Vivo Characterization of Linc-p21 
Reveals Functional cis-Regulatory DNA Elements. Cell Rep 16: 2178–2186. 
Grote P, Wittler L, Hendrix D, Koch F, Währisch S, Beisaw A, Macura K, Bläss G, Kellis 
M, Werber M, et al. 2013. The Tissue-Specific lncRNA Fendrr Is an Essential 
Regulator of Heart and Body Wall Development in the Mouse. Dev Cell 24: 206–
214. 
Grover R, Ray PS, Das S. 2008. Polypyrimidine tract binding protein regulates IRES-
mediated translation of p53 isoforms. Cell Cycle 7: 2189–2198. 
Guan Y, Kuo WL, Stilwell JL, Takano H, Lapuk A V., Fridlyand J, Mao JH, Yu M, Miller 
MA, Santos JL, et al. 2007. Amplification of PVT1 contributes to the 
pathophysiology of ovarian and breast cancer. Clin Cancer Res 13: 5745–5755. 
Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, Tsai M-C, Hung T, Argani 
P, Rinn JL, et al. 2010. Long non-coding RNA HOTAIR reprograms chromatin state 
to promote cancer metastasis. Nature 464: 1071–1076. 
155 
 
Gutschner T, Hammerle M, Eissmann M, Hsu J, Kim Y, Hung G, Revenko A, Arun G, 
Stentrup M, Gross M, et al. 2013. The Noncoding RNA MALAT1 Is a Critical 
Regulator of the Metastasis Phenotype of Lung Cancer Cells. Cancer Res 73: 1180–
1189. 
Guttman M, Amit I, Garber M, French C, Lin MF, Feldser D, Huarte M, Zuk O, Carey 
BW, Cassady JP, et al. 2009. Chromatin signature reveals over a thousand highly 
conserved large non-coding RNAs in mammals. Nature 458: 223–227. 
Hacisuleyman E, Goff LA, Trapnell C, Williams A, Henao-Mejia J, Sun L, McClanahan P, 
Hendrickson DG, Sauvageau M, Kelley DR, et al. 2014. Topological organization of 
multichromosomal regions by the long intergenic noncoding RNA Firre. Nat Struct 
Mol Biol 21: 198–206. 
Haeussler M, Schönig K, Eckert H, Eschstruth A, Mianné J, Renaud J-B, Schneider-
Maunoury S, Shkumatava A, Teboul L, Kent J, et al. 2016. Evaluation of off-target 
and on-target scoring algorithms and integration into the guide RNA selection tool 
CRISPOR. Genome Biol 17: 148. 
Hafner A, Bulyk ML, Jambhekar A, Lahav G. 2019. The multiple mechanisms that 
regulate p53 activity and cell fate. Nat Rev Mol Cell Biol 20: 199–210. 
Halaby M-J, Harris BRE, Miskimins WK, Cleary MP, Yang D-Q. 2015. Deregulation of 
Internal Ribosome Entry Site-Mediated p53 Translation in Cancer Cells with 
Defective p53 Response to DNA Damage. Mol Cell Biol 35: 4006–17. 
Hangauer MJ, Vaughn IW, McManus MT. 2013. Pervasive Transcription of the Human 
Genome Produces Thousands of Previously Unidentified Long Intergenic 
Noncoding RNAs ed. J.L. Rinn. PLoS Genet 9: e1003569. 
Hollander MC, Sheikh MS, Bulavin D V., Lundgren K, Augeri-Henmueller L, Shehee R, 
Molinaro TA, Kim KE, Tolosa E, Ashwell JD, et al. 1999. Genomic instability in 
Gadd45a-deficient mice. Nat Genet 23: 176–184. 
Horn HF, Vousden KH. 2007. Coping with stress: multiple ways to activate p53. 
Oncogene 26: 1306–1316. 
Hu WL, Jin L, Xu A, Wang YF, Thorne RF, Zhang XD, Wu M. 2018. GUARDIN is a p53-
responsive long non-coding RNA that is essential for genomic stability. Nat Cell Biol 
20: 492. 
Hu X, Feng Y, Zhang D, Zhao SD, Hu Z, Greshock J, Zhang Y, Yang L, Zhong X, Wang L-
P, et al. 2014. A Functional Genomic Approach Identifies FAL1 as an Oncogenic 
Long Noncoding RNA that Associates with BMI1 and Represses p21 Expression in 
Cancer. Cancer Cell 26: 344–357. 
Huarte M. 2015. The emerging role of lncRNAs in cancer. Nat Med 21: 1253–1261. 
Huarte M, Guttman M, Feldser D, Garber M, Koziol MJ, Kenzelmann-Broz D, Khalil AM, 
Zuk O, Amit I, Rabani M, et al. 2010. A Large Intergenic Noncoding RNA Induced 
by p53 Mediates Global Gene Repression in the p53 Response. Cell 142: 409–419. 
Hung T, Wang Y, Lin MF, Koegel AK, Kotake Y, Grant GD, Horlings HM, Shah N, 
Umbricht C, Wang P, et al. 2011. Extensive and coordinated transcription of 
noncoding RNAs within cell-cycle promoters. Nat Genet 43: 621–629. 
156 
 
Ihrie RA, Bronson RT, Attardi LD. 2006. Adult mice lacking the p53/p63 target gene 
Perp are not predisposed to spontaneous tumorigenesis but display features of 
ectodermal dysplasia syndromes [2]. Cell Death Differ 13: 1614–1618. 
Iyer MK, Niknafs YS, Malik R, Singhal U, Sahu A, Hosono Y, Barrette TR, Prensner JR, 
Evans JR, Zhao S, et al. 2015. The landscape of long noncoding RNAs in the human 
transcriptome. Nat Genet 47: 199–208. 
Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT, Weinberg 
RA. 1994. Tumor spectrum analysis in p53-mutant mice. Curr Biol 4: 1–7. 
Jain AK, Xi Y, McCarthy R, Allton K, Akdemir KC, Patel LR, Aronow B, Lin C, Li W, Yang 
L, et al. 2016. LncPRESS1 Is a p53-Regulated LncRNA that Safeguards Pluripotency 
by Disrupting SIRT6-Mediated De-acetylation of Histone H3K56. Mol Cell 64: 
967–981. 
Ji P, Diederichs S, Wang W, Böing S, Metzger R, Schneider PM, Tidow N, Brandt B, 
Buerger H, Bulk E, et al. 2003. MALAT-1, a novel noncoding RNA, and thymosin β4 
predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene 
22: 8031–8041. 
Jiang D, Brady CA, Johnson TM, Lee EY, Park EJ, Scott MP, Attardi LD. 2011. Full p53 
transcriptional activation potential is dispensable for tumor suppression in diverse 
lineages. Proc Natl Acad Sci 108: 17123–17128. 
Johnson L, Mercer K, Greenbaum D, Bronson RT, Crowley D, Tuveson DA, Jacks T. 
2001. Somatic activation of the K-ras oncogene causes early onset lung cancer in 
mice. Nature 410: 1111–1116. 
Joung J, Engreitz JM, Konermann S, Abudayyeh OO, Verdine VK, Aguet F, Gootenberg 
JS, Sanjana NE, Wright JB, Fulco CP, et al. 2017. Genome-scale activation screen 
identifies a lncRNA locus regulating a gene neighbourhood. Nature 548: 343–346. 
Kaiser AM, Attardi LD. 2018. Deconstructing networks of p53-mediated tumor 
suppression in vivo. Cell Death Differ 25: 93–103. 
Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, Xie M, Zhang Q, McMichael JF, 
Wyczalkowski MA, et al. 2013. Mutational landscape and significance across 12 
major cancer types. Nature 502: 333–339. 
Kastan MB, Zhan Q, El-Deiry WS, Carrier F, Jacks T, Walsh W V., Plunkett BS, 
Vogelstein B, Fornace AJ. 1992. A mammalian cell cycle checkpoint pathway 
utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71: 587–597. 
Kastenhuber ER, Lowe SW. 2017. Putting p53 in Context. Cell 170: 1062–1078. 
Kearns NA, Genga RMJ, Enuameh MS, Garber M, Wolfe SA, Maehr R. 2014. Cas9 
effector-mediated regulation of transcription and differentiation in human 
pluripotent stem cells. Dev 141: 219–223. 
Keniry A, Oxley D, Monnier P, Kyba M, Dandolo L, Smits G, Reik W. 2012. The H19 
lincRNA is a developmental reservoir of miR-675 that suppresses growth and Igf1r. 
Nat Cell Biol 14: 659–665. 
Kenzelmann Broz D, Spano Mello S, Bieging KT, Jiang D, Dusek RL, Brady CA, Sidow A, 
Attardi LD. 2013. Global genomic profiling reveals an extensive p53-regulated 
157 
 
autophagy program contributing to key p53 responses. Genes Dev 27: 1016–31. 
Khalil AM, Guttman M, Huarte M, Garber M, Raj A, Rivea Morales D, Thomas K, Presser 
A, Bernstein BE, van Oudenaarden A, et al. 2009. Many human large intergenic 
noncoding RNAs associate with chromatin-modifying complexes and affect gene 
expression. Proc Natl Acad Sci 106: 11667–11672. 
Kim J, Piao H-L, Kim B-J, Yao F, Han Z, Wang Y, Xiao Z, Siverly AN, Lawhon SE, Ton 
BN, et al. 2018. Long noncoding RNA MALAT1 suppresses breast cancer metastasis. 
Nat Genet 50: 1705–1715. 
Kim T, Jeon Y-J, Cui R, Lee J-H, Peng Y, Kim S-H, Tili E, Alder H, Croce CM. 2015. Role 
of MYC-Regulated Long Noncoding RNAs in Cell Cycle Regulation and 
Tumorigenesis. JNCI J Natl Cancer Inst 107: 26–45. 
Knudson CM, Johnson GM, Lin Y, Korsmeyer SJ. 2001. Bax accelerates tumorigenesis in 
p53-deficient mice. Cancer Res 61: 659–65. 
Kogo R, Shimamura T, Mimori K, Kawahara K, Imoto S, Sudo T, Tanaka F, Shibata K, 
Suzuki A, Komune S, et al. 2011. Long noncoding RNA HOTAIR regulates 
polycomb-dependent chromatin modification and is associated with poor prognosis 
in colorectal cancers. Cancer Res 71: 6320–6326. 
Konermann S, Brigham MD, Trevino AE, Joung J, Abudayyeh OO, Barcena C, Hsu PD, 
Habib N, Gootenberg JS, Nishimasu H, et al. 2014. Genome-scale transcriptional 
activation by an engineered CRISPR-Cas9 complex. Nature 517: 583–588. 
Konermann S, Lotfy P, Brideau NJ, Oki J, Shokhirev MN, Hsu PD. 2018. Transcriptome 
Engineering with RNA-Targeting Type VI-D CRISPR Effectors. Cell 173: 665-
676.e14. 
Kong Y, Hsieh C-H, Alonso LC. 2018. ANRIL: A lncRNA at the CDKN2A/B Locus With 
Roles in Cancer and Metabolic Disease. Front Endocrinol (Lausanne) 9: 405. 
Kopp F, Mendell JT. 2018. Functional Classification and Experimental Dissection of 
Long Noncoding RNAs. Cell 172: 393–407. 
Kretz M, Siprashvili Z, Chu C, Webster DE, Zehnder A, Qu K, Lee CS, Flockhart RJ, Groff 
AF, Chow J, et al. 2013. Control of somatic tissue differentiation by the long non-
coding RNA TINCR. Nature 493: 231–235. 
Krtolica A, Parrinello S, Lockett S, Desprez P-Y, Campisi J. 2001. Senescent fibroblasts 
promote epithelial cell growth and tumorigenesis: A link between cancer and aging. 
Proc Natl Acad Sci 98: 12072–12077. 
Kruiswijk F, Labuschagne CF, Vousden KH. 2015. p53 in survival, death and metabolic 
health: a lifeguard with a licence to kill. Nat Rev Mol Cell Biol 16: 393–405. 
Lai F, Damle SS, Ling KK, Rigo F. 2020. Directed RNase H Cleavage of Nascent 
Transcripts Causes Transcription Termination. Mol Cell 77: 1032-1043.e4. 
Lai K-MV, Gong G, Atanasio A, Rojas J, Quispe J, Posca J, White D, Huang M, Fedorova 
D, Grant C, et al. 2015. Diverse Phenotypes and Specific Transcription Patterns in 
Twenty Mouse Lines with Ablated LincRNAs ed. Q. Wu. PLoS One 10: e0125522. 
Lam BK, Frank Austen K. 2002. Leukotriene C4 synthase: a pivotal enzyme in cellular 




Latos PA, Pauler FM, Koerner M V., Senergin HB, Hudson QJ, Stocsits RR, Allhoff W, 
Stricker SH, Klement RM, Warczok KE, et al. 2012. Airn Transcriptional Overlap, 
But Not Its lncRNA Products, Induces Imprinted Igf2r Silencing. Science 338: 
1469–1472. 
Lee J-S, Mendell JT. 2020. Antisense-Mediated Transcript Knockdown Triggers 
Premature Transcription Termination. Mol Cell 77: 1044-1054.e3. 
Lee K-H, Li M, Michalowski AM, Zhang X, Liao H, Chen L, Xu Y, Wu X, Huang J. 2010. 
A genomewide study identifies the Wnt signaling pathway as a major target of p53 
in murine embryonic stem cells. Proc Natl Acad Sci 107: 69–74. 
Lee S, Kopp F, Chang T-C, Sataluri A, Chen B, Sivakumar S, Yu H, Xie Y, Mendell JT. 
2016. Noncoding RNA NORAD Regulates Genomic Stability by Sequestering 
PUMILIO Proteins. Cell 164: 69–80. 
Lennox KA, Behlke MA. 2016. Cellular localization of long non-coding RNAs affects 
silencing by RNAi more than by antisense oligonucleotides. Nucleic Acids Res 44: 
863–77. 
Léveillé N, Melo CA, Rooijers K, Díaz-Lagares A, Melo SA, Korkmaz G, Lopes R, 
Moqadam FA, Maia AR, Wijchers PJ, et al. 2015. Genome-wide profiling of p53-
regulated enhancer RNAs uncovers a subset of enhancers controlled by a lncRNA. 
Nat Commun 6: 6520. 
Lewandowski JP, Dumbović G, Watson AR, Hwang T, Jacobs-Palmer E, Chang N, Much 
C, Turner KM, Kirby C, Rubinstein ND, et al. 2020. The Tug1 lncRNA locus is 
essential for male fertility. Genome Biol 21: 237. 
Lewandowski JP, Lee JC, Hwang T, Sunwoo H, Goldstein JM, Groff AF, Chang NP, 
Mallard W, Williams A, Henao-Meija J, et al. 2019. The Firre locus produces a 
trans-acting RNA molecule that functions in hematopoiesis. Nat Commun 10: 5137. 
Li L, Liu B, Wapinski OL, Tsai M-C, Qu K, Zhang J, Carlson JC, Lin M, Fang F, Gupta 
RA, et al. 2013. Targeted Disruption of Hotair Leads to Homeotic Transformation 
and Gene Derepression. Cell Rep 5: 3–12. 
Li M, He Y, Dubois W, Wu X, Shi J, Huang J. 2012. Distinct Regulatory Mechanisms and 
Functions for p53-Activated and p53-Repressed DNA Damage Response Genes in 
Embryonic Stem Cells. Mol Cell 46: 30–42. 
Li Q, Zhang Y, El-Naggar AK, Xiong S, Yang P, Jackson JG, Chau G, Lozano G. 2014. 
Therapeutic efficacy of p53 restoration in Mdm2-overexpressing tumors. Mol 
Cancer Res 12: 901–911. 
Li X, Yang L, Chen LL. 2018. The Biogenesis, Functions, and Challenges of Circular 
RNAs. Mol Cell 71: 428–442. 
Li XL, Subramanian M, Jones MF, Chaudhary R, Singh DK, Zong X, Gryder B, Sindri S, 
Mo M, Schetter A, et al. 2017. Long Noncoding RNA PURPL Suppresses Basal p53 
Levels and Promotes Tumorigenicity in Colorectal Cancer. Cell Rep 20: 2408–
2423. 
Lim LJ, Jin Y, Yang H, Chung AYF, Goh BKP, Chow PKH, Chan CY, Blanks WK, Cheow 
159 
 
PC, Lee SY, et al. 2020. Network of clinically-relevant lncRNAs-mRNAs associated 
with prognosis of hepatocellular carcinoma patients. Sci Rep 10: 11124. 
Lin AW, Barradas M, Stone JC, Van Aelst L, Serrano M, Lowe SW. 1998. Premature 
senescence involving p53 and p16 is activated in response to constitutive 
MEK/MAPK mitogenic signaling. Genes Dev 12: 3008–3019. 
Liu JC, Guan X, Ryan JA, Rivera AG, Mock C, Agarwal V, Letai A, Lerou PH, Lahav G. 
2013a. High Mitochondrial Priming Sensitizes hESCs to DNA-Damage-Induced 
Apoptosis. Cell Stem Cell 13: 483–491. 
Liu Q, Huang J, Zhou N, Zhang Z, Zhang A, Lu Z, Wu F, Mo Y-Y. 2013b. LncRNA 
loc285194 is a p53-regulated tumor suppressor. Nucleic Acids Res 41: 4976–87. 
Liu SJ, Horlbeck MA, Cho SW, Birk HS, Malatesta M, He D, Attenello FJ, Villalta JE, 
Cho MY, Chen Y, et al. 2017. CRISPRi-based genome-scale identification of 
functional long noncoding RNA loci in human cells. Science (80- ) 355: eaah7111. 
Loda A, Heard E. 2019. Xist RNA in action: Past, present, and future ed. M.S. 
Bartolomei. PLOS Genet 15: e1008333. 
Loewer S, Cabili MN, Guttman M, Loh YH, Thomas K, Park IH, Garber M, Curran M, 
Onder T, Agarwal S, et al. 2010. Large intergenic non-coding RNA-RoR modulates 
reprogramming of human induced pluripotent stem cells. Nat Genet 42: 1113–1117. 
Lowe SW, Jacks T, Housman DE, Ruleyt AHE. 1994. Abrogation of oncogene-associated 
apoptosis allows transformation of p53-deficient cells. Cell Biol 91: 2026–2030. 
Lowe SW, Ruley HE, Jacks T, Housman DE. 1993a. p53-dependent apoptosis modulates 
the cytotoxicity of anticancer agents. Cell 74: 957–967. 
Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. 1993b. p53 is required for 
radiation-induced apoptosis in mouse thymocytes. Nature 362: 847–849. 
Mancini-Dinardo D, Steele SJS, Levorse JM, Ingram RS, Tilghman SM. 2006. 
Elongation of the Kcnq1ot1 transcript is required for genomic imprinting of 
neighboring genes. Genes Dev 20: 1268–82. 
Marchese FP, Grossi E, Marín-Béjar O, Bharti SK, Raimondi I, González J, Martínez-
Herrera DJ, Athie A, Amadoz A, Brosh RM, et al. 2016. A Long Noncoding RNA 
Regulates Sister Chromatid Cohesion. Mol Cell 63: 397–407. 
Marcotte R, Lacelle C, Wang E. 2004. Senescent fibroblasts resist apoptosis by 
downregulating caspase-3. Mech Ageing Dev 125: 777–783. 
Marín-Béjar O, Marchese FP, Athie A, Sánchez Y, González J, Segura V, Huang L, 
Moreno I, Navarro A, Monzó M, et al. 2013. Pint lincRNA connects the p53 pathway 
with epigenetic silencing by the Polycomb repressive complex 2. Genome Biol 14: 
R104. 
Marín-Béjar O, Mas AM, González J, Martinez D, Athie A, Morales X, Galduroz M, 
Raimondi I, Grossi E, Guo S, et al. 2017. The human lncRNA LINC-PINT inhibits 
tumor cell invasion through a highly conserved sequence element. Genome Biol 18: 
202. 
Maurano MT, Humbert R, Rynes E, Thurman RE, Haugen E, Wang H, Reynolds AP, 
Sandstrom R, Qu H, Brody J, et al. 2012. Systematic Localization of Common 
160 
 
Disease-Associated Variation in Regulatory DNA. Science 337: 1190–1195. 
McDade SS, Patel D, Moran M, Campbell J, Fenwick K, Kozarewa I, Orr NJ, Lord CJ, 
Ashworth AA, McCance DJ. 2014. Genome-wide characterization reveals complex 
interplay between TP53 and TP63 in response to genotoxic stress. Nucleic Acids Res 
42: 6270–6285. 
Meek DW. 2009. Tumour suppression by p53: a role for the DNA damage response? Nat 
Rev Cancer 9: 714–723. 
Mello SS, Sinow C, Raj N, Mazur PK, Bieging-Rolett K, Broz DK, Imam JFC, Vogel H, 
Wood LD, Sage J, et al. 2017. Neat1 is a p53-inducible lincRNA essential for 
transformation suppression. Genes Dev 31: 1095–1108. 
Melo CA, Drost J, Wijchers PJ, van de Werken H, de Wit E, Vrielink JAFO, Elkon R, 
Melo SA, Léveillé N, Kalluri R, et al. 2013. eRNAs Are Required for p53-Dependent 
Enhancer Activity and Gene Transcription. Mol Cell 49: 524–535. 
Melo CA, Léveillé N, Rooijers K, Wijchers PJ, Geeven G, Tal A, Melo SA, de Laat W, 
Agami R. 2016. A p53-bound enhancer region controls a long intergenic noncoding 
RNA required for p53 stress response. Oncogene 35: 4399–4406. 
Menendez D, Nguyen TA, Freudenberg JM, Mathew VJ, Anderson CW, Jothi R, Resnick 
MA. 2013. Diverse stresses dramatically alter genome-wide p53 binding and 
transactivation landscape in human cancer cells. Nucleic Acids Res 41: 7286–7301. 
Mercer TR, Dinger ME, Mattick JS. 2009. Long non-coding RNAs: insights into 
functions. Nat Rev Genet 10: 155–159. 
Michalak EM, Villunger A, Adams JM, Strasser A. 2008. In several cell types tumour 
suppressor p53 induces apoptosis largely via Puma but Noxa can contribute. Cell 
Death Differ 15: 1019–29. 
Mineo M, Lyons SM, Zdioruk M, von Spreckelsen N, Ferrer-Luna R, Ito H, Alayo QA, 
Kharel P, Giantini Larsen A, Fan WY, et al. 2020. Tumor Interferon Signaling Is 
Regulated by a lncRNA INCR1 Transcribed from the PD-L1 Locus. Mol Cell 78: 
1207-1223.e8. 
Muñoz-Espín D, Serrano M. 2014. Cellular senescence: From physiology to pathology. 
Nat Rev Mol Cell Biol 15: 482–496. 
Nag S, Qin J, Srivenugopal KS, Wang M, Zhang R. 2013. The MDM2-p53 pathway 
revisited. J Biomed Res 27: 254–271. 
Nagano T, Mitchell JA, Sanz LA, Pauler FM, Ferguson-Smith AC, Feil R, Fraser P. 2008. 
The Air noncoding RNA epigenetically silences transcription by targeting G9a to 
chromatin. Science 322: 1717–20. 
Nakagawa S, Naganuma T, Shioi G, Hirose T. 2011. Paraspeckles are subpopulation-
specific nuclear bodies that are not essential in mice. J Cell Biol 193: 31–39. 
Nakagawa S, Shimada M, Yanaka K, Mito M, Arai T, Takahashi E, Fujita Y, Fujimori T, 
Standaert L, Marine J-C, et al. 2014. The lncRNA Neat1 is required for corpus 
luteum formation and the establishment of pregnancy in a subpopulation of mice. 
Development 141: 4618–27. 
Nakano K, Vousden KH. 2001. PUMA, a novel proapoptotic gene, is induced by p53. Mol 
161 
 
Cell 7: 683–694. 
Nikulenkov F, Spinnler C, Li H, Tonelli C, Shi Y, Turunen M, Kivioja T, Ignatiev I, Kel A, 
Taipale J, et al. 2012. Insights into p53 transcriptional function via genome-wide 
chromatin occupancy and gene expression analysis. Cell Death Differ 19: 1992–
2002. 
Olivero CE, Dimitrova N. 2020. Identification and characterization of functional long 
noncoding RNAs in cancer. FASEB J 34: 15630–15646. 
Olivero CE, Martínez-Terroba E, Zimmer J, Liao C, Tesfaye E, Hooshdaran N, Schofield 
JA, Bendor J, Fang D, Simon MD, et al. 2020. p53 Activates the Long Noncoding 
RNA Pvt1b to Inhibit Myc and Suppress Tumorigenesis. Mol Cell 77: 761-774.e8. 
Olivier M, Hollstein M, Hainaut P. 2010. TP53 Mutations in Human Cancers: Origins, 
Consequences, and Clinical Use. Cold Spring Harb Perspect Biol 2: a001008–
a001008. 
Pageau GJ, Hall LL, Ganesan S, Livingston DM, Lawrence JB. 2007. The disappearing 
Barr body in breast and ovarian cancers. Nat Rev Cancer 7: 628–633. 
Pandey GK, Mitra S, Subhash S, Hertwig F, Kanduri M, Mishra K, Fransson S, 
Ganeshram A, Mondal T, Bandaru S, et al. 2014. The Risk-Associated Long 
Noncoding RNA NBAT-1 Controls Neuroblastoma Progression by Regulating Cell 
Proliferation and Neuronal Differentiation. Cancer Cell 26: 722–737. 
Perng M-D, Zhang Q, Quinlan RA. 2007. Insights into the beaded filament of the eye 
lens. Exp Cell Res 313: 2180–8. 
Petermann F, Pękowska A, Johnson CA, Jankovic D, Shih H-Y, Jiang K, Hudson WH, 
Brooks SR, Sun H-W, Villarino A V, et al. 2019. The Magnitude of IFN-γ Responses 
Is Fine-Tuned by DNA Architecture and the Non-coding Transcript of Ifng-as1. Mol 
Cell 75: 1229-1242.e5. 
Portoso M, Ragazzini R, Brencic Z, Moiani A, Michaud A, Vassilev I, Wassef M, Servant 
N, Sargueil B, Margueron R. 2017. PRC2 is dispensable for HOTAIR-mediated 
transcriptional repression. EMBO J 36: 981–994. 
Purvis JE, Karhohs KW, Mock C, Batchelor E, Loewer A, Lahav G. 2012. p53 Dynamics 
Control Cell Fate. Science 336: 1440–1444. 
Puvvula PK, Desetty RD, Pineau P, Marchio A, Moon A, Dejean A, Bischof O. 2014. Long 
noncoding RNA PANDA and scaffold-attachment-factor SAFA control senescence 
entry and exit. Nat Commun 5: 1–16. 
Quinn JJ, Chang HY. 2015. Unique features of long non-coding RNA biogenesis and 
function. Nat Rev Genet 17: 47–62. 
Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, Moskovits N, Bentwich 
Z, Oren M. 2007. Transcriptional Activation of miR-34a Contributes to p53-
Mediated Apoptosis. Mol Cell 26: 731–743. 
Riley T, Sontag E, Chen P, Levine A. 2008. Transcriptional control of human p53-
regulated genes. Nat Rev Mol Cell Biol 9: 402–412. 
Rinn JL, Chang HY. 2012. Genome regulation by long noncoding RNAs. Annu Rev 
Biochem 81: 145–66. 
162 
 
Rinn JL, Kertesz M, Wang JK, Squazzo SL, Xu X, Brugmann SA, Goodnough LH, Helms 
JA, Farnham PJ, Segal E, et al. 2007. Functional Demarcation of Active and Silent 
Chromatin Domains in Human HOX Loci by Noncoding RNAs. Cell 129: 1311–
1323. 
Ritter N, Ali T, Kopitchinski N, Schuster P, Beisaw A, Hendrix DA, Schulz MH, Müller-
McNicoll M, Dimmeler S, Grote P. 2019. The lncRNA Locus Handsdown Regulates 
Cardiac Gene Programs and Is Essential for Early Mouse Development. Dev Cell 
50: 644-657.e8. 
Ruhland MK, Loza AJ, Capietto A-H, Luo X, Knolhoff BL, Flanagan KC, Belt BA, Alspach 
E, Leahy K, Luo J, et al. 2016. Stromal senescence establishes an 
immunosuppressive microenvironment that drives tumorigenesis. Nat Commun 7: 
11762. 
Sahakyan A, Yang Y, Plath K. 2018. The Role of Xist in X-Chromosome Dosage 
Compensation. Trends Cell Biol 28: 999–1013. 
Sánchez Y, Segura V, Marín-Béjar O, Athie A, Marchese FP, González J, Bujanda L, Guo 
S, Matheu A, Huarte M. 2014. Genome-wide analysis of the human p53 
transcriptional network unveils a lncRNA tumour suppressor signature. Nat 
Commun 5: 5812. 
Sauvageau M, Goff LA, Lodato S, Bonev B, Groff AF, Gerhardinger C, Sanchez-Gomez 
DB, Hacisuleyman E, Li E, Spence M, et al. 2013. Multiple knockout mouse models 
reveal lincRNAs are required for life and brain development. Elife 2. 
Schlereth K, Beinoraviciute-Kellner R, Zeitlinger MK, Bretz AC, Sauer M, Charles JP, 
Vogiatzi F, Leich E, Samans B, Eilers M, et al. 2010. DNA Binding Cooperativity of 
p53 Modulates the Decision between Cell-Cycle Arrest and Apoptosis. Mol Cell 38: 
356–368. 
Schmitt AM, Garcia JT, Hung T, Flynn RA, Shen Y, Qu K, Payumo AY, Peres-da-Silva A, 
Broz DK, Baum R, et al. 2016. An inducible long noncoding RNA amplifies DNA 
damage signaling. Nat Genet 48: 1370–1376. 
Schorderet P, Duboule D. 2011. Structural and Functional Differences in the Long Non-
Coding RNA Hotair in Mouse and Human ed. W.A. Bickmore. PLoS Genet 7: 
e1002071. 
Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. 1997. Oncogenic ras Provokes 
Premature Cell Senescence Associated with Accumulation of p53 and p16INK4a. 
Cell 88: 593–602. 
Sharma S, Munger K. 2020. KDM6A-Mediated Expression of the Long Noncoding RNA 
DINO Causes TP53 Tumor Suppressor Stabilization in Human Papillomavirus 16 
E7-Expressing Cells ed. L. Banks. J Virol 94. 
Shechner DM, Hacisuleyman E, Younger ST, Rinn JL. 2015. Multiplexable, locus-specific 
targeting of long RNAs with CRISPR-Display. Nat Methods 12: 664–670. 
Smeenk L, van Heeringen SJ, Koeppel M, Gilbert B, Janssen-Megens E, Stunnenberg 
HG, Lohrum M. 2011. Role of p53 Serine 46 in p53 Target Gene Regulation ed. A. 
Gartel. PLoS One 6: e17574. 
Smeenk L, Van Heeringen SJ, Koeppel M, Van Driel MA, Bartels SJJ, Akkers RC, 
163 
 
Denissov S, Stunnenberg HG, Lohrum M. 2008. Characterization of genome-wide 
p53-binding sites upon stress response. Nucleic Acids Res 36: 3639–3654. 
Soto-Gamez A, Quax WJ, Demaria M. 2019. Regulation of Survival Networks in 
Senescent Cells: From Mechanisms to Interventions. J Mol Biol 431: 2629–2643. 
Speidel D. 2010. Transcription-independent p53 apoptosis: an alternative route to death. 
Trends Cell Biol 20: 14–24. 
Standaert L, Adriaens C, Radaelli E, Keymeulen A Van, Blanpain C, Hirose T, Nakagawa 
S, Marine J-C. 2014. The long noncoding RNA Neat1 is required for mammary 
gland development and lactation. RNA 20: 1844–1849. 
Stojic L, Niemczyk M, Orjalo A, Ito Y, Ruijter AEM, Uribe-Lewis S, Joseph N, Weston S, 
Menon S, Odom DT, et al. 2016. Transcriptional silencing of long noncoding RNA 
GNG12-AS1 uncouples its transcriptional and product-related functions. Nat 
Commun 7: 10406. 
Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich 
A, Pomeroy SL, Golub TR, Lander ES, et al. 2005. Gene set enrichment analysis: A 
knowledge-based approach for interpreting genome-wide expression profiles. Proc 
Natl Acad Sci 102: 15545–15550. 
Sullivan KD, Galbraith MD, Andrysik Z, Espinosa JM. 2018. Mechanisms of 
transcriptional regulation by p53. Cell Death Differ 25: 133–143. 
Sun Q, Hao Q, Prasanth K V. 2018. Nuclear Long Noncoding RNAs: Key Regulators of 
Gene Expression. Trends Genet 34: 142–157. 
Sunwoo H, Dinger ME, Wilusz JE, Amaral PP, Mattick JS, Spector DL. 2009. Men ε/β 
nuclear-retained non-coding RNAs are up-regulated upon muscle differentiation 
and are essential components of paraspeckles. Genome Res 19: 347–359. 
Symonds H, Krall L, Remington L, Saenz-Robles M, Lowe S, Jacks T, Van Dyke T. 1994. 
p53-Dependent apoptosis suppresses tumor growth and progression in vivo. Cell 
78: 703–711. 
Takagi M, Absalon MJ, McLure KG, Kastan MB. 2005. Regulation of p53 translation and 
induction after DNA damage by ribosomal protein L26 and nucleolin. Cell 123: 49–
63. 
Thakore PI, D’Ippolito AM, Song L, Safi A, Shivakumar NK, Kabadi AM, Reddy TE, 
Crawford GE, Gersbach CA. 2015. Highly specific epigenome editing by CRISPR-
Cas9 repressors for silencing of distal regulatory elements. Nat Methods 12: 1143–
1149. 
Tonelli C, Morelli MJ, Sabò A, Verrecchia A, Rotta L, Capra T, Bianchi S, Campaner S, 
Amati B. 2017. Genome-wide analysis of p53-regulated transcription in Myc-driven 
lymphomas. Oncogene 36: 2921–2929. 
Tripathi V, Ellis JD, Shen Z, Song DY, Pan Q, Watt AT, Freier SM, Bennett CF, Sharma 
A, Bubulya PA, et al. 2010. The nuclear-retained noncoding RNA MALAT1 regulates 
alternative splicing by modulating SR splicing factor phosphorylation. Mol Cell 39: 
925–938. 
Tsai M-C, Manor O, Wan Y, Mosammaparast N, Wang JK, Lan F, Shi Y, Segal E, Chang 
164 
 
HY. 2010. Long Noncoding RNA as Modular Scaffold of Histone Modification 
Complexes. Science 329: 689–693. 
Tseng YY, Moriarity BS, Gong W, Akiyama R, Tiwari A, Kawakami H, Ronning P, 
Reuland B, Guenther K, Beadnell TC, et al. 2014. PVT1 dependence in cancer with 
MYC copy-number increase. Nature 512: 82–86. 
Uszczynska-Ratajczak B, Lagarde J, Frankish A, Guigó R, Johnson R. 2018. Towards a 
complete map of the human long non-coding RNA transcriptome. Nat Rev Genet 
19: 535–548. 
Uxa S, Bernhart SH, Mages CFS, Fischer M, Kohler R, Hoffmann S, Stadler PF, Engeland 
K, Müller GA. 2019. DREAM and RB cooperate to induce gene repression and cell-
cycle arrest in response to p53 activation. Nucleic Acids Res 47: 9087–9103. 
Valente LJ, Gray DHD, Michalak EM, Pinon-Hofbauer J, Egle A, Scott CL, Janic A, 
Strasser A. 2013. p53 Efficiently Suppresses Tumor Development in the Complete 
Absence of Its Cell-Cycle Inhibitory and Proapoptotic Effectors p21, Puma, and 
Noxa. Cell Rep 3: 1339–1345. 
Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, Newman J, 
Reczek EE, Weissleder R, Jacks T. 2007. Restoration of p53 function leads to 
tumour regression in vivo. Nature 445: 661–5. 
Verfaillie A, Svetlichnyy D, Imrichova H, Davie K, Fiers M, Kalender Atak Z, Hulselmans 
G, Christiaens V, Aerts S. 2016. Multiplex enhancer-reporter assays uncover 
unsophisticated TP53 enhancer logic. Genome Res 26: 882–95. 
Villunger A. 2003. p53- and Drug-Induced Apoptotic Responses Mediated by BH3-Only 
Proteins Puma and Noxa. Science 302: 1036–1038. 
Vousden KH, Prives C. 2009. Blinded by the Light: The Growing Complexity of p53. Cell 
137: 413–431. 
Wang L, Park HJ, Dasari S, Wang S, Kocher J-P, Li W. 2013. CPAT: Coding-Potential 
Assessment Tool using an alignment-free logistic regression model. Nucleic Acids 
Res 41: e74. 
Wang T, Zeng J, Lowe CB, Sellers RG, Salama SR, Yang M, Burgess SM, Brachmann RK, 
Haussler D. 2007. Species-specific endogenous retroviruses shape the 
transcriptional network of the human tumor suppressor protein p53. Proc Natl 
Acad Sci 104: 18613–18618. 
Wei CL, Wu Q, Vega VB, Chiu KP, Ng P, Zhang T, Shahab A, Yong HC, Fu YT, Weng Z, et 
al. 2006. A global map of p53 transcription-factor binding sites in the human 
genome. Cell 124: 207–219. 
Weinberg RL, Veprintsev DB, Bycroft M, Fersht AR. 2005. Comparative Binding of p53 
to its Promoter and DNA Recognition Elements. J Mol Biol 348: 589–596. 
Werner MS, Ruthenburg AJ. 2015. Nuclear Fractionation Reveals Thousands of 
Chromatin-Tethered Noncoding RNAs Adjacent to Active Genes. Cell Rep 12: 
1089–1098. 
Werner MS, Sullivan MA, Shah RN, Nadadur RD, Grzybowski AT, Galat V, Moskowitz 
IP, Ruthenburg AJ. 2017. Chromatin-enriched lncRNAs can act as cell-type specific 
165 
 
activators of proximal gene transcription. Nat Struct Mol Biol 24: 596–603. 
West JA, Davis CP, Sunwoo H, Simon MD, Sadreyev RI, Wang PI, Tolstorukov MY, 
Kingston RE. 2014. The long noncoding RNAs NEAT1 and MALAT1 bind active 
chromatin sites. Mol Cell 55: 791–802. 
Wiley CD, Brumwell AN, Davis SS, Jackson JR, Valdovinos A, Calhoun C, Alimirah F, 
Castellanos CA, Ruan R, Wei Y, et al. 2019. Secretion of leukotrienes by senescent 
lung fibroblasts promotes pulmonary fibrosis. JCI Insight 4. 
Wilusz JE, JnBaptiste CK, Lu LY, Kuhn C-D, Joshua-Tor L, Sharp PA. 2012. A triple 
helix stabilizes the 3’ ends of long noncoding RNAs that lack poly(A) tails. Genes 
Dev 26: 2392–407. 
Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, Cordon-Cardo 
C, Lowe SW. 2007. Senescence and tumour clearance is triggered by p53 restoration 
in murine liver carcinomas. Nature 445: 656–660. 
Yang L, Duff MO, Graveley BR, Carmichael GG, Chen LL. 2011a. Genomewide 
characterization of non-polyadenylated RNAs. Genome Biol 12: R16. 
Yang L, Lin C, Liu W, Zhang J, Ohgi KA, Grinstein JD, Dorrestein PC, Rosenfeld MG. 
2011b. ncRNA- and Pc2 Methylation-Dependent Gene Relocation between Nuclear 
Structures Mediates Gene Activation Programs. Cell 147: 773–788. 
Yang Y, Wang C, Zhao K, Zhang G, Wang D, Mei Y. 2018. TRMP, a p53-inducible long 
noncoding RNA, regulates G1/S cell cycle progression by modulating IRES-
dependent p27 translation. Cell Death Dis 9: 886. 
Yao R-W, Wang Y, Chen L-L. 2019. Cellular functions of long noncoding RNAs. Nat Cell 
Biol 21: 542–551. 
Yildirim E, Kirby JE, Brown DE, Mercier FE, Sadreyev RI, Scadden DT, Lee JT. 2013. 
Xist RNA is a potent suppressor of hematologic cancer in mice. Cell 152: 727–742. 
Yin Y, Yan P, Lu J, Song G, Zhu Y, Li Z, Zhao Y, Shen B, Huang X, Zhu H, et al. 2015. 
Opposing Roles for the lncRNA Haunt and Its Genomic Locus in Regulating HOXA 
Gene Activation during Embryonic Stem Cell Differentiation. Cell Stem Cell 16: 
504–516. 
Yoon J-H, Abdelmohsen K, Srikantan S, Yang X, Martindale JL, De S, Huarte M, Zhan 
M, Becker KG, Gorospe M. 2012. LincRNA-p21 Suppresses Target mRNA 
Translation. Mol Cell 47: 648–655. 
Young TL, Matsuda T, Cepko CL. 2005. The Noncoding RNA Taurine Upregulated Gene 
1 Is Required for Differentiation of the Murine Retina. Curr Biol 15: 501–512. 
Younger ST, Kenzelmann-Broz D, Jung H, Attardi LD, Rinn JL. 2015. Integrative 
genomic analysis reveals widespread enhancer regulation by p53 in response to 
DNA damage. Nucleic Acids Res 43: 4447–62. 
Yun J, Espinoza I, Pannuti A, Romero D, Martinez L, Caskey M, Stanculescu A, 
Bocchetta M, Rizzo P, Band V, et al. 2015. p53 Modulates Notch Signaling in MCF-7 
Breast Cancer Cells by Associating With the Notch Transcriptional Complex Via 
MAML1. J Cell Physiol 230: 3115–3127. 
Zhang A, Zhou N, Huang J, Liu Q, Fukuda K, Ma D, Lu Z, Bai C, Watabe K, Mo Y-Y. 
166 
 
2013a. The human long non-coding RNA-RoR is a p53 repressor in response to 
DNA damage. Cell Res 23: 340–350. 
Zhang B, Arun G, Mao YS, Lazar Z, Hung G, Bhattacharjee G, Xiao X, Booth CJ, Wu J, 
Zhang C, et al. 2012. The lncRNA Malat1 Is Dispensable for Mouse Development 
but Its Transcription Plays a cis-Regulatory Role in the Adult. Cell Rep 2: 111–123. 
Zhang E b., Yin D d., Sun M, Kong R, Liu X h., You L h., Han L, Xia R, Wang K m., Yang 
J s., et al. 2014. P53-regulated long non-coding RNA TUG1 affects cell proliferation 
in human non-small cell lung cancer, partly through epigenetically regulating 
HOXB7 expression. Cell Death Dis 5: e1243–e1243. 
Zhang M, Zhao K, Xu X, Yang Y, Yan S, Wei P, Liu H, Xu J, Xiao F, Zhou H, et al. 2018. A 
peptide encoded by circular form of LINC-PINT suppresses oncogenic 
transcriptional elongation in glioblastoma. Nat Commun 9: 1–17. 
Zhang X, Hamblin MH, Yin KJ. 2017. The long noncoding RNA Malat1: Its physiological 
and pathophysiological functions. RNA Biol 14: 1705–1714. 
Zhang X, He Y, Lee KH, Dubois W, Li Z, Wu X, Kovalchuk A, Zhang W, Huang J. 2013b. 
Rap2b, a novel p53 target, regulates p53-mediated pro-survival function. Cell Cycle 
12: 1279–1291. 
Zhao Y, Katzman RB, Delmolino LM, Bhat I, Zhang Y, Gurumurthy CB, Germaniuk-
Kurowska A, Reddi H V, Solomon A, Zeng M-S, et al. 2007. The notch regulator 
MAML1 interacts with p53 and functions as a coactivator. J Biol Chem 282: 11969–
81. 
Zhou H, Sun L, Wan F. 2019. Molecular mechanisms of TUG1 in the proliferation, 
apoptosis, migration and invasion of cancer cells. Oncol Lett 18: 4393–4402. 
Zhou M, Hu L, Zhang Z, Wu N, Sun J, Su J. 2018. Recurrence-Associated Long Non-
coding RNA Signature for Determining the Risk of Recurrence in Patients with 






INFORMATION TO ALL USERS 
The quality and completeness of this reproduction is dependent on the quality  
and completeness of the copy made available to ProQuest. 
Distributed by ProQuest LLC (        ). 
Copyright of the Dissertation is held by the Author unless otherwise noted. 
This work may be used in accordance with the terms of the Creative Commons license 
or other rights statement, as indicated in the copyright statement or in the metadata  
associated with this work. Unless otherwise specified in the copyright statement  
or the metadata, all rights are reserved by the copyright holder. 
This work is protected against unauthorized copying under Title 17, 
United States Code and other applicable copyright laws. 
Microform Edition where available © ProQuest LLC. No reproduction or digitization  
of the Microform Edition is authorized without permission of ProQuest LLC. 
ProQuest LLC 
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, MI 48106 - 1346 USA 
28257787
2021
